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Thesis abstract 
The co-occurrence of problematic substance use and non-substance use psychopathology is very 
common in psychiatry, and is generally referred to as comorbidity. The phenomenon has been the 
subject of debate and widespread research, yet remains poorly understood.  
The thesis aimed to examine the association between psychopathology and substance use in young 
people in South African settings, to determine the nature and prevalence of comorbidity, and to 
identify sociodemographic factors that might influence the associations, as well as the influence of 
comorbidity on substance use treatment outcomes. 
A comprehensive review of the recent literature on comorbid psychopathology and substance use 
identified facets of comorbidity from studies in community and substance use treatment settings, 
cross-sectional and  longitudinal studies, and  different demographic groups including females, males, 
and various racially classified social groups. The literature review highlighted deficits in knowledge 
of comorbidity in developing countries, including South Africa.  
The association between psychopathology and substance use was examined through a series of 
empirical studies, each different from the other by the inclusion of a dimension which set it apart from 
the other studies. All the samples consisted of both males and females. Data were analysed using 
STATA to generate descriptive statistics and determine associations through regression analyses. The 
results of associations are presented as unadjusted and adjusted odds ratios, with 95% confidence 
intervals and p-values. 
The first empirical study examined the association between psychopathology and substance use in a 
sample of Grade 8 (n=480) and Grade 11 (n=459) adolescents (ages 14-24 years), randomly-selected 
from 39 high schools in Cape Town. These students completed a self-administered questionnaire to 
obtain basic demographic information and lifetime prevalence rates of cigarette, alcohol, cannabis and 
inhalant use. Psychopathology scores were calculated using the Harvard Trauma Questionnaire, the 
Beck Depression Inventory and the Zung Self-Rating Anxiety Scale. Logistic regression, using survey 
design analyses, indicated significant associations between PTSD and all substances of use (with ORs 
ranging from 1.016-1.050), between depression and alcohol (OR=1.050; 95%CI 1.011-1.091), 
cannabis and inhalant use (OR=1.080; 95% CI 1.007-1.159), and between anxiety and cannabis use 
(OR=1.035; 95%CI 0.963-1.112). Evidence indicated a role for grade, gender, age and racially 
classified social group in these associations, and further investigation is recommended to examine 
this. 
The second study examined comorbidity in a sample of young substance users who were in inpatient 
treatment for their substance use (n=95; ages 17-30 years). Patients were selected consecutively, in 
order of admission, from three substance use treatment centres in Cape Town. An interview schedule 
was used to elicit sociodemographic and substance use information. Psychopathology was assessed 
using the computer-assisted Diagnostic Interview Schedule (C-DIS) for Diagnostic and Statistical 
Manual (DSM) -IV. The results indicated a high prevalence of previously-undiagnosed psychiatric 
disorder (95.8%), with disruptive behaviour disorders predominating (antisocial personality disorder 
87.4%; conduct disorder 67.4%; oppositional defiant disorder 33.7%). Substance use was 
characterised by daily use of cigarettes, and primary use of heroin and crystal methamphetamine. 
Evidence suggested marginal unadjusted associations between anti-social personality disorder and 
cannabis as first substance of use (p=0.061), between conduct disorder and cannabis as first substance 
of use (p=0.031), between specific phobia and cannabis as first substance of use (adjusted OR=4.74; 
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95% CI 0.99-22.66, p=0.051). It was suggested that the study be replicated with a larger and more 
representative sample and an appropriate control group, to clarify finer nuances in the results 
obtained. 
In the third study, the substance use inpatients from the previous study were followed up in the year 
following their treatment (n=86) to establish associations between their psychopathology on 
admission, and their treatment and substance use status after discharge from their inpatient treatment 
programme. Follow-up interviews were conducted using an interview schedule to elicit substance use 
and treatment status information. The results indicated that single and male patients were more likely 
to complete the inpatient programme, while females were more likely to resume substance use and 
return to substance use treatment after the inpatient programme. Patients who sought treatment for 
heroin use were more likely still to be in treatment after the initial inpatient programme, than were 
those who sought treatment for substances other than heroin use. Patients who sought treatment for 
methamphetamine use were more likely to complete the inpatient programme, and were less likely to 
relapse or resume treatment, than were those who sought treatment for substances other than 
methamphetamine. Patients whose first substance of use was methamphetamine were less likely to 
relapse after inpatient treatment than were those whose first substance of use was not 
methamphetamine. No significant associations were found between psychopathology on admission 
and treatment completion or relapse after inpatient treatment. Methodological limitations of the study 
are discussed, as is the difficulty posed from the extremely high percentages of comorbidity, and 
suggestions are made for future research in light of evidence for the role of sociodemographic factors 
and substance use history in comorbidity, and substance use and treatment status after inpatient 
treatment. 
The fourth and final study examined data from the nationally-representative South African Stress and 
Health (SASH) survey to determine associations between psychopathology and substance use. In this 
study, a subsample from the SASH survey, comprising 1766 community members aged 18 to 30 
years, were interviewed using the Composite International Diagnostic Interview Version 3 (CIDI 3.0). 
Basic demographic information was elicited, together with lifetime and 12-month psychiatric 
diagnoses and lifetime substance use. The results indicated that substance users were more likely to 
have had anxiety disorders (ORs from 1.7 to 2.0 for lifetime anxiety) and major depression ORs from 
1.8 to 5.6), compared with non-substance users. Evidence was obtained for associations between 
specific substances and specific psychiatric disorders, and particularly between mood disorders and 
substance use. Age, gender and racially classified social group emerged as factors to be further 
examined with respect to comorbidity. In light of the rigour with which this study was conducted, 
these results will make an important contribution to knowledge of comorbid psychopathology and 
substance use in South Africa. In addition, this study contributes to global information, by providing 
standardised data that can appropriately be compared with similar World Health Organisation (WHO) 
World Mental Health (WMH) initiatives elsewhere. 
These studies thus all investigated associations between psychopathology and substance use in young 
people, providing strong evidence of associations in community settings, but less so in the setting of a 
substance use treatment population. The evidence appears to point in the direction of more likely 
associations between certain psychiatric diagnoses in relation to specific substances of use, possibly 
influenced by factors such as age, gender, racially classified social group and school grade. These 
results also highlight the need to consider methodological and conceptual issues when designing and 
executing research projects that involve comorbid psychopathology and substance use. It is clear that 
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further investigation will be needed to refine the results obtained and to establish greater clarity of the 
dynamic that exists when psychopathology and substance use co-occur. 
In conclusion, this thesis has raised the profile of comorbidity research in Cape Town and in South 
Africa, has highlighted some important issues in the debate on comorbid psychopathology and 
substance use, has uncovered potential pitfalls of comorbidity research, and has provided a baseline 
from which further comorbidity studies can be developed.  
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CHAPTER 1 
Introduction 
While many users of substances such as tobacco, alcohol and cannabis do not experience substance-
related problems, some individuals do develop problematic substance use (Diegenhardt et al., 2001). 
Some individuals might even meet criteria for diagnoses of substance abuse or substance dependence 
as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM) (Robins et al., 2002), 
and are treated within the ambit of psychiatry.  Evidence from epidemiological studies [such as the 
Epidemiologic Catchment Area (ECA) (Robins et al., 1991), the National Epidemiologic Survey on 
Alcohol and Related Disorders (NESARC) (Grant et al., 2004),  and the National Comorbidity 
Surveys (Kessler et al., 1994; 1996; 2005)] have reinforced  a long history of clinical observations 
that suggest associations between problematic substance use and other psychiatric morbidity 
(Weinberg and Glantz, 1999). However, though recognition of the co-occurrence of disease symptoms 
and disorders has been longstanding, recent developments have altered the manner in which such co-
occurrence is being treated (Angold et al., 1999). 
Co-occurrence of diseases (individual and well-defined clinical entities) or disorders (behavioural and 
psychological syndromes that deviate from established norms) is generally referred to as 
‘comorbidity’ (Angold et al., 1999), and is characterised by an overlap of disease or disorder 
symptoms. Thus, the co-occurrence of problematic substance use and psychiatric disorder constitutes 
a form of psychiatric comorbidity. Common forms of substance use and other psychiatric comorbidity 
include associations between alcohol use and anxiety disorders, antisocial personality disorders, 
affective disorders and schizophrenia (Hall and Farrell, 1997), smoking and depression (Goodman 
and Capitman, 2000),  and between cannabis use and psychiatric disorder such as attention deficit 
disorder, conduct disorder, oppositional disorders, anxiety and depressive disorders (McGee et al., 
2000). Comorbid substance use and psychiatric disorder is also recognised as a common occurrence 
(Volkow, 2000), amongst both clinically-derived and population-based samples, and amongst adults 
and adolescents (Weinberg and Glantz, 1999).  
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Comorbid substance use and psychiatric disorder, however, remains a phenomenon that is relatively 
poorly understood (Volkow, 2000), with various aspects being the subject of continuing discussion, 
including, i) whether comorbidity is a ‘real’ phenomenon, or an artefact of diagnostic symptoms, 
diagnostic techniques, chance, referral biases or sampling procedures (Wittchen, 1996a), ii) consistent 
use of terms such as ‘comorbidity’, ‘co-occurring disorders’, ‘dual’ and ‘triple diagnosis’ (Chambers 
2008a, b), and distinguishing between concurrent, sequential and lifetime disorders or symptoms 
(Angold et al., 1999),  iii) distinguishing between primary and secondary psychiatric diagnoses, and 
the temporal relationship between these,  iv) explaining the common co-occurrence of seemingly 
unrelated disorders (Angold et al., 1999),  v) the use of clinical samples to examine comorbidity when 
these samples have the potential to produce overestimates of comorbid diagnoses because they may 
be biased in favour of possibly more, and/or, more severe symptoms of disorders, unless a disorder is 
rare or most likely to precipitate treatment-seeking, and  vi) the need for more longitudinal 
comorbidity studies, particularly with samples of children, adolescents and young adults. 
However, notwithstanding the controversial nature of comorbidity, the importance of examining 
associations between substance use and psychiatric disorder remains indisputable. Firstly, such 
research will improve understanding of the aetiology of psychiatric and substance use-related 
disorders (Angold et al., 1999; Diegenhardt et al., 2001). Secondly, comorbid disorders have 
implications for both the treatment and management of the individuals involved. Thus, if persons with 
problematic substance use have an increased chance of having or developing an associated psychiatric 
disorder, or if people  with psychiatric disorder have an increased risk of problematic substance use or 
substance use disorder, service provision will have to include assessment for co-occurring disorders 
and their subsequent treatment and management (Degenhardt et al., 2001).  
Though research into associations between substance use and psychiatric disorder has been extensive, 
relatively few studies have addressed associations between specific substances of use and psychiatric 
problems or disorder (Degenhardt et al., 2001). In addition, information is lacking regarding the role 
of gender or age in comorbidity (Angold et al., 1999). Moreover, as shown by the literature review 
completed for this thesis, there is a paucity of comorbidity research from developing countries 
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compared with developed countries, with a particularly low research output in this field from Africa 
and South Africa. This thesis attempts to address these issues by increasing information on substance 
use and related psychiatric problems and disorders, and highlighting demographic and social factors 
that might influence such comorbidity, within the South African context. 
More specifically, the thesis examines the association between psychiatric disorder and specific 
substances of use in a) a community sample of school-going adolescents and young adults, b) a 
sample of adolescents and young adult substance users in inpatient treatment for problematic 
substance use, and c) a community sample of young adults drawn from a representative sample of 
South African adults. In addition, the thesis includes a follow-up of the treatment sample of inpatient 
substance users, examining associations between identified psychiatric disorder and substances of use 
at baseline, and post-treatment status as defined by treatment completion, relapse and treatment 
resumption.  
This chapter will elaborate on the importance of examining associations between psychiatric disorder 
and substance use. Specific reference will be made to the burden of disease posed by psychiatric 
disorder, substance use and associations between psychiatric disorder and substance use. The chapter 
will highlight the need to examine associated psychiatric disorder and substance use in young people 
particularly, and will discuss the challenges that conceptual, diagnostic and definitional issues pose to 
research in this area. Suggested explanations for associated psychiatric disorder and substance use, 
will be outlined. The status of research and knowledge regarding associations between psychiatric 
disorder and substance use will be discussed. The chapter will conclude with a rationale for the thesis 
and details of its aims and objectives, and a brief indication of the construction of the thesis and the 
contents of each chapter. 
Substance use, psychiatric disorder and the global burden of disease 
The report from the 2008 World Health Organisation (WHO) on the global burden of diseases 
(Hoelzer, 2009) indicated that cardiovascular diseases were the leading cause of mortality globally, 
and identified tobacco use as one of the risk factors in this statistic. Neuropsychiatric conditions 
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(including alcohol use and psychiatric disorder) were reported to be the leading causes of disability, 
accounting for a third of all years lost due to disability (YLD) in individuals aged 15 years and older.  
Chronic diseases such as psychiatric disorder and substance use are recognised as simultaneously the 
most common, costly and preventable global health problems (Hoelzer, 2009). The burden of cost to 
the State associated with chronic illnesses is comparatively larger in countries where budgets for 
health funding and resources are smaller. In such under-resourced countries, the financial and social 
burdens of chronic diseases are further increased by limited available resources to deal with the needs 
of caregivers and service providers of individuals affected by chronic diseases (Adewuya et al., 2010).      
In particular, the African continent’s burden of disease (and specifically that of sub-Saharan Africa) 
has been linked to factors such as increased life expectancy, poverty, urbanisation, globalisation and 
lifestyle changes (de-Graft Aikens et al., 2010). In a recent review of the literature on the associations 
between poverty and mental disorders, Lund et al., (2010) concluded that there can no longer be any 
question as to whether poverty influences common mental disorders in low and middle income 
countries. Instead, these authors suggested that research must now be geared towards identifying 
which are the most important poverty factors that affect mental disorders. Furthermore, attempts to 
address the burden of disease in sub-Saharan Africa have been hampered by inadequate or insufficient 
relevant information because of the low research output regarding the burden of chronic disease in the 
region (de Graft-Aikens et al., 2010).  
The WHO has recognised the need to gather information on the global burden of chronic diseases, and 
aims to invest in increasing both knowledge and understanding regarding these illnesses.  The 
intention is to inform policy, particularly in developing countries, regarding the recognition of health 
priorities and the appropriate allocation of available resources. This approach is grounded in the view 
that health should be aspired to both for its own sake, and because it impacts on the economic growth 
and competitiveness of the countries involved (Baumberg, 2006). 
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The burden of psychiatric disorder 
Generally, the burden of psychiatric disorder is larger than that of most chronic physical 
diseases because mental disorders often have an earlier age of onset than many physical 
chronic illnesses (Kessler et al., 2007). Problems associated with mental illness, for example 
violent behaviour, can cause injury to both the perpetrator and the victim of the violence, 
resulting in physical injuries that can increase the load on health services and providers, and 
could also result in reduced productivity due to the victim’s absence from work. The 
consequent mental and emotional anguish suffered by the victims and perpetrators is more 
difficult to quantify, and might thus remain incalculable, unknown or be ignored (Desjarlais 
et al., 1995).  
Similarly, non-natural deaths can result in significant distr ss in the dependants. Moreover, 
the underlying behavioural or mental problems of victims of non-natural deaths often go 
unrecognised. For example, the victim of a successful suicide attempt might be recorded as 
having had a non-natural death, and the role of a possible underlying depression in the suicide 
might remain unrecorded. As a result, statistics relating to the prevalence of mental disorders 
and other behavioural problems are often underestimates (Desjarlais et al., 1995). 
According to Kessler et al. (2009), the occurrence of psychiatric disorder worldwide is 
generally very common (12.0-47.4%), irrespective of whether the country is a developed or 
developing country. According to the World Mental Health (WMH) surveys (Kessler et al., 
2009), the most commonly-occurring lifetime psychiatric disorders in the community were 
the anxiety disorders (4.8-31.0%), followed by mood disorders (3.6-21.4%), the externalising 
disorders (0.3-25.0%) and substance use disorders (1.3-15.0%). Similar trends, but involving 
lower proportions, apply to the 12-month prevalence rates of these disorders.  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
6 
 
The South African Stress and Health (SASH) survey, the South African arm of the WHO 
WMH surveys (Stein et al., 2009), found that 30.3% of a nationally representative sample had 
a mental disorder, with 11.2% and 3.5% having two or more, and three or more, disorders 
respectively. The most-commonly occurring lifetime disorders were the anxiety disorders 
(15.8%) followed by substance use disorders (13.3%) and mood disorders (9.8%) (Herman et 
al., 2009). The South African prevalence rates for the anxiety disorders thus loosely 
approximated the WMH mid-range, while the South African prevalence rate for mood 
disorders veered more towards the lower end of the WMH range. In South Africa the 
substance use disorder prevalence rate was closer to the WMH upper limit.  
The SASH survey also reported that a quarter of individuals with severe or moderate 
psychiatric disorders had received psychiatric treatment in the year prior to interviews for the 
survey, with primarily mood and anxiety disorder consultations, while 13.4% of  individuals 
with no psychiatric disorders had received treatment for psychiatric disorder (Seedat et al., 
2009). These findings highlight the need gap between disease burden and actual utilisation of 
services, as well as the need for access to services, and provide some insight into the manner 
in which current available services are utilised.  
Some attempts have  been made, largely in developed countries, to calculate the burden of disease due 
to psychiatric disorder. Economic costs associated with psychiatric disorders have been estimated to 
approximate 79 billion dollars per annum in the United States of America, and 3% to 4% of Gross 
Domestic Product (GDP) per annum in the European Union (EU) member countries (Ngui et al., 
2010)   
However, there are many difficulties in obtaining valid cost estimates for the burden of psychiatric 
disorder. Wealthy and poorer countries differ in their ability to meet the costs associated with 
psychiatric disorder. Attempts to address this imbalance have been complicated by a lack of available 
data in most countries, and particularly in developing countries, with respect to the burden of disease 
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in general, psychiatric disorder in particular (Levinson et al., 2010) and the costs associated with these 
illnesses and their short-term or long-term effects (Kessler et al., 2009).  
To address this deficit, the WHO embarked on the World Mental Health (WMH) surveys that 
currently provide information on the global burden of psychiatric disorder from 28 countries. 
These surveys generate data regarding the prevalence and severity of mental disorders and 
their correlates, as measured by the Composite International Diagnostic Interview (CIDI), 
and measures of the extent to which the mental disorders disable the affected individuals. 
Furthermore, the WMH surveys provide prevalence rates for individual disorders, thus 
allowing comparisons of prevalence rates across countries, and identification of disease areas 
where resources and intervention need to be prioritised. 
The burden of substance use 
Use of substances with psychoactive effects has long been part of cultures across the world 
(Anderson, 2006), and have historically included, among others, alcohol (from fermented 
fruits, grain, honey), nicotine (from tobacco or pituri plants), caffeine (from coffee beans), 
cocaine (from the coca plant), and heroin and opium (from poppy seeds). Global substance 
use estimates for 2002 indicate that 146.2 million adults used cannabis, 29.6 million used 
amphetamines and 13.3 million used cocaine globally, with an estimated 15.3 million people 
diagnosed with substance use disorders, and usage largely driven by a complex dynamic that 
includes, among other factors, affordability and availability of substances (Anderson, 2006).  
Globally, tobacco use has been recognised as the ‘most preventable cause of death’, as ‘a risk 
factor in six of the eight primary causes of death’, is known to have doubled or tripled the 
mortality rate in smokers compared with non-smokers, and is estimated to have contributed to 
the deaths of 100 million people in the 21
st
 century (Hoelzer, 2009:4). According to the latter 
report, tobacco use globally was most prevalent amongst men and individuals aged 18 to 25 
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years, declined in the United States, and had 70% of its consumption in lower income 
countries.  
In comparison, alcohol use accounted for 4% of the global burden of disease, and for one-
third of the male neuropsychiatric burden, and made its largest contribution to the burden of 
substance use in central and South America (Hoelzer, 2009). Alcohol was the substance of 
choice amongst US adolescents and young adults (aged 16 to 25 years), and played a 
contributory role in some cancers, epilepsy, motor vehicle accidents and homicides (Hoelzer, 
2009). 
Estimating the global economic and social cost of alcohol consumption has been 
complicated. Suggested reasons for this include methodological differences between studies, 
that identify who pays the costs involved, difficulties in calculating the  economic ‘benefits’ 
of dying young from alcohol-related disorders, difficulties with attributing a causal role to 
alcohol in mortality, problems with calculating the indirect costs of alcohol use (for example, 
its contribution to an individual’s reduced productivity), and the possibly differential impact 
of alcohol use in developed and developing countries (Baumberg, 2006). As a result, the true 
cost of alcohol use remains unknown, as are the estimates of measurement error in the 
calculated costs (Rehm et al., 2006). General consensus seems to hold, though, that the costs 
(social, economic or any other) of alcohol use outweigh the perceived benefits, and exert a 
substantial global economic burden (Baumberg, 2006). 
In South Africa, details of various forms of substance use and abuse are recorded 
systematically and regularly as part of an ongoing surveillance programme, hosted by the 
South African Community Epidemiology Network on Drug Use (SACENDU, 2009). The 
SACENDU statistics report patterns of admission for treatment of problems relating to drug 
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and alcohol use in South Africa, at substance use treatment centres across the country, and 
provide an opportunity to track the changes in substance use admission patterns over time.  
The SACENDU reports for January-June 2009 indicated that alcohol was the primary 
substance of abuse amongst individuals aged older than 20 years who sought treatment for 
their substance use while cannabis use was high across all age groups. Community studies 
found widespread use of cigarettes, alcohol, cannabis and inhalants amongst high school 
students in the Cape Town area of South Africa (Flisher et al., 2002; Patrick et al., 2009), 
while Taylor et al. (2003) similarly reported use of cigarettes, alcohol, cannabis, benzene, 
paint thinners, glue and petrol amongst rural high school students in the Kwazulu-Natal area 
of South Africa. These results were borne out by the South African (SA) National Youth Risk 
Behaviour Survey (NYRBS) of school-going students from Grades 8 through 11 (Reddy et 
al., 2007). The latter report also indicated increased rates of illicit drug use over time in this 
group, and suggested that this increase was largely the result of increased use of heroin, 
believed to have been driven by an increase in the heroin supply and a decrease in the price of 
heroin. Results from the SASH nationally-representative survey indicated that alcohol was 
the most common substance of use (38.7%) in the adult community, while 30% of those 
sampled used tobacco, and 8.4% used cannabis (van Heerden et al., 2009).  
Use of substances such as alcohol and tobacco has been listed as responsible for 
approximately 4% of disability adjusted life years lost [World Health Organisation (WHO), 
World Health Report 2002]. Substance use, particularly amongst adolescents and young 
adults, has been linked to problematic behaviours such as risky sexual behaviour (Pahl et al., 
2010), HIV (Myer et al., 2009b), dropout from school (Myer et al., 2009a),  and unnatural 
deaths such as homicides, pedestrian victims of motor vehicle accidents, and victims of fire 
accidents (Matzopoulos and Lerer, 1995; Seedat et al., 2009). Risk factors for substance use 
identified in studies include poverty (with respect to illicit substances), lower educational 
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levels (with respect to tobacco use), higher income (with respect to tobacco use), single-
parent households, and having family members who use substances (Anderson, 2006). 
Factors that appear to protect against substance use include harmonious domestic and family 
relationships, and adult supervision (Anderson, 2006), and intelligence, problem-solving 
ability and supportive family (Weinberg et al., 1998). However, there appears to be no single 
resilience factor that protects against substance use or its consequences (Weinberg et al., 
1998).  
Co-occurring psychiatric disorder and substance use 
Information from the United States Substance Abuse and Mental Health Services 
Administration and United States National Comorbidity Survey indicated that individuals 
with psychiatric disorder were more likely to be dependent on substances (27%) than were 
individuals who had no psychiatric disorder (8%) (Buckley, 2007).  Conversely, individuals 
who abused substances doubled their risk of psychiatric disorder compared with individuals 
who did not use illicit substances (Buckley, 2007). Co-occurring psychiatric disorder and 
substance use is seen to reflect both the risk of substance use in individuals with psychiatric 
disorder as well as the potential for substance use to trigger psychiatric disorder (Volkow, 
2001). The commonness of this co-occurrence has been demonstrated by results from several 
different studies conducted in different geographical regions (Saban and Flisher, 2010).  
However, despite the frequency with which co-occurring psychiatric disorder and substance 
use is encountered, the associations between the two remain “poorly understood”, particularly 
with respect to the nature of the associations, their origins, and the manner in which they 
interact and influence each other (Volkow, 2001:1181). In addition, relatively few studies 
have rigorously examined associations between psychiatric disorder and specific substances 
of use (Jane-Llopis and Matytsina, 2006), while most of the studies have been conducted in 
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developed countries (Saban and Flisher, 2010). The findings from these developed countries 
might apply to developing countries, and co-occurring psychiatric disorder and substance use 
trends might not be specific to particular cultures. However, differences in prevalence rates of 
comorbidity in samples from the same populations, with no conclusive explanations for these 
differences, and varying study designs that make cross-study comparisons very difficult, 
indicate the need for further investigations into patterns of association between psychiatric 
disorder and substance use, with a particular view to obtaining cross-nationally comparable 
data (Jane-Llopis and Matytsina, 2006). 
 Epidemiology  
Reported prevalence rates for any psychiatric disorder in individuals with alcohol use 
disorder or dependence have ranged from 28% for 12-month disorders in the National 
Epidemiological Survey on Alcohol and Related Conditions (NESARC) (Grant et al., 2004), 
48% for lifetime disorders in the National Comorbidity Survey (NCS) (Kessler et al., 1996) 
and the National Comorbidity Survey-Replication (NCS-R) (Kessler et al., 2005). The 
NESARC study also found a prevalence rate of 47% for alcohol problems or disorder in those 
with any psychiatric disorder. The comparative figures for alcohol use and alcohol 
dependence were 7% and 14%  respectively in the National Household Survey on Drug 
Abuse amongst the general US population, 29% for alcohol problems and 36% for alcohol 
dependence in the NCS and NCS-R, and 16% for alcohol problems and 23% for alcohol 
dependence in the Mental Health Supplement to the Ontario Health Survey (Jane-Llopis and 
Matytsina, 2006). Co-occurring mental illness and substance use has also been more 
prevalent in treatment samples as compared with community samples (Kessler et al., 1996). 
A possible reason for this might be that the presence of more than one disorder might be 
more likely to result in treatment-seeking behaviour for either disorder (Angold and Costello, 
1993). Evidence also indicates that psychiatric disorder is more likely to be associated with 
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substance dependence than abuse (Kessler et al., 1996) suggesting that psychiatric disorder 
might be more likely with increasing severity of the substance use.  
 Patterns of co-occurrence  
The results of the National Comorbidity Survey (Kessler et al., 1996) showed statistically 
significant associations between mood or anxiety disorders (12-month and lifetime) and 
substance use and substance use disorders. Schizophrenia has been associated with multiple 
substance use, and mania has been associated with alcohol use (Goldsmith, 1999). Thought 
problems, attention problems, and delinquent and aggressive behaviour have been associated 
with tobacco use in adolescents and young adults (Ferdinand et al., 2001). Alcohol and other 
substance use (including cannabis) have been associated with conduct disorder in adolescents 
(Brown et al., 1996), use of opioids has been associated with antisocial personality disorder 
and major depression in adults (Brooner et al., 1997), and use of illicit drugs have been 
associated with increased risk of mood disorders in children and young adults (Kandel et al., 
1997). Other evidence has indicated associations between bipolar disorder and substance use, 
as well as between attention-deficit hyperactivity disorder (ADHD) and substance use and 
related disorders in adolescents (Deas, 2006). There, is, thus, extensive evidence to suggest 
associations between psychiatric disorder and substances of use.  
 Associated factors 
Various studies have examined factors that appear to play a role in the association between 
psychiatric disorder and substance use (Jane-Llopis and Matytsina, 2006). These factors can 
be categorised as individual biological or psychological characteristics, or factors that involve 
social or environmental aspects of the individual’s life (Weinberg and Glantz, 1999). Factors 
examined have included  gender (Goldsmith, 1999; Jane-Llopis and Matytsina, 2006), age 
(Jane-Llopis and Matytsina, 2006), school grade (Monshouwer et al., 2006), urbanicity 
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(Chong et al., 1999), socioeconomic status or economic deprivation (Jane-Llopis and 
Matytsina, 2006), homelessness (Goldsmith, 1999), ethnicity  or racially-classified social 
group (Chatterji et al., 2009), biological markers or genetic factors (Ciccheti and Rogosch, 
1999), and medical illnesses (Goldsmith, 1999). These factors have been examined with 
respect to their role as either risk or protective factors for psychiatric disorder or/and 
substance use. 
 Pathways to co-occurrence 
Identifying the pathways that lead to co-occurring psychiatric disorder and substance use or 
substance use disorders is important for three reasons. Firstly, it can enable one to understand 
the mechanisms underlying associated disorders (Volkow, 2001). Secondly, it can assist in 
identifying temporal associations between disorders (Jane-Llopis and Matytsina, 2006), 
thereby facilitating the identification of possible causal associations. Thirdly, identified 
pathways can assist with the development o  targeted interventions to prevent, treat or 
manage the co-occurring disorders and the individuals involved (Jane-Llopis and Matytsina, 
2006). 
Various pathways have been suggested to assist in understanding the development of co-
occurring psychiatric disorder and substance use. The most common of these are i) 
temporality/causality, ii) self-medication, and iii) a genetic predisposition (Diegenhardt et al., 
2001).  
The temporal or causal theory holds that if one disorder precedes another, the preceding 
disorder could have caused the other disorder. However, Lillienfeld and Stolley (1994) 
proposed that demonstrating a temporal association between two factors is not enough to 
indicate causality. Instead, these authors suggest that when reviewing the evidence arising 
from the literature, temporality needs to be accompanied by additional factors before 
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causality can be accepted. These additional factors include the strength of the association, the 
consistency of the association, the specificity of the associated factors, and whether the 
observed association occurs in keeping with known scientific principles.  
Establishing causality between psychiatric disorder and substance use has been hampered by 
inconsistent or contradictory findings. For example, the Pomerleau hypothesis (McGee et al., 
1998) held that psychiatric disorder preceded cigarette smoking, played a role in inhibiting 
quitting smoking, and was accompanied by contributory socioeconomic factors like 
disadvantaged backgrounds. This hypothesis thus suggested the possibility that the 
psychiatric disorder might have caused the smoking initially by attempts to alleviate the 
symptoms of psychiatric disorder, and subsequently led to smoking-related disorders (McGee 
et al., 1998). The suggestion had earlier been supported by evidence from the National Health 
and Nutrition Examination Survey on the dynamics of depression and cigarette smoking 
(Anda et al., 1990). The NCS similarly found that mental disorders usually preceded 
substance use disorders (Kessler et al., 1996). However, data from the 1972-1973 Dunedin 
Multidisciplinary Health and Development Study indicated little evidence to support the 
Pomerleau hypothesis (McGee et al., 1998), while the International Consortium on 
Psychiatric Epidemiology found that the temporal order of co-occurring disorders differed for 
different countries (Jane-Llopis and Matytsina, 2006).   
The self-medication hypothesis proposes that patients with mental health problems might 
attempt to alleviate the symptoms of these problems with substance use, for example reports 
of people claiming to feel more relaxed when drinking moderately or socially (Breslau et al., 
1998). However, the empirical evidence associates consumption of alcohol with increased 
physiological indicators of tension, in moderate drinkers, heavy drinkers, and in young men 
who either had or did not have family histories of alcoholism (Breslau et al., 1998). In cases 
of acute alcohol withdrawal, consumption of alcohol was found to alleviate tension in the 
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short term, but ultimately the symptoms of anxiety persisted with continued drinking and 
only decreased with abstinence over time (Breslau et al., 1998). However, as mentioned by 
Jane-Llopis and Matytsina (2006: 532), “if all or most co-occurring substance use was 
motivated by need for self-medication, specific substances would probably be linked to 
specific conditions”. However, very few conditions seem to have such specificity of 
associations, while substances of choice appear to be influenced by factors that include the 
cultural environment of the individual, the cost, and the availability of substances. Thus the 
self-medication hypothesis appears to be an unlikely explanation for all co-occurrence of 
psychiatric disorder and substance use (Jane-Llopis and Matytsina, 2006).  
Genetic factors have been proposed as responsible for predisposing an individual to either the 
substance use, or the psychiatric disorder, or both. Though the evidence to support a genetic 
basis for comorbidity has in the past been considered unreliable (Schuckit et al.,1990), more 
recent reports of twin studies have demonstrated a role for genetic factors in patterns of 
comorbidity (Kendler et al., 2003), and also proposed a contributory role for shared 
environmental risk factors, such as family disruption, poor parental monitoring or low social 
class of rearing, in comorbidity (Kendler et al., 2003). 
It has also been suggested that psychiatric disorders could play a role in changing the course 
of the prevailing substance abuse (Bukstein et al., 1989), with the emergence, occurrence or 
presence of a psychiatric disorder able to alter the manner, intensity, severity or type of 
substance abuse and its consequences. More recently, Chambers (2007) found that various 
psychiatric disorders were characterised by neurobiological conditions that resulted in the 
psychiatric symptoms. Though these psychiatric symptoms were often independent of any 
substance use, the author held that the neurobiological condition could pose a vulnerability to 
problematic substance use in the event of exposure to substance use. In these cases, the 
psychopathology and substance use would share a common neurocircuitry that would 
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predispose the individual independently to both the psychopathology and the problematic 
substance use. 
These proposed pathways to the development of co-occurring psychiatric disorder and 
substance use seem to suggest that the development of such co-occurrence might be 
heterogeneous. It is possible that the co-occurrence might be influenced by factors such as 
individual, social, environmental and/or biological characteristics which protect or place the 
individual at risk for substance use and/or psychiatric disorder, and by the severity of either 
the substance use or the psychiatric disorder. Weinberg and Glantz (1998) have thus proposed 
that non-linear pathways that consider the interactive, dynamic and developmental aspects be 
explored to explain the aetiology of co-occurring psychiatric disorder and substance use. This 
view is based on the idea that, since co-occurring disorders develop over time and are thus 
integrally connected to the development of the individual, explanations for the co-occurrence 
should be sought through a developmental approach. 
  
Intervention, management and treatment 
Social stigma and cultural stereotypes accompany both problematic substance use and 
psychiatric disorder (Goldsmith, 1999). Individuals who enter treatment for either problem as 
adolescents or adults, usually have a history characterised by social dysfunction, problem 
behaviours and a lack of academic success, have exhausted, disgraced, disgusted or enraged 
their families and friends (Goldsmith, 1999), and are often poorly motivated or inadequately 
prepared for treatment (Riggs, 2003).  
Research on the treatment of co-occurring psychiatric disorder and substance use has been 
reported relatively infrequently, considering the high prevalence of the phenomenon (70-80% 
in clinical samples) (Kaminer et al., 2007). Some suggested reasons for the low research 
output in this area have included problems with diagnosing the co-occurrence, the individuals 
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involved being “unstable” and difficult to recruit, or engage or retain in treatment, 
traditionally separated facilities for the treatment of psychiatric disorder and substance use 
problems, and separation of the major funding sources for psychiatric disorder and substance 
use (McHugo et al., 2006: 655).  
Once diagnosed, co-occurring psychiatric disorder and substance use treatment usually 
require that the individual be stabilised and abstain from use of substances. Research-based 
interventions for substance use and related psychiatric disorder include medications, 
behavioural or psychosocial interventions, cognitive behavioural therapy, motivational 
enhancement therapy and community-based treatment programmes, with psychosocial 
approaches being the preferred initial treatment for substance use (Riggs, 2003). Other 
treatment modalities include multisystemic therapy, contingency management reinforcement 
and the Minnesota 12-step model (Kaminer et al., 2007). 
Sequential or parallel treatment programmes for co-occurring psychiatric disorder and 
substance use have largely been found to be ineffective (Craig et al., 2008). As a result, it has 
been suggested that the co-occurring psychiatric disorder and substance use be treated 
simultaneously, with recognition of the possibility of interactions between substances of use 
and medications, lack of compliance with medication, and potential medication side-effects 
(Kaminer et al., 2007). Promising results, including symptom reduction and cost-
effectiveness, have been obtained from some integrated interventions (Craig et al., 2008), but 
it appears that continuity of care would still be advised to ensure treatment retention 
(Kaminer et al., 2007). 
  
Treatment outcomes 
As previously mentioned, the co-occurrence of psychiatric disorder in substance users has 
been found to complicate the treatment of both the psychiatric disorder and substance use 
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through the potential for side-effects from medication and interactions between medications. 
The presence of concurrent psychiatric disorder in substance users has also been associated 
with increased relapse rates one year after completion of substance use treatment programmes 
(Compton et al., 2003). However, few studies have clearly identified the role of specific 
psychiatric disorder in relapse and other outcomes following treatment for substance use 
(Landheim et al., 2006). Furthermore, studies that have examined the role of co-occurring 
psychiatric disorder in substance use treatment outcome have largely examined short-term 
outcomes, while those that have examined longer-term outcomes (5 years and more) have 
been confined to limited samples (for example, individual facilities for the treatment of 
substance use) (Landheim et al., 2006). As a result, information on the long-term outcome of 
substance use treatment in individuals with co-occurring psychiatric disorder remains limited. 
Considering some of the problems experienced by individuals with either a psychiatric 
disorder or problematic substance use or a substance use disorder (for example psychosocial 
impairment, reduced productivity), it can be expected that the problems of individuals with 
co-occurring psychiatric disorder and substance use would be compounded (MacKay, 2005). 
However, it appears that, overall, difficulties associated with outcomes from treatment for co-
occurring psychiatric disorder and substance use are often more than a summation of the 
challenges experienced due to each condition individually. 
Compton et al. (2003), in a prospective study of substance users admitted to substance use 
treatment facilities in St Louis, Missouri in the United States of America,  found that lifetime 
occurrence of antisocial personality disorder or major depression was associated with an 
increase in the number of illicit substances used one year after completion of substance use 
treatment. However, the association between psychiatric disorder and substance use treatment 
outcome varied with the kind of psychiatric disorder and gender. For example, the presence 
of phobic disorder was associated with reduced substance use at one-year follow-up, while 
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the co-occurrence of depression resulted in better treatment outcomes in females compared 
with males. Inconsistent results across studies were identified by Landheim et al. (2006). For 
example, one study found that, in women, depression was associated with increased alcohol 
consumption on follow-up (Schutte et al., 1997), while another study found the converse 
(Kranzler et al., 1996). Though these differences might reflect actual inconsistencies in the 
association between the psychiatric disorder and the substance use, it is possible that 
methodological differences (relating to, for example, the nature of the samples, follow-up 
period, the severity of the disorders) between the studies being compared could have 
contributed to the differences in the findings. It has also been suggested that substance use 
treatment outcome might be a function of the degree to which the co-occurring psychiatric 
disorder had been treated. Evidence has indicated that use of antidepressants was associated 
with a reduction in substance use, although this association was found to depend on the 
severity of the extant depression (MacKay, 2005).  
It thus appears that the association between psychiatric disorder and outcome after substance 
use treatment might be influenced by several factors. These include sociodemographic factors 
such as i) age and marital status, with relapsers being more likely to be younger and single 
(Landheim et al., 2006), ii) gender, and iii) the kind of psychiatric disorder prevalent, with 
major depression, antisocial personality disorder and generalised anxiety disorder being 
associated with worse substance use treatment outcomes in males only (Compton et al., 2003) 
although the latter associations have not always been consistent (Landheim et al., 2006), iv) 
the severity of the psychiatric disorder, and whether the psychiatric disorder was current, 12-
month or lifetime (MacKay, 2005). Relevant substance use factors include the kind of 
substances used, the severity of the substance use (MacKay, 2005), the onset of a substance 
use disorder (Landheim et al., 2006), the selection of outcome measures, and treatment for 
comorbid psychiatric disorder (MacKay, 2005). 
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 The burden of co-occurring psychiatric disorder and substance use 
Co-occurring psychiatric disorder and substance use has been shown to increase the 
prevalence of associated physical illnesses (Clark et al., 2009), and has been associated with 
increased utilisation of psychiatric disorder treatment services (Clark et al., 2009), with 
consequent potential increased costs in time ( for example, due to lost productivity for the 
individual and the assisting family members) and money to the individual, the involved 
families, medical insurance and the State (Clark et al., 2009). Though some of these costs 
have proven difficult to calculate (Clark et al., 2009), evidence suggests that families of 
individuals with co-occurring psychiatric disorder and substance use provide the primary 
source of funding for treatment (Clark, 1994; Wynaden et al., 2006) and contribute 
additionally to the maintenance of the individuals by devoting time for their care (Clark and 
Drake, 1994; Ostman et al., 2000).  
  
Definitional and diagnostic issues 
The co-occurrence of more than one disorder is commonly referred to as “comorbidity”, a 
term that is literally derived from Latin, with “co” meaning “together” and “morbus” 
meaning “disease” (Wittchen, 1996b). Comorbidity can be the co-occurrence, in one 
individual, of more than one type of the same disorder; for example, the occurrence of two 
types of substance use disorders, or the occurrence of two types of psychiatric disorder. Such 
comorbidity is commonly referred to as homotypic comorbidity.  Comorbidity may also refer 
to the co-occurrence of two or more disorders of different types. For example, an individual 
might be diagnosed with both a substance-related disorder as well as a non-substance-related 
(and usually) psychiatric disorder. The latter co-occurrence is commonly referred to as 
heterotypic comorbidity (Degenhardt et al., 2001). According to this definition, comorbidity 
thus refers to the overlap of phenomena that meet criteria for diagnoses of disorder.  
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However, the term “comorbidity” is also commonly used very loosely to describe either an 
overlap of diagnostic classes, or “any type of association of psychopathological phenomena 
(symptomatic or asymptomatic overlap), irrespective of whether the phenomena met the 
criteria for a mental disorder”, thus including overlap of diagnoses, or of symptoms or 
syndromes of disorders (Wittchen, 1996b: 9; 10).  
Discussion of the definition of comorbidity has included whether to define comorbidity only 
when distinct diagnostic categories can be identified in terms of strict Diagnostic and 
Statistical Manual (DSM, Robins et al., 1989) or similar criteria, or whether symptoms of 
disorders should be considered as relevant to the diagnosis of comorbidity. Further discussion 
has involved what to call the phenomenon.  Chambers (2008a, b) examined the options of 
whether to refer to comorbidity as ‘dual diagnosis’, ço-occurring disorders’ or ‘double 
trouble’ (Chambers, 2008a) or even ‘triple diagnosis’, where appropriate (Chambers, 2008b). 
Comorbid conditions have also variably been defined as a) those that occur at the same time 
(concurrent comorbidity), b) those that have occurred in tandem (sequential comorbidity), or 
c) those that have occurred at some time in the person’s life, though not necessarily at the 
same time (lifetime comorbidity) (Degenhardt et al., 2001). In the absence of specifying the 
kind of comorbidity, cross-study comparisons (for example, comparisons of current versus 
lifetime comorbidity prevalence rates) can be inappropriate  
Discussion of the definition of “comorbidity” has also opened debate on the reliability and 
validity of diagnostic criteria and categories of instruments such as the DSM (Robins et al., 
1989). For example, Wittchen’s (1996b) view held that the notion of comorbidity was a 
consequence of the specific diagnostic categories of the classification systems such as the 
DSM. Comorbidity would thus not exist if it were not for the DSM categories because the 
DSM draws borders to create artificial diagnostic categories (van Praag, 1996). The definition 
and diagnosis of comorbidity at this conceptual level are thus directly dependent on the 
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available and used diagnostic criteria and categories. As a result, different studies using 
different definitions could arrive at different diagnoses. This could increase or decrease the 
chances of deriving a comorbid diagnosis, once again with implications for the comparison of 
prevalence rates of comorbidity across studies.  
The importance of researching co-occurring psychiatric disorder and substance use in 
adolescents and young adults 
Adolescence has been identified as the developmental stage at which onset of psychiatric 
disorder (Kessler et al., 2005), experimentation with substances of use (Fergusson et al., 
2001) and the initiation of substance use (Kandel, 1975) are most likely. These events 
(namely onset of a psychiatric disorder, substance use) can influence, or play a role in 
influencing, future events in the life of the adolescent. For example, adolescents or young 
adults who use substances are at risk of continuing their substance use into adulthood 
(Robertson, 1996) with potentially negative effects on their economic productivity, and social 
relationships. Furthermore, substance use has been associated with risk-taking behaviours in 
other areas of the lives of young (and older) people, including, for example, sexual inhibition 
leading to unwanted pregnancies and sexually-transmitted diseases (Myer et al., 2009b). In 
addition, use of one substance has often been found to be succeeded by use of other 
substances, with the increased possibility of future  use of more dangerous substances, as well 
as the possibility of multiple substance use. (Dawes and Donald, 1994). Substance use in 
young people has also been associated with social dysfunction, school absenteeism and 
academic deterioration, possibly negatively affecting future achievement (Dawes and Donald, 
1994), while the transition from adolescence to adulthood is also often marked by the onset of 
depression. (Reinherz et al., 2000). It is, therefore, necessary to address the adolescent events 
and characteristics, identified as risk factors for future problems, to develop appropriate 
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interventions that will minimise their potential negative effects on the lives of the individuals 
involved. 
Additional evidence has indicated high prevalence rates of substance use amongst 
adolescents, and increasing evidence for associations between psychiatric disorder and 
substance use, although the prevalent symptoms might not always meet diagnostic criteria 
(Deas, 2006). Yet relatively few community studies have been conducted on adolescent 
substance use and associated psychiatric disorder (Langenbach et al., 2010). The studies on 
co-occurring psychiatric disorder and substance use in youth have largely been confined to 
specific mental disorders, and to substance use treatment outpatients or inpatients 
(Langenbach et al., 2010). This has resulted in limited information being available on 
comorbid substance use and psychiatric disorder in young people in inpatient treatment for 
substance use (Langenbach et al., 2010).  
Further advantages for investigating comorbidity in young people would include that, with 
younger individuals, problems associated with recall regarding onset of symptoms might be 
reduced. Younger individuals have a longer opportunity to be followed up than older people. 
Thus well-designed cohort studies have opportunities to observe the course of disorders and 
treatment outcome for longer periods in younger people than would be possible with older 
people. Furthermore, investigating young people can provide opportunities for early 
diagnoses with the potential for early intervention and treatment. 
Operational definitions 
Specific terms have been operationalised for use in this thesis. Co-occurring non-substance 
use psychiatric disorder and substance use will generally be referred to as ’comorbidity’, 
unless otherwise stated. The term ‘psychopathology’ will refer to psychiatric symptoms in 
those cases where a diagnosis had not been made or confirmed, and to psychiatric disorders 
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or mental illness in those cases where a diagnosis had been confirmed. The term substance 
use will be used to refer to any substance use, regardless of whether the substance use 
involves casual use, problematic use, misuse, abuse, or dependence, unless these latter terms 
are specified. 
Rationale 
The research for this thesis was conducted to explore the notion of comorbidity in adolescents 
and young adults within a South African context. In so doing, the thesis addresses a topic that 
has not been extensively researched in developing countries such as South Africa. The studies 
for the thesis also examine the occurrence and nature of comorbid psychopathology and 
substance use in adolescents and young adults, a group that has been recognised as under-
researched with respect to comorbidity (Angold et al., 1999). Furthermore, this thesis 
addresses the need for increased knowledge about comorbidity in both community and 
treatment samples, and provides insights into factors that potentially influence substance use 
treatment outcomes in inpatient substance users. 
Aims (Table 1) 
The general aim of this thesis is:  
To examine the association between psychopathology and substance use in adolescents (aged 
14 to 17 years) and young adults (aged 18 to 30 years). 
The specific aims of the thesis are: 
1. To examine the frequency of occurrence, and nature, of psychopathology, substance 
use, and comorbidity in Cape Town high school students, young adult substance use 
inpatients, and in the broader South African community of young adults. 
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2. To examine the role of sociodemographic factors in comorbid psychopathology and 
substance use in Cape Town high school students, young adult substance use 
inpatients, and in the young adult South African population. 
3. To examine the role of sociodemographic factors and comorbid psychopathology in 
the substance use inpatient treatment outcomes of young adults.  
The thesis objectives are: 
1. To quantify the occurrence of psychopathology, substance use and comorbidity in 
adolescents and young adults. 
2. To measure strengths of association between specific psychopathology and specific 
substances of use. 
3. To identify demographic and/or social factors that influence comorbidity. 
4. To identify demographic and/or social, psychopathology and substance use factors 
that influence substance use inpatient treatment outcomes as defined by treatment 
completion, relapse and treatment resumption. 
Development of the research  
The intention was for the completed thesis to consist of a cross-sectional and longitudinal 
community study of Cape Town high school adolescents and young adults, and a cross-
sectional and longitudinal study of Cape Town adolescent and young adult substance users in 
inpatient substance use treatment. 
The thesis was embarked upon to examine associations between psychopathology and 
substance use in young people, and involved conducting an extensive literature review as 
well as empirical studies.  
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The literature review was conducted to gain an understanding of the issues pertinent to 
research in comorbid psychopathology and substance use in young people, and to identify 
areas of comorbidity research where questions remained unanswered.  
For the empirical components of the thesis, the initial intention was to conduct secondary 
analysis studies involving school-going young people, and primary studies of treatment 
centre-based adolescents and young adults. The school studies were to take the form of a 
cross-sectional study of young people (Grades 8 and 11, and aged 18-24 years), followed by a 
longitudinal study of the original Grade 8 students in Grade 10 and again in Grade 12. The 
treatment centre studies were intended to involve a cross-sectional and, subsequently, a 
longitudinal, study of adolescent and young adult substance-using inpatients, in treatment for 
their substance use and of ages similar to those of the high school students, would be 
conducted. However, during the execution of the thesis plans, two main changes to the 
original protocol became necessary due to circumstances beyond the control of the 
researcher.  
Firstly, the longitudinal study of school-going students was abandoned: it was found, after 
lengthy examination of the data, that the longitudinal data set for the high school students was 
inappropriate for the intended analyses due to its pattern of missing data, despite earlier 
statistical advice that the missing data could be imputed. Subsequent analyses identified that 
the gaps in the missing data were not random, but pertained largely to students who had 
earlier reported substance use. This finding had potential implications for the results of the 
study pertaining to associations between psychopathology and substance use, thus rendering 
imputation of the missing data inappropriate.  
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It was then decided that a secondary analysis of young adults from a different data set 
[namely, from the  South African Stress and Health (SASH) survey] would be completed in 
place of the longitudinal analysis of the high school adolescents.  
Secondly, the upper age limit for participants sampled for the treatment centres and SASH 
studies was extended to 30 years, thus exceeding the age of the oldest student in the high 
schools study. The reasoning was as follows: during the sampling of inpatients, the treatment 
centres selected as study sites experienced an unanticipated and dramatic decrease in 
inpatient admissions, particularly among adolescents and young adults, with one treatment 
centre electing to close its dedicated adolescent chemical dependency unit because of a lack 
of financial viability. Though the reason for this slump was not clear, it coincided with the 
global economic recession, and/or possibly parents could not afford to have their substance-
using adolescent children in protracted inpatient treatment programmes. The implications of a 
reduced sample size were serious for the research plan, and decisions had to be made to 
accommodate the unanticipated circumstances. It was decided that, since the SASH study 
sampled only individuals who were aged 18 years and older, and the inpatient substance use 
treatment centres were not admitting many adolescents younger than 18 years, the age limits 
for the inpatient study sample would be extended. The upper age limit was set at 30 years for 
these samples (inpatient baseline and follow-up studies, and the SASH study), to approximate 
the ages considered for the literature review (already published by this time), and to ensure at 
least adequate sample sizes within the time constraints of the projects involved.  
The different study samples in the thesis, therefore, consist of adolescents aged 14 to 17 years 
and young adults aged 18 to 24 years for the high schools study, adolescents aged 17 years 
and young adults aged 18 to 30 years for the substance use inpatient studies, and young adults 
aged 18 to 30 years for the SASH study. Thus, broadly speaking, the study samples consisted 
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of young adults, remaining faithful to the original plan of investigating comorbidity amongst 
young people. 
Construction of the thesis  
This thesis is built upon four separate studies. Each of the studies examines the association 
between psychopathology and substance use in young people, and includes a dimension that 
sets it apart from each of the other studies (Table 2). Table 1 summarises the studies 
completed for this thesis, detailing the aims and objectives of the various studies, and the 
status of the related journal articles.  
Overview of chapters 
Following this introductory chapter, Chapter 2 provides a review of the recent literature as it 
relates to the association between substance use and psychopathology in general. Particular 
emphasis is placed on the literature relating to the association between substance use and 
psychopathology from the perspective of identified adolescent and young adult substance 
users who have psychiatric problems, as opposed to reviewing the literature relating to the 
substance use problems of identified psychiatric patients. Chapter 3 describes a survey of 
high schools in Cape Town, South Africa, in which Grade 8 and Grade 11 students were 
compared with regards to the association between their substance use and psychopathology. 
In Chapter 4 a study that examined the association between substance use and 
psychopathology in individuals who attended inpatient treatment for substance use is 
presented. Chapter 5 is a follow up of those patients in Chapter 4 who had been in inpatient 
treatment for their substance use, and examines treatment outcomes in relation to 
comorbidity.   Chapter 6 outlines the findings of the South African Stress and Health (SASH) 
survey in relation to the association between substance use and psychopathology in a 
representative, nationwide community survey.  Chapter 7 is the final chapter of this thesis, 
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and presents over-arching conclusions from the studies conducted. In addition, this chapter 
highlights points of discussion from each study, discusses recognized strengths and 
limitations of the studies, and suggests recommendations for future research.  
Thus, in summary, this thesis consists of an introductory chapter (Chapter 1), a literature 
review (Chapter 2), four empirical studies (Chapters 3, 4, 5 and 6), and a discussion chapter 
(Chapter 7). 
Finally, to address the period between completion of the literature review (2008) and 
submission of the thesis for examination, Chapters 1 and 7 include discussion of more recent 
empirical studies, while the Introductions of each of Chapters 3 through 6 include updated 
reviews of more recent relevant literature. 
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Table 1: Aims and objectives of thesis projects  
 
  
STUDY 1 
 
STUDY 2 
 
STUDY 3 
 
STUDY 4 
 
STUDY 5 
 
TITLE 
 
The association between 
psychopathology and 
substance use: a review of the 
literature 
 
Association between 
psychopathology and 
substance use amongst 
school-going adolescents 
in Cape Town, South 
Africa 
 
Young substance users 
in treatment: the 
association between 
psychopathology and 
substance use 
 
Comorbid 
psychopathology and 
substance use: a 
follow-up of inpatient 
substance users in 
Cape Town, South 
Africa 
 
Association between 
psychopathology and 
substance use : results 
from the SASH survey 
 
GENERAL AIM 
 
 
To examine the association 
between psychopathology and 
substance use 
 
To examine the association 
between psychopathology 
and substance use 
 
To examine the 
association between 
psychopathology and 
substance use 
 
To examine the 
association between 
comorbidity and 
substance use 
treatment outcomes 
 
To examine the 
association between 
psychopathology and 
substance use 
 
SPECIFIC AIMS AND 
OBJECTIVES 
 
 
1. To synthesise 
findings from other 
comorbidity research. 
2. To understand recent 
developments in, and 
current status of 
 
1. To determine the 
occurrence and 
nature of 
psychopathology, 
substance use, and 
comorbidity 
 
1. To determine 
the occurrence 
and nature of 
psychopatholo
gy, substance 
use, and 
 
1. To identify 
psychopatholo
gy, substance 
use and 
demographic 
factors that 
 
1. To determine the 
prevalence and 
nature of 
psychopathology
, substance use, 
and comorbidity 
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debate concerning, 
comorbidity. 
3. To identify 
knowledge gaps. 
4. To identify factors 
that influence 
comorbidity. 
 
 
 
 
 
2. To examine the 
role of 
sociodemographic 
factors in 
comorbidity 
 
 
 
comorbidity 
 
 
2. To examine 
the role of 
sociodemograp
hic factors in 
comorbidity 
 
 
 
influence 
substance use 
treatment 
outcomes 
  
 
 
 
 
2. To examine the 
role of 
sociodemographi
c factors in 
comorbidity 
 
 
 
 
STATUS OF ARTICLE 
 
 
Published 
Saban, A. and Flisher, A.J. 
(2010). The association 
between psychopathology and 
substance use in young people: 
a review of the literature. 
Journal of Psychoactive Drugs, 
42(1): 37-47. 
 
Published 
Saban, A; Flisher, A.J. and 
Distiller, G. (2010). 
Association between 
psychopathology and 
substance use among 
school-going adolescents 
in Cape Town, South 
Africa. Journal of 
Psychoactive Drugs, 42(4) 
 
In review 
Drug and Alcohol 
Review 
 
In review 
Journal of Groups in 
Addiction and 
Recovery 
 
In review 
Drug and Alcohol 
Dependence 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
41 
 
Table 2: Comparative summary description of thesis studies 
 
  
STUDIES 
 
DESCRIPTION 
 
High school students 
(STUDY 2) 
Baseline 
Inpatient substance users 
(STUDY 3) 
Follow-up 
Inpatient substance users 
(STUDY 4) 
 
South African Stress and 
Health (SASH) study 
(STUDY 5) 
 
SAMPLE 
 
 
 
DEMOGRAPHICS 
Age 
Gender 
Racially classified social group (RCSG) 
Education 
Marital status 
 
 
Random 
Local, Cape Town 
 
 
12-24 years 
Males and females 
All 
Grades 8 and 11 
Not married 
 
 
Consecutive 
Local, Cape Town 
 
 
17-30 years 
Males and females 
White, Coloured, Indian 
Highest level completed 
Married/Not married 
 
 
Consecutive 
Local, Cape Town 
 
 
17-30 years 
Males and females 
White, Coloured, Indian 
Highest level completed 
Married/Not married 
 
 
Random 
National, South Africa 
 
 
18-30years 
Males and females 
All 
Highest level completed 
Married/Not married 
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Employment 
 
PSYCHOPATHOLOGY 
Instrument
†
 
 
 
 
 
Diagnoses: 
   
 
 
 
SUBSTANCE USE 
Instrument 
   
 
 
Not applicable 
 
 
Harvard Trauma Scale, 
Beck Depression 
Inventory 
Zung Anxiety Scale 
 
 
Current PTSD 
Current Depression 
Current Anxiety 
 
 
 
Questionnaire 
 
 
Employed/Unemployed 
 
 
C-DIS IV 
 
 
 
 
 
Any 12-month 
 
 
 
 
 
Questionnaire and C-DIS 
IV 
 
Employed/Unemployed 
 
 
C-DIS IV 
 
 
 
 
 
Any 12-month 
 
 
 
 
 
Questionnaire and C-DIS 
IV 
 
Employed/Unemployed 
 
 
CIDI 
 
 
 
 
 
12-month and lifetime  
Mood and anxiety disorders 
 
 
 
 
CIDI 
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Substances 
   
 
Ever smoked a whole 
cigarette 
Ever had more than sip  of 
alcohol 
Ever used cannabis, 
inhalants 
 
 
Any 
 
 
 
Any 
 
 
Ever smoked >100 cigarettes 
Ever used alcohol, cannabis, 
other or extra-medical drugs 
 
 
 
†
 C-DIS IV: Computer-assisted Diagnostic Interview Schedule for Diagnostic and Statistical Manual IV 
  CIDI: Composite International Diagnostic Interview 
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Abstract--This article reviews the recent literature on the association between psychopathology 
and substance use in young people. An electronic literature search, using PSYCINFO/PSYCLIT 
and PUBMED/MEDLINE, yielded 93 English-language articles for the period 1990-2008. Of 
these articles, 89 (95.7%) reported studies conducted in developed countries, 57 (61.3%) had 
community or population samples, 38 (40.9%) had sample sizes ranging from 500 to 2000 
subjects, and 33 (36.7%) had sample sizes of between 50 and 500. The most commonly-used 
assessment tool (n =29, 31.2%) was the Diagnostic Interview Schedule. Evidence exists for 
associations between depression and cigarette smoking, between anxiety and cigarette smoking, 
and between anxiety and alcohol use. The strength of the associations is increased with greater 
frequency and quantity of substance use, and is influenced by the nature of the psychopathology, 
the specific substances of use, and demographic factors such as gender, age or developmental 
stage. The need for more longitudinal studies on community populations, and increased access to 
funds and resources for researchers in developing countries is highlighted. 
 
 
 
Keywords--Psychopathology; Substance use; Comorbidity; Young people  
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Various studies have suggested that the co-occurrence of substance use and 
psychopathology can be reached via a variety of pathways. For example, evidence for a statistical 
association between substance use and psychopathology would imply that a dynamic links the 
prevailing conditions. Thus, the one condition might have caused the other, triggered an existing 
predisposition for the other, increased the risk of developing the other condition, or changed the 
course of the other condition. The most frequently cited explanations for co-occurring substance 
use and psychopathology include that of causality based on a temporal relationship, self-
medication, where attempts are made to alleviate the symptoms of mental illness by using 
substances, risk factors for either the substance use or psychiatric illness, or that factors may 
mediate or moderate the association between co-occurring or comorbid substance use and 
psychopathology (Degenhardt, Hall & Lynskey 2001). 
Several reviews address comorbid substance use and psychopathology. Many of these 
were published more than a decade ago (Bukstein, Brent & Kaminer 1989; el-Guebaly 1990; 
Woody, McClellan & O’Brien 1990; Wilens & Biederman 1993), or examine associations 
between specific psychopathologies and specific substances of use and abuse (Gerstley et al. 
1990; Kushner, Sher & Beitman 1990; Angold & Costello 1993; Glassman 1993; Schuckit and 
Hesselbrock 1994). The more recent review articles on comorbid substance use and 
psychopathology confine themselves to a subset of substances and psychiatric disorders. For 
example, Rey et al. (2004) examine only cannabis use and juvenile psychiatric disorder; 
Upadhyaya et al. (2002) examine only adolescent cigarette smokers; Weinberg & Glantz (1999) 
examine only child psychopathology risks for drug abuse; Angold, Costello &Erkanli (1999) 
review only population  comorbidity studies in relation to the psychiatric disorders that are 
regarded as common in children and adolescents; Armstrong & Costello (2002) review only 
community studies on adolescent substance use and psychiatric comorbidity; and Jane-Lopis & 
Matytsina (2006) review only studies from high-income countries. 
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We undertook this literature review to synthesise the findings of previous research, and to  
understand the recent development and current status of the broader debate concerning the 
association between substance use and psychopathology in general, with a view to identifying 
areas of research that require further investigation. This was done to provide a springboard from 
which to launch a series of studies in a developing country where the association between 
psychopathology and substance use has had limited investigation, particularly amongst the youth. 
With these aims in mind, the articles selected for review were not limited to particular substances 
or psychiatric disorders, or to specific settings or countries. Instead, this review highlights those 
issues relating to any comorbid psychopathology and substance use that are pertinent to 
adolescents and young adults, emphasizing the most common associations that have been 
identified in both community and clinical settings, and the salient factors that impact on these 
associations. As such, the present review explores the geographical locations in which empirical 
studies have been conducted, the sizes and kinds of samples used, the instruments used to assess 
psychopathology and substance use, the kinds of psychopathology and substance use 
investigated, the statistical analyses employed, and the outcomes discussed as they pertain to 
associations between psychopathology and substance use. 
 
METHODS 
We searched for English language articles, using the PUBMED/MEDLINE and 
PSYCLIT/PSYCINFO databases and the keywords “comorbidity and substance use”, “comorbid 
substance use and psychopathology”, “substance use and psychopathology” and “dual-diagnosis”. 
Online links, related articles and the reference lists of relevant published articles were sourced, 
and key researchers in the field were consulted.  
Articles were sourced from the period 1990-2008. The year 1990 was selected as the 
starting date for the literature search since Bukstein, Brent & Kaminer’s (1989) review was 
completed the prior year, and appears to have identified and summarized the major role players 
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comprehensively, capturing the important conceptual and clinical issues relevant to the debate to-
date.  
The inclusion criteria for article selection were empirical studies, published in English 
between 1990 and 2008, that have been done in the area of substance use and associated 
psychopathology, using adolescent and young adult samples within the ages of approximately 14 
to 25 years.  All articles relating exclusively to the comorbidity of psychotic disorders with 
substance use were excluded from consideration for the present literature review, unless these 
articles referred to research that included the investigation of non-psychotic disorders as well. The 
psychotic disorders were excluded from the present review because the association between 
substance use and the psychotic disorders is very common and has been well-documented (Castle 
& Murray, 2004). In those studies that used clinical or treatment samples, articles that referred to 
patients in treatment for substance use were selected, as opposed to selecting articles relating to 
patients who were in treatment for psychiatric disorders. Sourced articles were reviewed with 
reference to the geographical location of the study, sample size, study design, types of 
psychopathology and substance use investigated, assessment instruments used, and study 
outcomes (Tables 1-3 are available on request from the primary author). 
 
RESULTS 
Ninety-three articles were found to be relevant for review.  
Geographic location of research 
The large majority of articles reviewed relate to studies that were completed on the North 
American continent, with 67 articles (72%) from the United States of America and two (2.2%) 
from Canada. Two articles each (2.2%) were from South Africa and the United Kingdom, five 
(5.4%) from Australia, four articles each (4.3%) from the Netherlands and New Zealand, three 
(3.2%) from Germany, and one article each (1.1%) from Brazil, Taiwan, Italy and Switzerland.  
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 Sampling strategies 
Most of the articles reviewed (n = 57; 61.3%) used community or population samples, 
while 28 (30%) articles used treatment samples. Eight articles (8.6%) used samples that included 
both community members and patients, while one study sample (1.1%) consisted of only 
substance-using army draftees. Fifty-five (59.1%) studies used a cross-sectional and 38 (40.9%) 
used a longitudinal design. Relatively few studies had sample sizes larger than 2000 (n = 22; 
23.7%), but five studies (5.6%) had sample sizes between ten thousand and more than twenty 
thousand.  Several of the studies (n = 38; 40.9%) had sample sizes ranging from 500 too 1999, 
while 33 (35.4%) had sample sizes of 50 to 500. Two of the studies (2.2 %) had sample sizes of 
fewer than 50 subjects with Horner and Scheibe (1997) having a sample size of 30.  
Sample demographics 
Race/Ethnicity.  
In 20 (21.5%) articles, samples had a distinctly significant majority of one population 
group. Breslau, Kilbey &Andreski (1991), Rounsaville et al. (1991), Breslau, Kilbey &Andreski 
(1993), Dunn al. (1993), Kendler et al. (1993), Fals-Stewart & Angarano (1994), Grilo et al. 
(1995), Kandel et al. (1997), Biederman et al. (1997), Horner & Schiebe (1997), Breslau & Klein 
(1999), Costello et al. (1999), Disney et al. (1999), Greene & Biederman (1999), Reinherz et al. 
(2000) and Goodman et al. (2003) had samples that were largely or exclusively White. Compton 
et al. (2003) and Miller- Johnson et al. (1998) had samples that were largely African-American, 
Novins et al. (1996) had a sample consisting of only American Indian patients, while Obando et 
al. (2004) sampled only Costa Ricans. Though these samples were not necessarily biased, in that 
they might have truly been representative of the populations from which they were drawn, they 
provide for limited conclusions beyond the ethnic composition of the samples. 
Age. The ages of subjects varied greatly. Some subjects were selected at birth for later 
follow-up in a longitudinal study (Fergusson, Lynskey &Horwood 1996; Hayatbakhsh et al, 
2007) while some studies investigated subjects within a relatively narrow age range (14-15 years, 
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in Patton et al. 1998, or all 17 years old in Disney at al. 1999). Most of the studies (66.7%; n = 
62) investigated largely children or young adults. Of the remaining studies, 29 (31.2%) had their 
age range lower limit in the adolescent or young adult sector.   
Assessment and diagnosis. The most commonly used assessment and diagnostic 
instrument (n=29; 31.2%) was the Diagnostic Interview Schedule (DIS; children and adult 
versions). Thereafter the most common means of assessment were questionnaires, self-reports, 
rating scales and structured interviews (n=28; 30.1%). Some studies elected to make their 
assessments, particularly assessments of psychopathology, by means that require clinical 
judgement (Kendler et al. 1993), while other studies used instruments such as the DIS (King et al. 
1996; Breslau et al. 1997; Kandel et al.1997; Roberts, Roberts & Xing 2007) and Composite 
International Diagnostic Interview (CIDI) (Kessler et al. 1997; Ross & Shirley 1997; Lieb et al. 
2002; Zimmermann et al. 2003; Wittchen et al. 2007) which allow for use by lay interviewers. In 
some cases the same instrument was used to assess both psychopathology and substance use 
because the instrument allowed for this to be done (for example, Anda et al. 1990; Schuckit, 
Irwin & Brown 1990; Fals-Stewart & Angarano 1994; Merikangas & Klein 1994; Lieb et al. 
2002; Zimmermann et al. 2003; Roberts, Roberts & Xing 2007; Wittchen et al. 2007). This 
occurred particularly in studies where the DIS or CIDI was used as the primary diagnostic 
instrument (for example, Glassman et al. 1990; Regier et al. 1990; Deykin, Buka & Zeena 1992; 
Breslau, Kilbey & Andreski 1993). In some studies, more than one instrument was used to assess 
either substance use (for example, Riggs et al. 1995) or psychopathology (for example, Sonne, 
Brady & Morton 1994; Kandel et al. 1997), or a subscale or module of an instrument like the DIS 
was used to assess the pathology or substance use of interest (for example, Henry et al. 1993; 
Fals-Stewart & Angarano, 1994). 
In several studies, more than one instrument was used to assess psychopathology (for 
example, Dunn et al. 1993). This was the case both in those studies in which more than one kind 
of psychopathology was being assessed (for example, Dunn et al. 1993; Fals-Stewart & 
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Angarano, 1994), as well as in studies where there was one major pathology of interest (Sonne, 
Brady & Morton 1994). For example, in Boyle et al. (1992) any psychopathology was of interest, 
and the Youth Self Report and Child Behaviour Checklist as well as structured, self administered 
questionnaires were used to assess these disorders. Similarly, Sonne, Brady & Morton et al. 
(1994) used the SCID, as well as Hamilton’s Depression Rating Scale and the Young Mania 
Rating Scale. More examples of multiple instrument use to assess either pathology or substance 
use are listed in Table 2. 
Several studies investigated more than one type of substance use or abuse (for example, 
Deykin & Buka, 1992; Henry et al.1993; Biederman et al. 1995). Thus, one study might attempt 
to determine any substances of use (for example, King et al. 1996; Novins et al. 1996; Brooner et 
al. 1997), while another would test for only one type of substance of use or abuse (for example, 
Moscato et al. 1997; McGee, Williams & Stanton 1998; Patton et al. 1998). Other studies looked 
at a variety of different, but defined, substances of use, for example, tobacco, alcohol, cannabis 
(Degenhardt, Hall & Lynskey 2001). Still other studies, for example Ferdinand, Blum & Verhulst 
(2001), looked at some defined substances of use and abuse, namely tobacco and alcohol use, as 
well as any other drug use. It is, however, quite clear that, of those studies that investigated 
specific substances of use and abuse, tobacco (n=29; 32.2%) and alcohol (n=45; 50%) were the 
most frequently emphasized. Several studies used more than one instrument to assess substance 
use. Thus, for example, even though Kushner, Sher & Erickson (1999) assessed only alcohol use, 
they used the DIS as well as the Short Michigan Alcohol Screening Test (S-MAST).  
Statistical analyses 
The main statistical analyses used varied greatly, from some studies concentrating largely 
on descriptive statistics (for example, Rounsaville et al. 1991; Sonne, Brady & Morton 1994; 
Grilo et al. 1996), t-tests and chi-squared tests (for example, Araujo & Monteiro 1995; Hovens, 
Cantwell & Kiriakos 1994;) to others that used a variety of comparatively highly sophisticated 
statistical techniques (for example, Brook et al. 1996; Fergusson, Lynskey & Horwood 1996; 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 52 
Kendler et al. 1993; Patton et al. 1998). Most commonly, regression analyses were used, while 
similar associations are illustrated using discriminant function analyses in a few studies (Brown et 
al. 1996; King et al. 1996; Brooner et al. 1997).  
Findings 
 This section records the outcomes of the reviewed studies, with regards to the 
associations between psychopathology and substance use, and the identified salient 
sociodemographic and other factors that appear to impact these associations. Particular attention 
is paid to the roles of age and gender on comorbid associations, to associations between 
psychopathology and cigarette smoking, alcohol and cannabis use, as well as to temporal 
associations among these. 
Age. Certain patterns have emerged across ages and stages of development. For example, 
according to Henry et al. (1993) pre-adolescent conduct problems and depressive symptoms (at 
age 11 years) predicted multiple drug use by age 15 years, with the depressive symptoms 
appearing to have a more significant role in this association than the conduct problems. Sonne, 
Brady & Morton. (1994) found that 20 years of age is significant in that those who used 
substances were more likely to develop mood disorders with onset before 20 years of age. On 
examining 12-18 year olds, Brook et al. (1995) found that childhood personality traits were 
associated with adolescent personality traits as they pertained to substance use. Similarly, Grilo et 
al. (1995) found that childhood conduct disorder was associated with adolescent substance use, 
while Ferdinand, Blum & Verhulst (2001) found that behavioural and emotional problems in 
adolescence related to substance use in young adulthood. It thus appears that developmental stage 
might play an important role in the association between psychopathology and substance use, and 
that the role of developmental stage could possibly exceed that of chronological age. However, 
unless stages in between those of the suggested developmental stages are also examined for an 
association of this nature in equivalent studies, the validity and relevance of the developmental 
stages in contrast to chronological age remain unclear. 
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Gender. Gender appears to play a significant role in the course and development of some 
pathologies. For example, Glassman et al. (1990) found that males are more likely than females to 
have ever smoked and been successful in smoking cessation, but that these gender differences 
tend to disappear in the presence of comorbid major depressive disorder or lifetime diagnosis of 
major depression (MD). More evidence for the role of gender in the association between 
psychopathology and substance use is provided by the following studies. Brooner et al. (1997) 
found that their male and female opioid dependents differed markedly, with females being more 
likely to have Axis I disorders and males more likely to have personality disorders. Henry et al. 
(1993) found that childhood conduct problems and depressive symptoms predicted adolescent 
multiple drug use in males, while in adolescent females, only childhood conduct problems were 
strongly associated with substance use.   Hofstra et al. (2001) found that childhood aggressive 
behaviour predicted adult alcohol misuse or dependence in females, but not in males. Hovens, 
Cantwell & Kiriakos (1994) found that male substance abusers were more likely to have conduct 
disorders while female abusers were more likely to have anxiety disorders. Deykin & Buka 
(1997) found that in males, substance abuse preceded onset of PTSD while in females the reverse 
occurred. Costello et al. (1999) found a strong association between depression and substance use 
in males, as well as a strong association between conduct disorders and substance use in females. 
Similarly, Henry et al. (1993) found that only in females at age 15 years was there a strong 
association between conduct problems and multiple substance use. Moscato et al. (1997) found 
that females were more likely to have depressive symptoms while males were more likely to have 
alcohol problems. They also found that depressive symptoms preceded and predicted alcohol 
problems in females who initially had no alcohol problems, but that no such significant 
relationship existed in males. This result concurred with the finding of King et al. (1996) that 
depression leads to alcohol abuse in females.  
Yet the role of gender in comorbid psychopathology and substance use remains unclear 
because of several conflicting findings. For example, Fergusson, Lynskey & Horwood (1996) 
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found no significant differences between males and females as regards comorbid depression and 
nicotine dependence, while Costello et al. (1999) found a strong association between depression 
and substance use but only in males. Similarly conflicting findings are illustrated by the findings 
of the following studies. Shrier et al. (2003) found that anxiety symptoms were most common in 
females but that these were not associated with substance use disorders. Fergusson, Lynskey & 
Horwood (1996) found no difference between males and females regarding their comorbid 
depression and nicotine dependence at age 16 years.  
Association between psychopathology and smoking. Several of the studies reviewed 
have identified an association between depression and smoking. Of these, 11 studies were 
longitudinal studies which used community samples (Anda et al, 1990; Glassman et al., 1990; 
Breslau, Kilbey & Andreski 1993; Fergusson, Lynskey & Horwood 1996; Breslau et al. 1998; 
McGee, Williams & Stanton 1998; Patton et al. 1998; Brook, Cohen & Brook 1998; Johnson et 
al. 2000; Escobedo, Reddy & Giovino 1998; Kessler et al. 1996; King, Iacono & McGue 2004; 
Costello et al. 1999) while the remainder were cross-sectional studies which used community 
samples either in clinical settings (Riggs et al. 1995) and/or or from the community (Breslau, 
Kilbey & Andreski 1993; Kendler et al. 1993; Fernander et al. 2006; Kessler et al. 1996). Anda et 
al. (1990) found that with an increase in the level of depression (as measured by the CES-D 
score), the prevalence of smoking increased. They also found that those people with increased 
CES-D scores were less likely to have quit smoking and, as found by Glassman et al. (1990), 
were less likely to quit smoking over time. A strong association between major depression and 
smoking was reported by Kendler et al. (1993). Fergusson, Lynskey & Horwood (1996) identified 
a significant association between nicotine dependence and affective disorder, particularly for 
depression and depressive disorder, in 16 year olds. The presence of this association was later 
borne out by the results of Breslau et al. (1998), McGee, Williams & Stanton (1998), Brook, 
Cohen & Brook (1998) and Fernander et al. (2006) who similarly found associations between 
smoking and depression, while Escobedo, Reddy & Giovino (1998) reported that depressed 
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adolescents were more likely to initiate smoking, Patton et al. (1998) established an association 
between depression, anxiety and smoking initiation, and Johnson et al. (2000) found an 
association between anxiety disorders and cigarette smoking. 
It thus appears that there is strong evidence for an association between depression and 
cigarette smoking, and possibly between anxiety disorders in general and cigarette smoking. It 
also seems clear that with increased levels of depression, there is likely to be an associated 
increased prevalence of cigarette smoking, an increased chance of smoking initiation, and a 
decreased likelihood of smoking cessation both in the short and long term.  
Association between psychopathology and alcohol use. Several studies explore the 
association between psychopathology and alcohol use. Some of these studies used cross-sectional 
community samples (Schuckit, Irwin & Brown 1990; Kendler et al.1993; Merikangas, Risch & 
Weissman 1994; Schmidt 1995; King et al. 1996;; Kessler et al. 1997; Kushner, Sher & Erickson 
1999; Dixit & Crum, 2000; Rodgers et al. 2000; Hofstra, van der Ende & Verhulst 2001; 
Steinhausen & Metzke, 2003; Goodman et al. 2003; Grant et al. 2004), some used longitudinal 
community samples  (Rohde, Lewinsohn & Seeley 1996; Brown et al. 1996; Moscato et al. 1997; 
Costello et al. 1999 and Ferdinand, Blum & Verhulst 2001), while  Clark et al. (1997) used a 
convenience sample of a treatment experimental group and voluntary controls, and Dunn et al. 
(1993) and  Compton et al. (2003) used  cross-sectional treatment samples of substance users.  
The results of these studies indicate that, in general, there appears to be little doubt that 
anxiety symptoms commonly occur on cessation of alcohol drinking (Schuckit, Irwin & Brown 
1990) However, as indicated by Roberts et al. (1999), these anxiety symptoms are often 
temporary and are specifically related to the abstinence and subsequent withdrawal. As such, the 
latter authors strongly recommend that one delay making a diagnosis of comorbid anxiety and 
problem drinking, as the anxiety symptoms commonly remit with time. Thus, it is important to 
distinguish between anxiety symptoms that are associated with, or constitute, a psychiatric 
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diagnosis of anxiety, and those anxiety symptoms that are commonly as a result of alcohol 
abstinence, and are temporary.  
Regier et al. (1990) found that there was a greater association between anxiety disorders 
and other drugs than between anxiety and alcohol dependence. Nace, Davis & Gaspari (1991), 
when examining a group of 100 inpatient substance users found that those with personality 
disorders were more likely to abuse alcohol. Merikangas & Klein (1994) looked at non-
hospitalised subjects with Major Depression, and found that anxiety disorders preceded 
alcoholism in 65% of those who were diagnosed with comorbid anxiety and alcoholism. Schmidt 
(1995) found that patients admitted for psychiatric problems such as anxiety, depression, 
hostility, phobia, somaticism, paranoia and obsessive-compulsive disorders were more likely than 
non-admitted community members to have been drinking heavily. In 1997, Biederman et al. 
reported that anxiety and depression were weakly associated with the development of subsequent 
problematic substance use. Clark et al. (1995) examined 43 adolescents who were hospitalized for 
alcohol abuse or dependence and found that, o  these patients, 40% had at least one anxiety 
disorder, of which social phobia was the most common. This anxiety prevalence rate was also 
higher than that in the control group of volunteer community adolescents. Similarly, Araujo & 
Monteiro (1995) found an association between depression, generalised anxiety and alcohol use. In 
contrast, however, Shrier et al. (2003) found that anxiety symptoms in a convenient clinical 
sample were not associated with substance use disorders. 
Some studies examined the association between psychopathology other than anxiety, and 
the use of alcohol. For example, Deykin, Buka & Zena (1992), on examining a group of alcohol 
and other substance users in treatment, found a greater association between substance abuse and 
depression as compared with that in the community. Dunn et al. (1993) found an association 
between depression and PTSD and alcohol use. Clark et al. (1997) found that alcohol dependence 
led to an increased prevalence rate of other psychiatric problems, and particularly that of major 
depression and PTSD, with the Major Depression and PTSD being able to either follow or 
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precede the alcohol use disorder. Biederman et al. (1995) found that the presence of ADHD with 
childhood onset increased the lifetime risk of drug or alcohol abuse or dependence. Brown et al. 
(1996) established an association between Conduct Disorder and alcohol and other drug use in a 
largely White sample of substance users in treatment.  
Since the abovementioned studies used largely treatment samples, it is important to 
compare the results they obtained with the results of those studies that examined community non-
clinical samples particularly since comorbid psychopathology and substance use is more likely to 
be found within a treatment setting, both as a result of Berkson’s Bias and because people with 
one extant condition are mathematically more likely to seek treatment for a second condition (Du 
Forte, Newman & Bland 1993). Bearing this in mind, we find that Kendler et al.’s (1993) study of 
female twins reported a highly significant association between Major Depression and alcoholism, 
even though they were unable to establish which disorder was the preceding one. Breslau et al. 
(1997) found a similar association when examining mothers from three study sites in the USA. 
The latter authors concluded that a significant association exists between PTSD and lifetime 
occurrence of MD, anxiety disorders, alcohol abuse or dependence, and that PTSD increased the 
risk for first onset of MD and alcohol abuse or dependence. These results concurred with the 
earlier findings of Rohde, Lewinsohn & Seeley (1996) and the later findings of Dixit & Crum 
(2000). Rohde, Lewinsohn & Seeley (1996) found that other psychiatric disorders can lead to 
alcohol disorder, and that early age onset of alcohol disorder can increase the risk of developing 
comorbid depression and behavioural disorders. Dixit & Crum (2000) found that a history of 
depression increased the risk for heavy alcohol use.  
Kushner, Sher & Erickson (1999) found that the presence of an anxiety disorder or 
alcohol abuse or dependence increased the likelihood of developing the other disorder 
concurrently. In contrast, Costello et al. (1999) found no evidence for an association between 
anxiety disorders and ADHD and the likelihood of substance use. Grant et al. (2004) found a 
strong association between all mood and anxiety disorders and drug dependence. Henry et al. 
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(1993) similarly found an association between conduct problems, depressive symptoms and 
multiple drug use that included alcohol. Boyle et al. (1992) found an association between conduct 
disorder and marijuana, but not with the use of tobacco and alcohol. Hofstra, van der Ende & 
Verhulst (2001) found an association between childhood aggressive behaviour and adult alcohol 
misuse, but only in females. 
In summary, it thus appears that there is evidence for an association between anxiety and 
alcohol use, even though anxiety symptoms appear to be associated with cessation of heavy or 
prolonged alcohol use, while anxiety disorders are more likely to be associated with use of   
substances other than alcohol. In the event of comorbid anxiety and problematic alcohol use, it 
appears that the anxiety is more likely to have preceded the alcohol use. Heavy drinking and 
related disorders appear to be associated with psychiatric problems such as PTSD and depression, 
and, while major depression and alcoholism commonly co-exist, the order in which these 
disorders occur is unclear. 
Association between psychopathology and cannabis. Four studies looked exclusively at 
cannabis in association with mental disorder (Rey, Andres & Krabman 2002; Monshouwer et al. 
2006; Troisi et al., 1998; Hayatbakhsh et al. 2007). Troisi et al. (1998) examined the association 
between any psychopathology (but mainly depression) in a sample of 133 Italian male army 
draftees; Rey, Andres & Krabman (2002) sampled 1261 adolescents from the National Survey of 
Mental Health and Wellbeing (in Australia); Monshouwer et al. (2006) sampled 5551 adolescents 
from the Dutch Health Behaviour in School-aged Children schools survey, while Hayatbakhsh et 
al. (2007) did a secondary analysis of data obtained from the Mater University Study of 
Pregnancy (MUSP) and  followed up newborns until age 21 years. 
Troisi et al. (1998) found that the entire sample of cannabis users, abusers, and 
dependents suffered from a psychiatric disorder. These included Axis I and Axis II disorders, and 
mainly affective (depressive) disorders. This study makes specific mention of the possible effects 
of the nature of the sample and the circumstances under which the sample was selected. However, 
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despite the noted limitations of this study, the results indicate a distinct increase in psychiatric 
disabilities with increased use of cannabis. The Monshouwer et al. (2002) study specifically 
aimed to investigate the role of confounders in the association between cannabis use and mental 
health as measured by the Youth Self Report. Their results, too, demonstrated an increase in the 
strength of the association with increased frequency of cannabis use, but found that gender and 
age were not operative confounding factors in this association. More specifically, this study found 
a strong association between aggressive behaviour and cannabis use, while a weak association 
was found between cannabis use and depressive disorders. The findings of Rey, Andres & 
Krabman (2002) largely concurred with the findings of the other two studies, demonstrating an 
association between cannabis use and depression and behavioral disorders. The Hayatbakhsh et 
al. (2007) study found a significant association between anxiety/depression and cannabis use, but 
found that, though early cannabis use was significantly associated with anxiety/depression in 
young adults, anxiety/depression in adolescence did not predict early cannabis use, regardless of  
possible differences in socioeconomic and demographic factors. 
Several other studies also specified examining the role of cannabis in the association 
between psychopathology and substance use, but included the role of other substances of interest 
in this association (Boyle et al. 1992; Henry et al. 1993; Miller-Johnson et al. 1998; Clark & 
Parker 1999; Costello et al. 1999; Kandel et al. 1999; McGee et al. 2000; Degenhardt, Hall & 
Lynskey 2001; Goodman et al. 2003; King et al. 2004; Wittchen et al. 2007), and varied in terms 
of the results reported. For example, Boyle et al. (1992) found a weak association between 
psychopathology and cannabis use; Wittchen et al. (2007) reported an association between 
cannabis use and all mood disorders; Henry et al. (1993) reported an association between conduct 
problems, depressive symptoms and multiple drug use; Miller-Johnson et al. (1998) reported an 
association between CD and substance use; Kandel et al. (1999) reported an association between 
substance use disorders and psychiatric disorders, while Goodman et al. (2003) demonstrated an 
increased risk for psychiatric disorder if cannabis had been used. Degenhardt, Hall & Lynskey 
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(2001) found an association between cannabis use and mental health problems but found no 
association between cannabis use and anxiety and affective disorders. This is in keeping with the 
findings of Costello et al. (1999) that there is no association between anxiety disorders (or 
ADHD) and the likelihood of substance use. 
These results indicate that the association between psychiatric problems and cannabis use 
is beyond doubt. And despite some contradictory findings, there appears to be clear evidence for 
an increase in the strength of the association between psychopathology and cannabis use with 
increased use and increased frequency of cannabis use.  
Temporal associations between psychopathology and substance use. Schmidt (1995) 
reported that in patient self-reports, some patients said that they drink alcohol because of their 
emotional problems while others say that their substance abuse caused their mental problems. 
Similarly, Rohde, Lewinsohn & Seeley (1996) reported that other psychiatric problems may lead 
to alcohol-related disorders while an increase in alcohol-related problems increases the likelihood 
of psychiatric disorder. These findings clearly demonstrate some of the conflicting results and 
seeming contradictions that have been highlighted in research on the temporal association 
between substance use and psychopathology.  
Further examination of this literature reveals that Costello et al (1999) found that most 
psychiatric disorders preceded substance use, drug use preceded Major Depression in all the cases 
(Hovens, Cantwell & Kiriakos 1994), and that moderate nicotine dependence greatly increased 
the likelihood of developing Major Depression compared with an absence of nicotine dependence 
(Breslau, Kilbey & Andreski 1991). Chong, Chan & Cheng (1999) found that adolescents with 
psychiatric disorders were at risk for substance use disorders, but Patton et al. (1998) found that 
smoking did not predict mental health problems. More specifically, Costello et al. (1999) found 
no temporal association between anxiety disorders and ADHD and the likelihood of substance 
use, Kushner et al. (1999) found that anxiety disorders predicted alcohol use, that alcohol use did 
not predict anxiety disorders, and McGee, Williams & Stanton (1998) found that mental health is 
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only weakly predictive of smoking. Robins & Price (1991) reported that conduct problems can 
lead to substance abuse and depression or anxiety, or first to depression and then to substance use. 
Kendler et al. (1993) found that there was a highly significant comorbidity between major 
depression and alcoholism, yet there was no clear indication as to which disorder was the 
preceding one. Further work by Kendler, Neal et al. (1993) demonstrated a strong association 
between smoking and future episodes of major depression, but concluded that the smoking did 
not cause the major depression and neither did the major depression cause the smoking. As 
previously mentioned, Hovens, Cantwell & Kiriakos (1994) found that drug abuse preceded 
major depression in all their subjects. (The reliability and validity of the latter result should, of 
course be considered in light of the fact that the sample size was relatively small, namely n = 80.) 
The temporal association between substance use and psychopathology becomes further 
highlighted by noting that, for example, according to Sonne, Brady & Morton (1994), substance 
users had earlier onset of mood disorders and were more likely to have mood disorders before the 
age of 20 years. Brook, Cohen & Brook (1998) found that adolescent drug use leads to depressive 
and disruptive disorders in young adulthood. Kandel et al. (1999) found that adolescents with 
lifetime substance use disorders were at as high a risk for psychiatric disorders as adults, and 
Ferdinand, Blum & Verhulst (2001) found that adolescent behavioural and emotional problems 
related to substance use in young adulthood.  Merikangas, Risch & Weissman (1994) found that 
anxiety disorders preceded alcoholism in 65% of their cases with both anxiety and alcoholism. 
These authors also concluded that, despite anxiety appearing more likely to precede alcoholism, it 
did not seem that alcoholism leads to anxiety. Grilo et al. (1995) found that early conduct disorder 
was associated with an increased risk of substance use disorders in later adolescence. Similarly, 
Pardini, White and Stouthamer-Loeber (2007) found that early adolescent conduct disorder 
symptoms increased the risk for increased alcohol use disorder symptoms and alcohol 
dependence by early adulthood. But these findings contradicted those of some other community 
and inpatient studies. For example, Brown et al. (1996) found that conduct disorder was 
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secondary to substance abuse. In contrast, Breslau et al. (1998) found that early conduct problems 
were associated with an increased risk for progression to daily smoking, indicating the possibility 
that conduct problems could lead to an increase in substance use, a finding that was echoed by 
Miller-Johnson et al. (1998). However, Breslau et al. (1998) also found that daily smoking could 
lead to an increased risk of first onset major depression, and that daily smoking was associated 
with an increased risk for first time panic attack (Breslau & Klein, 1999) with this risk being 
higher in current rather than past smokers. Yet Patton et al. (1998) found that even though 
smoking did not predict mental health problems, depression and anxiety predicted smoking 
initiation. Brook, Cohen & Brook (1998) found that adolescent drug use led to depressive and 
disruptive disorders in young adulthood, while Reinherz et al. (2000) found that early attention 
problems were predictive of drug disorders, and that early aggressive behaviour could lead to an 
increased risk of substance use disorders. Rey et al. (2002) reported that use of cannabis increased 
the chances of having emotional and behavioural problems, concurring with Goodman et al. 
(2003) who found that regular smoking, drinking or use of cannabis increased the risk for a 
psychiatric diagnosis. 
These findings highlight the definitive existence of a temporal association between 
psychopathology and substance use, and simultaneously illustrate the conflicting findings of a 
variety of studies with respect to these temporal associations. However, what does seem clear is 
that the temporal association between psychopathology and substance use appears to be governed 
by the kinds of psychopathology and substance use involved, as well as factors such as gender, 
age or developmental stage, age of substance use onset, and frequency of use. 
 
DISCUSSION 
 
 With regards to methodological strategies, this review illustrates an obvious 
predominance of studies on the association between psychopathology and substance use in the 
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developed countries compared with the developing countries, possibly reflecting the relative ease 
of access to funding and the required resources for the research of interest in the wealthier 
countries, and the need for improved access to funds for researchers in developing countries. The 
larger epidemiological studies appear to have gone to great lengths to ensure that the study 
samples were representative of the populations from which they were drawn. The smaller 
community studies, and some patient samples, appear to have relied on random selections from 
specific groups to ensure representivity, while some clinical samples were consecutive selections 
from available groups of interest. A multitude of diagnostic instruments have been used in recent 
research of the association between substance use and psychopathology. Predominance of use of 
the DIS might suggest a tendency to employ the assistance of lay interviewers, thereby reducing 
the need for, and possible increased cost associated with using, limited clinically-trained staff, 
while at the same time being able to obtain comprehensive, valid diagnoses. The variety of 
diagnoses of interest to researchers and the variety of terms used to describe the diagnoses of 
interest are also noted. For example, some studies include dependence and abuse of substances 
when referring to substance use, while others refer to substance use when both occasional and 
regular use is included. The difficulties of comparing the diagnoses of interest become more 
evident when the criteria for assessing diagnoses differ across studies (for example, Biederman et 
al. (1996) who used DSM III criteria to determine the existence of substance use disorders, and  
Costello et al. (1999) who used DSM IV criteria to assess the same diagnoses). It is also evident 
that the studies conducted used largely cross-sectional sampling strategies, indicating a possible 
tendency to limit costs and project duration that would usually be associated with longitudinal 
studies, while at the same time suggesting the need for more longitudinal studies and their added 
advantage of increasing the possibility of identifying causal relationships.  
In unraveling the details of the association between psychopathology and substance use, 
it appears that attempts to establish which factor is the cause and which the effect remain largely 
unresolved. As previously mentioned, this might be an artifact of the study design, with cross-
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sectional studies limiting a conclusion of causality, and longitudinal studies producing 
contradictory findings. A second factor appears to be that the temporal association between 
psychopathology and substance use might be specific to the nature of the psychopathology and/or 
substance use. A third factor might be that of age or developmental stage. Thus, in younger age 
groups the psychopathology might precede the onset of substance use while in older individuals 
the substance use might precede the psychopathology. Fourthly, the association might be 
influenced by gender so that the association might occur in one direction for males and specific 
disorders, and in the opposite direction for females with the same disorders. Lastly, it is possible 
that individuals’ experience of particular associations in their psychopathology and substance use 
might be influenced by genetic predisposition and environmental factors in each case. 
In short, it appears that, while there is little doubt that psychopathology and substance use 
are associated, the nature of this association might be subject to a variety of factors (genetic 
predisposition, environmental factors, gender, severity of symptoms) as well as the nature of the 
interplay between these factors. 
One of the main challenges of comparing studies relating to the association between 
substance use and psychopathology appears to lie in the nature of the studies themselves. As is 
evident in this review, the studies examined differed on a variety of levels (demographically, 
sampling, kinds of pathologies and substances of use, assessment, data analyses). These 
differences impact on the kinds and generalisability of results reported, posing further challenges 
for attempts to establish associations between substance use and psychopathology.  
Further attempts to explain associations between psychopathology and substance use 
include that of Upadhyaya et al. (2002) who proposed envisaging the association between 
cigarette smoking and psychiatric disorder as having a bidirectional relationship in which the one 
condition can alter and possibly worsen the other condition in terms of both its symptoms and 
outcome. Another model for understanding comorbid associations is provided by Marsden et al. 
(2000) who proposed that the association between psychiatric symptoms and substance use be 
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envisaged as “conditional” rather than as “directional”, particularly in relation to opiate 
dependence, thus emphasizing the need to take into account the effects of factors other than the 
substance use or psychiatric symptoms which might impact on the association between the 
psychiatric condition and substance use, echoing Patton et al.’s (1998) views of “unmeasured 
liability”.  
It appears that stronger evidence exists for relatively clear associations between some 
comorbidly-occurring conditions and not for others. Certain substances of use and their related 
disorders also appear to have been investigated more frequently than have other substances of use 
and their related psychiatric conditions. This results in certain substances and their associated 
conditions having more, and often more definitive, information available than is found for some 
other substances. The gaps in knowledge can thus be expected to become exacerbated as more 
and new substances of use proliferate, particularly among the youth. 
Conceptual issues and concerns 
Two particular areas of concern need to be addressed with regards to the association 
between psychopathology and substance use, namely that of the definition of comorbidity, and 
the role of potential risk and protective factors. In the first instance, attempts to compare the 
findings of studies on comorbidity or associations between psychopathology and substance use 
require that the nature of the comorbidity be identified as being either lifetime, sequential or 
concurrent comorbidity so as to ensure equitable comparisons. Secondly, the role of substance 
use and psychopathology as potential risk factors for each other across different developmental 
stages must be identified, particularly since the possible effects of factors other than 
psychopathology and substance use appear to be significant in the development of either (or both) 
psychopathology or substance use.  
Methodological issues and concerns 
The above findings demonstrate both the similar and contradictory findings of studies 
which have examined the association between psychopathology and substance use. These 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 66 
findings highlight the challenges which arise when trying to compare the findings of studies 
which used different, and different kinds of, samples, employed different research designs and 
data analyses, identified symptoms and obtained diagnoses of pathology by differing means, and 
were conducted in differing contexts at different times. The review of these studies also 
recognizes the pitfalls of adults trying to recall the onset of childhood illnesses and the 
implications that this has for longitudinal retrospective research. The studies identify the 
importance of distinguishing between behaviour patterns, symptoms of a disorder, and the 
diagnosis of a disorder, both in relation to psychopathology and substance use, because of the 
serious implications of seemingly innocuous behaviour patterns .  
 Strengths 
This review provides a comprehensive and systematic analysis of recent literature 
relating to the association between substance use and psychopathology. It includes all non-
psychotic disorders and all substances of abuse as discussed in the selected articles on empirical 
studies from both treatment and community populations. It highlights the roles of factors that 
have been examined in relation to the association between substance use and psychopathology. 
However, more importantly, this review identifies those areas of research where controversy 
rages and where important questions remain unanswered.  
 Limitations 
This review has been limited to those English-language empirical studies that have been 
published and listed in PUBMED/MEDLINE and PSYCLIT/PSYCINFO. Thus articles that do 
not feature in these data bases, or are written in other languages, could have been missed, 
although it is hoped that some of the former have been accessed via cross-referencing of 
published reference lists. The review has also concentrated on adolescents and younger adults, 
thus excluding those studies that examined children or older adults exclusively. Lastly, the 
reviewed articles examined clinical samples of substance users who have comorbid 
psychopathology, and excluded samples of psychiatric patients with comorbid substance use. 
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CONCLUSION 
The association between substance use and psychopathology is clearly not in doubt, and 
there appears to be global consensus on the need to investigate the finer details of this association. 
The review highlights some of the areas where focused research is required. It appears that more 
longitudinal studies are needed to ameliorate or eliminate the confounding effects of retrospective 
recall regarding the occurrence of significant events, and to gauge the development of the 
association over time. In addition, more studies need to be conducted on community populations 
to overcome the possible confounding effects of a multitude of comorbidly-occurring illnesses in 
patients who are already in treatment for one illness or another.  There appears to be an over-
arching need in research on comorbidity to standardize studies in a way to provide opportunities 
for meaningful comparison between studies. An increase in the number of studies that examine 
the association between substance use and psychopathology in adolescents and young adults 
would seal a recognized gap in current research in this area, particularly in developing countries.  
Once answers to the many questions filter through, it is hoped that the details of the association 
between psychopathology and substance use will become more defined, and that the information 
obtained will be used in meaningful ways to inform policy and effect implementation for the 
greater good of the management and treatment of the affected individuals.  
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Table 1: Reviewed articles: Demographic details 
 
 
AUTHORS; 
STUDY LOCATION 
 
STUDY DESIGN; 
TYPE OF SAMPLE 
 
SAMPLE SIZE; 
AGE  
Anda et al., 1990, 
USA 
Cross-sectional; 
Community sample 
N = 2963; 
Ages 24-74yrs 
Glassman et al., 1990, 
USA 
Cross-sectional; 
retrospective 
Community and Institutional sample;  
ECA Study sample. 
 
N=3213 
Mean age 42.5yrs; 
18% betw. 18 and  24yrs 
Regier et al.,1990, 
USA 
Cross-sectional; 
Retrospective 
Community and Institutional sample; 
ECA Study sample 
 
 
N=20 291; 
Ages > 18yrs 
Schuckit et al., 1990; 
San Diego, USA 
Consecutive; 
Treatment sample of primary alcoholics; 
Only ♂s, in treatment  for alcoholism. 
 
N= 171; 
Mean age 45.1+10.56yrs 
Breslau et al., 1991; 
Michigan, USA  
Cross-sectional; random sample; all HMO members; 80.7% White N = 1007;  
Ages 21-30yrs 
Nace et al; 1991; 
USA 
Consecutive sample; 
Treatment sample of inpatient substance abusers 
N = 100 
Age > 18yrs 
Robins and Price, 1991; 
USA 
Community sample; ♀♂s; 
Part of ECA Study; 
Multi-site 
N=19482 
Age > 18 years 
Rounsaville et al., 1991; 
Connecticut, USA 
 
Cross-sectional sample; 
Retrospective 
Treatment sample of inpatient and outpatient adults, seeking treatment for cocaine abuse; 64% White; 
69% ♂ 
N = 298 
Ages > 18yrs 
Mean age 27.7yrs 
 
Boyle et al., 1992; 
Ontario, Canada 
Cross-sectional; 
Population sample; 
FU after 4 yrs; 
Prospective cohort study. 
Sample from Ontario Child Health Study ; ♀♂ 
N = 726 
12-16yrs old at baseline; 
FU ages 16-20yrs old 
Deykin et al., 1992; 
Massachusetts,USA 
Cross-sectional; 
Treatment sample; very few on Medical Insurance 
N=223; 
Ages 15-19yrs 
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Breslau et al., 1993; 
USA 
Cross-sectional; 
Random sample. 
Community sample; all members of an HMO; 80.7% White; 
61.7% ♀. 
N=1007; 
Ages 21-30yrs 
Breslau et al., 1993; 
USA 
Cross-sectional 
Prospective study; 
FU after 14 months; 
81% White; 
Community sample 
N=995; 
Ages 21-30 yrs 
Dunn et al., 1993; 
USA 
Cross-sectional; 
Treatment sample of substance users/abusers; 
Sample 74% White; 
All ♂s 
N=265; 
Ages 23-73yrs 
(Mean age 44.33yrs) 
Henry et al., 1993; 
New Zealand 
Cohort; 
Part of Dunedin Multi-disciplinary Health+ Development Study; Community sample 
N=752; 
Baseline age=11yrs; 
FU at 15yrs. 
Kendler et al., 1993;  
USA 
Cross-sectional; 
Retrospective; 
Community sample; All ♀; All twins 
N=2163 
 
Mean age 30.1 + 7.6yrs 
Kendler et al., 1993; 
Virginia, USA. 
Cross-sectional; 
Retrospective; Population sample; 
All twins; All ♀; All white 
N = 1566; 
Mean age = 30.9 + 7.1 years 
Lehman et al., 1993; 
USA 
Cross-sectional; 
Consecutive; 
Treatment sample of dual and single diagnosis mentally ill patients and SUD patients. 
Inner city sample; all English-speaking 
N = 314; 
Age 18-65 yrs. 
Fals-Stewart &Angarano, 
1994; 
NY, USA 
Cross-sectional;  
Treatment sample from substance use treatment centre; 
70% White; mostly male 
N = 217; Age range 17-50yrs; 
Mean age 25.6yrs 
Hovens et al., 1994; 
Burbank, LA, USA 
Prospective; 
Clinical 
♂♀; 
2 groups(not matched for age or gender; 
i) Substance abusers 
ii) Non-abusers, but had a psychopathology; 
N=80 
Age < 18yrs 
Merikangas et al., 1994; 
USA 
Family study; 
Non-hospitalised subjects with MD, hospitalised subjects with MD; Normal community control 
group;Used data from a family study 
N = 215 probands matched for sex and 
age 
 
 
Sonne et al., 1994 
South Carolina, USA 
Cross-sectional;  
psychiatric patients 
N = 50; 
Age > 18yrs 
Araujo&Monteiro, 1995; 
Brazil 
Cross-sectional; 
Only ♂s. Treatment sample, inpatients+outpatients. 
N=166. 
Aged >15yrs 
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Biederman et al., 1995; 
USA 
Cross-sectional; 
Consecutive sample of adults; 
All subjects had childhood onset of ADHD. All positive for ADHD. Pre-existing study group used as 
comparison. 
N=120; 
Age > 18yrs; 
 
Brook et al., 1995; 
NY, USA 
Cohort;  
Longitudinal; F-U over 4yrs; 
Community; 93% White; 
N=976; 
Ages 5.5-22yrs old 
Grilo et al, 1995; 
Yale Psychiatric Institute, 
USA  
Cross-sectional; 
Consecutive sample; ♂♀s. 
Psychiatric patients; (Private hospital); Mostly Caucasian 
N=138; 
Ages 12-18yrs 
Riggs et al, 1995; 
USA 
Consecutive Rx sample;  
admitted for substance use; All ♂. 
N=99;  
Ages 13-19yrs 
Schmidt,  1995; 
California, USA 
Cross-sectional; 
Psychiatric inpt + outpt sample for exptal gp; 
Community sample for control gp. 
N=406 exptal gp; 
N=718 control gp. 
Age18+ yrs 
Triffleman et al; 1995; 
San Francisco, USA 
Cross-sectional; consecutive;; 
Inpatient Rx sample; all substance abusers; all male. 
N = 46; 
Mean age = 44.9yrs 
Brook et al., 1996; 
NY, USA 
Cohort;  
Prospective; F-U after 8yrs, 10yrs, 16yrs;  
Community; 91% White 
N=500; 
Ages 5-27yrs old 
Brown et al., 
1996; 
SanDiego, California, USA 
Prospective; Longitudinal over 2 yrs; 
Rx sample; mostly lower to middle-class; 
Rx sample of alcohol + other drug abusers; 80% White; 
N=166; 
Ages 12-18yrs 
King et al., 1996; 
Urban, USA 
Consecutive;  
Clinical sample; 87% Caucasian 
N=103; 
Mean age 15.3yrs 
Fergusson et al., 1996; 
New Zealand 
Longitudinal, 16 yr follow-up; 
Community sample 
N=947; 
0-16yrs 
Novins et al., 1996; 
USA 
Cross-sectional; 
Treatment sample of pts in treatment for substance abuse; 
All American Indian pts; ♂♀s 
N=64; 
Ages 11.7-19.7yrs 
Grilo et al., 1996; 
New Haven, Connecticut, 
USA 
Cross-sectional; 
Treatment sample; All inpts in Rx for psychiatric problems; 
♀♂; Mostly Caucasian; middle-class 
N=165; 
Mean age 15.5yrs 
Kessler et al., 1996;  
USA 
Cross-sectional;  
Community; Part of NCS 
N=5877; 
Ages 15-24years 
Rohde et al., 1996; 
Oregon, USA 
 
Longitudinal; 
Community High school sample; 
Urban+rural; Largely White, Middle class 
N=1507; 
Ages 14-18yrs 
Breslau, Davis et al., 1997;  
USA 
Stratified random sample; 
All ♀s; All mothers; 
3 study sites, differing samples; 
Urban component of sample largely Black, single mothers who did not complete high school 
N=801; 
Mean age 33.1yrs 
Brooner, King et al., 1997; Consecutive; N= 716; 
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Baltimore, Md; USA Outpatient treatment sample of opioid-dependents; 
♂♀s, admitted to methadone maintenance clinic 
Age range 20-58yrs; 
Mean age 34.8 + 6.49 yrs 
Kandel et al., 1997; 
USA; Puerto Rico 
Cross-sectional; 
Random population sample; ♂♀children and their parents; 
78% Caucasian 
N=1285; 
children aged 9-18yrs 
Kessler, Crum et al., 1997;  
USA 
Retrospective;Household survey; 
Community; Sample data from National Comorbidity Survey 
N=8098 with 82.4% response; 
15-54yrs 
Clark et al., 1997; 
Pittsburgh, USA 
Convenient Clinical Exptal group; Volunteer Community Control gp N=251; 
Ages 14-18yrs old 
Biederman, et al., 1997; 
USA 
Prospective;  Urban F-U over 4yrs;Exptal gp=Clinical sample; 
All Caucasian; All ♂ 
N=260;  
Ages 6-17yrs old 
Deykin+Buka, 1997; 
Massachusetts,USA 
Cross-sectional; 
Treatment sample of chemically-dependent adolescents 
N=297(222=♂); 
Ages 15-19yrs. 
Horner&Scheibe, 1997 
USA 
Consecutive;  
Treatment sample; Mostly Caucasian 
N=30; 
16♂; 14♀; Aged 14-19yrs 
Moscato et al.,1997;  
Erie County, NY, USA 
Longitudinal; FU at 3, 4, 7 yrs; 
Community sample 
N=1306; 
Ages 19-85yrs 
Ross & Shirley, 1997; 
Ontario, Canada 
Cross-sectional; Sample from Mental Health Supplement to the Ontario Health Survey; Only ♀s; 
Community sample 
N=4285; 
Ages 15-64yrs 
Breslau, et al.,1998;  
Michigan, USA 
Longitudinal; Prospective; FU over 5yrs; Random sample; 
Treatment sample 
N=974; 
Ages 21-30yrs 
Escobedo et al., 1998;  
USA 
Longitudinal; Prospective; Community 
Part of Teenage Attitudes and Practices Survey (TAPS) 
N = 9135 at baseline; N=7960 at FU; 
Ages 12-18 years 
McGee et al., 1998; 
New Zealand 
Longitudinal; 
Community 
N=773; 
Ages 5-15yrs 
Miller-Johnson et al, 1998; 
USA 
Prospective, longitudinal sample; Community sample; 
♀♂s; All African American 
N=340; 
Grades 6, 8, 10 
Patton et al., 1998; 
Australia 
Cohort; 
School students 
N=2032; 
14-15yrs 
Brook et al., 1998; 
NY, USA 
Longitudinal; F-U over 9yrs; 
Community 
N=975; 
1-10yrs old at baseline 
Troisi et al., 1998;  
Italy. 
Cross-sectional sample; 
All army draftees; All males; All cannabis-only users 
N=133; 
No ages provided 
Breslau and Klein, 1999;  
Michigan, USA 
Cross-sectional community sample; 
Prospective cohort; 
All members of Health Maintenance Organisation (HMO); 
FU over 5 years; 80% White; 62% ♀ 
N = 974 
 
Ages 21-30yrs  
Chong et al.; 1999; 
Taiwan 
 
Cross-sectional; Community sample; 
Random sample of Gr 9 students; 
♀♂s; (PAST study) 
N=774; 
Ages 14-16yrs 
(Mean age 15.23yrs) 
Clark+Parker, 1999; 
Pittsburgh, USA 
Longitudinal; 
Mixed sample(Treatment group +Volunteers); 
Only ♂s; Divided into 2gps viz. 
N=380; 
Ages about 11-16yrs 
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i)Fathers with SUD, 
ii)Fathers without SUD; 
Costello et al., 1999; 
North Carolina, USA 
Longitudinal; 
Community sample; 
Rural; Mostly Caucasian 
N=1420; 
Aged 9-16yrs 
Costello et al., 1999;  
USA 
Longitudinal (predominantly rural); 
Community; 
Part of Great Smoky Mountains study; 
Largely Caucasian because population largely White. Representative sample 
N=1420; 
Age closest to 9, 11 and 13 years; 
Age range 9-16 years, including ages at 
FU 
Disney et al., 1999; 
Minneapolis, USA 
 
 
Cross-sectional sample; 
All reared-together twin pairs from the Minnesota Twin Family Study; 
98% Caucasian 
N = 626 pairs of twins; (674 ♀s; 578♂s). 
All 17yrs old; 
Mean age = 16.93yrs; SD = 0.57 
 
Greene and Biederman, 
1999; 
Boston, USA 
Longitudinal; 
FU after 4 yrs; 
Non-clinical  
Community sample related to a previous Treatment sample; 
All Caucasian; 
All upper or middle class SES. 
N=186; 
♂♀ siblings of a former research gp of 
boys; 
 
Baseline ages 9-18yrs; 
 
FU ages 12-22yrs 
Kandel et al., 1999; 
USA 
X-sectional; ♂♀s; Community sample; 
Probability sample of children and caregivers taken from MECA study. 
N=401; 
Ages 14-17yrs. 
Kushner et al., 1999;  
USA (Midwestern Univ.) 
Prospective; Community sample of University students; 
Baseline = 1
st
 yr university; FU at 4 and 7 yrs 
N= 489; 
Mean age 18.6yrs 
Roberts et al., 1999; 
Cape Town, SA 
Consecutive; 
Clinical 
N=146; 
Mean 38.5+8.49yrs 
Rao et al., 1999; 
USA 
Cross-sectional,; 7yr F-U; 
Clinical sample 
N=63; 
Mean Age 15yrs 
Johnson et al., 2000; 
NY, USA 
Prospective, Longitudinal; 
Community 
688; 
Mean age 14-22yrs 
Dixit&Crum, 2000; 
Baltimore, USA 
Prospective; 1-yr follow-up; Community; 
Part of ECA Study; only ♀s 
N=1383;  
Ages !8yrs and older 
Marsden et al., 2000; 
UK 
Cross-sectional; 
Treatment sample of substance users; 
Mostly ♂s 
N = 1075 
Age range 16-58yrs; 
Mean age 29.3 + 6.7yrs 
McGee et al., 2000; 
New Zealand 
Community sample; Longitudinal;  
FU every 2 years; Sample part of Dunedin Multi-disciplinaryHealth and Development Study (DMHDS); 
Economically advantaged group 
N=1037; 
Ages 3-26yrs; 
 
Rao et al., 2000; 
LA County, USA 
Longitudinal; 
Community Public High School sample; FU each yr for 5yrs; 
Only ♀s 
N=155; 
Ages 17-19yrs 
Reinherz et al., 2000; 
USA 
Longitudinal; Community sample; ♂♀; 
98% White; mostly working- or lower middle class 
N = 360; 
Ages 5 yrs; FU at 21 yrs 
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Rodgers et al., 2000; 
Canberra, 
Australia 
Cross-sectional; Population sample; 
Potential participants for the Stress and Wellbeing Project. 
N = 2725 
Aged 18-80yrs; Mean Age = 42.6yrs 
Degenhardt et al., 2001; 
Australia 
Cross-sectional; 
Community 
N=10641; 
18+ years 
Hofstra et al., 2001; 
Netherlands 
Longitudinal 10yr follow-up; Community 
♀♂ 
N=1615; 
Ages 11-19yrs,  
Ferdinand et al., 2001; 
Netherlands 
Prospective; Fu over 8 yrs; 
Community sample 
N=787; 
Ages 10-14yrs 
Dierker et al., 2002; 
New Haven, Connecticut, 
USA 
Prospective; 
Treatment sample from substance use clinic + anxiety clinic. 
Controls from Community 
N= 133 probands, 
Ages 25-56yrs. 
N= 273 relatives, aged 18-80yrs 
Rey et al., 2002; 
Australia  
Cross-sectional; Retrospective; 
Community sample from National Survey of Mental Health and Wellbeing 
N = 1261 
Ages 13-17 years 
 
Compton et al., 2003; 
USA 
Random sample of admitted patients; 
Treatment sample of drug-dependents; 
Data from Drug Abuse and Risk of  Study; 
61% African-American; 66% ♂; 68% unemployed 
N=425 
FU  N = 401(94%) 
Mean Age = 32.5yrs 
SD=6.5 
Goodman et al., 2003; 
England,Scotland, Wales 
Cross-sectional; Community sample;  
90% White 
N = 2624 
Ages 13-15yrs 
Shrier et al., 2003; 
Boston, USA 
Cross-sectional; Convenience sample; Clinical; 
 mostly non-white; 68% female 
N=538 
14-18yrs old 
Steinhausen an Metzke, 
2003;  
Switzerland 
Cross-sectional Community  
sample from the Zurich Adolescent Psychology and Psychopathology study (ZAPPS); 
Sample representative of population 
N=794 
Ages 13-20 years 
De Graaf et al., 2004;  
Netherlands 
 
Longitudinal; Prospective; FU over 3 years. 
Sample from the Netherlands Mental Health Survey and Incidence Study (NEMESIS) 
N=7076 at baseline. 
Ages 18-64 years. 
Grant et al., 2004; 
USA 
Cross-sectional; sample of civilian, non-institutionalised individuals; Part of NESARC study N=43093 
Ages > 18yrs 
King et al., 2004; 
USA 
Longitudinal; Community; Twins study; 
Part of Minnesota Twin Family Study 
699 twin girls; 655 twin boys; 
Ages 11yrs at baseline and 14yrs at FU; 
Age range 10-12yrs. Average age: 11yrs 
Obando, et al., 2004 
USA 
Cross-sectional; Community N=4967 high school students, 218 
youths in Rx for  
substance use, 83 street youth; 
Ages 12-20yrs 
Fernander et al., 2006; 
Cape Town, South Africa 
Cross-sectional sample; 
 
N=620; 
High school students 
Monshouwer et al., 2006;  
Netherlands 
Cross-sectional; Community; 
Part of Dutch Health Behaviour in School-aged Children (HBSC) schools survey 
N=5551. 
Ages 12-16 years 
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Hayatbakhsh et al. 2007 
Australia 
Longitudinal; Community; 
Part of MUSP study 
N=7223 at baseline; 3239 at 21yrs FU 
Ages birth, FU at 14yrs and 21yrs 
Pardini et al., 2007 
USA 
Longitudinal; Community; 
Part of Pittsburgh Youth Study (PYS) 
N=506; Only boys 
Ages Mean = 13.9yrs 
Roberts et al. 2007 
USA 
Cross-sectional; Community N=4500 
Ages 11-17yrs 
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Table 2: Reviewed articles: Psychopathology and substance use details 
 
 
AUTHORS; 
STUDY LOCATION 
 
 
PSYCHOPATHOLOGY 
 
 
 
DIAGNOSTIC 
TOOLS 
 
 
 
SUBSTANCE 
USE 
 
 
 
ASSESSMENT 
TOOLS 
 
 
Anda et al., 1990, 
USA 
Depression CES-D (Centre for 
Epidemiologic Studies-
Depression Scale) 
Cigarette smoking Interview + quit ratio of 
CES-D to define smoking 
cessation 
Glassman et al., 1990, 
USA 
Major depression (MD) Diagnostic Interview Scheule 
(DIS) 
Cigarette smoking DIS 
Regier et al.,1990, 
USA 
Any NIMH DIS 
 
Alcohol + any other 
drugs 
DIS 
Schuckit et al, 1990; 
San Diego, USA 
Any Alcohol Research Centre 
Interview (ARC) developed 
from SADS-L and DIS 
Alcohol abuse and 
dependence 
ARC 
Breslau et al., 1991; 
Michigan, USA  
Any, including substance use 
disorders, and specifically nicotine 
dependence 
NIMH-DIS(for DSM III-R 
diagnoses) 
Any, but Nicotine 
primarily 
NIMH-DIS for DSM III 
Naceet al., 1991; 
USA 
Personality disorders Structured Clinical Interview 
for DSM  
SCID II 
Alcohol and 
anything else 
Alcohol Use Inventory; 
MMPI; 
Health Daily Living 
Forum; Shipley Institute 
of Living Scale; Chemical 
Use Inventory; 
Satisfaction Questionnaire 
Robinsand Price, 1991; 
USA 
Conduct problems used as childhood 
symptoms of anti-social personality; 
10 DSM III diagnoses 
DSM III-R Any DSM III-R 
Rounsaville et al., 1991; 
Connecticut, USA 
Any SADS-Lifetime and RDC Cocaine and other SADS-L and RDC 
Boyle et al., 1992; 
Ontario, Canada 
Any Youth Self Report (YSR); 
Child Behaviour.Checklist 
(CBC) 
Tobacco, alcohol, 
marijuana, hard 
drugs 
Self-report 
Deykin et al., 1992; 
Massachusetts, USA 
Depression; 
Drug dependence 
DSM III-R; 
NIMH-DIS 
Alcohol; 
Other drugs 
DSM III criteria; 
Family+Social History 
Interview 
Breslau et al.; 1993; 
USA 
Neuroticism; Negative affect; 
Hopelessness; general emotional 
distress. 
NIMH-DIS Nicotine NIMH-DIS 
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Breslau et al.; 1993; 
USA 
Major depression disorder (MDD) NIMH-DIS Nicotine 
(dependence) 
NIMH-DIS 
Dunn et al., 1993; 
USA 
Depression; PTSD; affective 
disorders; psychotic disorders; 
adjustment disorder; anxiety 
disorders; dissociative disorders 
Shipley-Hartford Institute of 
Living Scale; Routine 
psychological examination; 
Dissociative Experiences Scale 
Alcohol; Cocaine; 
Multiple substances 
Self-reports 
Henry et al., 1993; 
New Zealand 
Depression 
 
 
 
Conduct problems 
Diagnostic Interview Schedule 
for Children- Child Version 
(DISC-C) 
 
DISC-C Oppositional 
Behaviour Subscale 
Marijuana; 
Glue sniffing; 
Alcohol; 
Other drugs 
Self-report Early 
Delinquency 
instrument(SRED) 
Kendler et al., 1993;  
USA 
Major depression Structured Clinical Interview 
for DSM III an RDC 
Alcohol DSM III criteria 
Kendler et al., 1993; 
Virginia, USA. 
Major depression Structured Clinical Interview 
for DSM III-R diagnosis 
Cigarette smoking Self-Report 
Lehman et al., 1993; 
USA 
Axis I primary mental disorder, and 
psychoactive substance use disorder. 
DSM-III-R SCID Any Addiction Severity Index; 
Modified SCID 
Fals-Stewart & 
Angarano, 1994; 
NY, USA 
Psychoactive SUDs DSM III-R SCID-R 
psychoactive subsance use and 
OCD modules;  
Yale-Brown Obsessive-
Compulsive Scale and 
Symptom Checklist 
Any, excluding 
nicotine or alcohol 
as primary drug of 
choice 
SCID-R 
Hovens et al., 1994; 
Burbank, LA, USA 
Conduct+/or oppositional defiant 
disorder (non-abusing group); 
Depression; 
ADDH 
DSM III-R SADS-E 
 
 
Parent info via interview 
Any DSM III-R and Halikas 
criteria 
Merikangas et al., 1994; 
USA 
Anxiety; 
Depression 
Interviews using RDC criteria 
and modified DSM III 
symptomatic criteria 
Alcoholism Interviews using RDC 
criteria 
Sonne et al; 1994 
South Carolina, USA 
Bipolar Affective Disorder DSM-III-R-SCID; 
Hamilton’s rating Scale for 
Depression; 
Young Mania rating Scale 
Any SCID 
Araujo&Monteiro, 
1995; 
Brazil 
Depression, 
Generalised anxiety, panic attacks, 
suicide attempts 
DSM III SCID Alcohol DSM III SCID 
Biederman et al., 1995; 
USA 
ADHD; 
Anxiety syndrome 
Structured Clinical Interview 
for DSM III-R (SCID); 
Kiddies-SADS-E 
Alcohol; 
Drug abuse 
SCID 
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Brook et al., 1995; 
NY, USA 
Personality, behavioural,  
attitudinal characteristics 
Structured interviews Any Self-administered 
questionnaires 
Grilo et al, 1995; 
Yale Psychiatric Institute, 
USA  
Axis I and II diagnoses DSM III Schedule for Affective 
Disorders and Schizophrenia for 
School-Age Children- 
Epidemiologic Version 
(Kiddies SADS-E) 
 
Personality Disorder 
Examination 
Any DSM III 
Riggs et al, 1995; 
USA 
Depression; 
MD; Mood and anxiety disorders 
 
 
 
CD 
DISC-C; 
Children’s Depression Rating 
Scale using additional 
questionnaire to supplement 
DISC; 
 
Child Behaviour Checklist 
Any Comprehensive Addiction 
Severity Index-
Adolescents 
(CASI-A); 
Composite International 
Diagnostic Interview-
Substance Abuse Module 
(CIDI-SAM) 
Schmidt,  1995; 
California, USA 
Somaticism; obsessive-compulsive 
disorders; interpersonal sensitivity; 
depression; anxiety; hostility; 
phobia; paranoia; psychoticism. 
Caseness assessed. 
Structured interviews; 
Brief Symptom Inventory (BSI) 
Alcohol Interview +  
questionnaire 
Triffleman et al; 1995; 
San Francisco, USA 
Childhood trauma exposure Traumatic Antecedents 
Questionnaire (TAQ);  
DSM III-R-SCID PTSD 
Module 
Any Addiction Severity Index 
Brook et al., 1996; 
NY, USA 
Personality, Behaviour, Mental 
health 
Structured interviews Any Self-administered 
questionnaires 
Brown et al., 1996; 
SanDiego, California, 
USA 
Conduct Disorder; 
Anti-Social Personality Disorder 
(ASPD) 
DSM III-R Alcohol; 
Other drugs 
Customary Drinking + 
Drug Use Record (CDDR) 
King et al., 1996; 
Urban, USA 
Behavioural  
disorders 
Depression 
 
 
 
DISC +  
Adolesc DISC. 
Children’s Depression  
Rating Scale (CDRS-R);  
Hamilton rating Scale. 
Any DISC 
Fergusson et al., 1996; 
New Zealand 
Depression DIS-C; 
DSM-III-R 
Nicotine dependence Self-Report 
Novins et al., 1996; 
USA 
Depression 
Anti-social behaviour and suicide 
Beck Depression Inventory; 
Intake questionnaire 
Any Medical record review 
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attempts 
Grilo et al., 1996; 
Connecticut, USA 
Conduct disorder; Substance use 
Disorder 
KSADS-E Any KSADS-E; 
DSM III criteria 
Kessler et al., 1996; 
 USA 
Any affective or anxiety disorders. WHO Composite International 
Diagnostic Interview(WHO-
CIDI) 
Any addictive 
disorders 
CIDI 
Rohde et al., 1996; 
Oregon, USA; 
 
Any K-SADS; K-SADS-P; 
DSM III-R 
Alcohol DSM IV criteria 
Breslau et al.; 1997; USA PTSD; 
Depression; 
Anxiety 
NIMH-DIS using DSM III-R 
criteria 
Alcohol abuse or 
dependence; 
Illicit drug abuse or 
dependence 
NIMH-DIS using DSM 
III-R criteria 
Brooner et al; 1997; 
Baltimore, Md; USA 
Any Structured Clinical Interview of 
DSM III-R 
Any Addiction Severity Index 
(ASI) 
Kandel et al, 1997; 
USA; Puerto Rico 
Anxiety; 
Mood and disruptive behavioural 
disorders; eating, elimination, tic 
disorders 
NIMH DISC; Service 
Utilisation and Risk factors 
Interview (SURF) 
Cigarettes; 
Alcohol; 
Other substances 
DISC-2.3; 
 
Frequency of substance 
use determined using Self-
Reports 
Kessler et al., 1997; USA Anxiety disorders, affective 
disorders, conduct disorders 
Modified CIDI Alcohol,  
drug use 
Modified CIDI 
Clark et al., 1997; 
Pittsburgh, USA 
Any mental disorders, but anxiety 
disorders in particular 
Schedule for Affective  
Disorders+Schizophrenia  
for School Age  
Children (K-SADS)  
Any 
 
 
Alcohol 
Structured Clinical 
Interview for DSM III 
 
Lifetime History of 
Alcohol Use Interview 
Biederman, et al., 1997; 
USA 
ADHD 
+associated disorders 
Structured clinical Interview for  
DSM III-R + K-SADS  
Epidemiologic Version 
Alcohol; Drug abuse DSM III criteria 
Deykin+Buka, 1997; 
Massachusetts, 
USA 
PTSD DIS Alcohol + 
Other drugs 
DSM III criteria for 
dependence 
Horner&Scheibe, 
1997 
USA 
ADHD Wender Utah rating 
Scale(WURS); Self Evaluation 
(Teenagers) Self-Report; 
Child Attention Problems Scale 
Any drugs Interview + History-taking 
Moscato et al., 1997; 
Erie County, NY, USA 
Depression; 
Alcoholism 
CES-D  Alcohol DSM III criteria 
Ross & Shirley, 1997; 
Ontario, Canada 
MD; Mood disorders; anxiety 
disorders; bulimia; ASP 
Modified version of WHO-
CIDI 
Alcohol; any drugs; 
Tobacco use 
DSM III-R 
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Breslau, et al., 
1998; Michigan, USA 
CD, MD + other psychiatric 
disorders 
NIMH-DIS Cigarettes; 
Alcohol 
DSM III criteria 
Escobedo et al., 1998; 
USA 
Depressive symptoms Mellinger Depressive 
Symptoms Scale 
Cigarette smoking Standard questionnaire via 
pone or mail 
McGee et al.,1998; 
New Zealand 
Attention deficit disorder, conduct 
disorder, oppositional disorders, 
anxiety, depression 
Self, parent teacher reports, 
DISC-C, Revised Behavior 
Problem Checklist 
Smoking Self-Report 
Miller-Johnson et al, 
1998; USA 
Depression; 
CD 
Child Assessment Interview Alcohol; tobacco; 
marijuana 
National Youth Survey 
Patton, et al., 1998; 
Australia 
Anxiety,  
depression 
CIS Cigarette  
smoking 
Self report 
Brook, et al., 1998; 
NY, USA 
Any DISC Any Structured interviews 
Troisi et al., 1998;  
Italy. 
Any, 
But mainly depression and anxiety 
Beck Depression Inventory; 
Spielberger State-Trait Anxiety 
Index; 
Revised Toronto Alexithymia 
Scale; 
Structured Clinical Interview 
for DSM-III-R (SCID) 
Cannabis SCID 
Breslau and Klein, 1999; 
Michigan, USA 
Panic attack; 
Panic disorder 
NIMH-DIS Smoking DIS using DSM III-R 
criteria and  CIDI from 
NCS Tobacco Supplement 
Chong et al.; 1999; 
Taiwan 
(PAST study) 
Any, including SUD’s K-SADS-E 
(Chinese version) 
Any, including 
alcohol, cigarettes, 
betel 
DSM III-R 
Clark+Parker, 1999; 
Pittsburgh, USA 
Any K-SADS Alcohol; cannabis DSM III-R 
Costello et al., 1999; 
North Carolina, USA 
Any Child + Adolescent Psychiatric 
Assessment (CAPA) 
Tobacco; Alcohol; 
Cannabis; other 
substances 
CAPA  interviews; 
DSM IV criteria 
Costello et al., 1999; 
USA 
Any Child and Adolescent 
Psychiatric Assessment 
(CAPA) 
Tobacco, Alcohol; 
Cannabis and several 
other substances 
CAPA 
Disney et al.; 1999; 
Minneapolis, USA 
Any, but specifically ADHD, 
conduct disorder and adult anti-
social behaviour 
DSMIII-R and Diagnostic 
Interview for Children and 
Adolescents-Revised 
Any CIDI + computer-assisted 
substance use and abuse 
questionnaire 
Greene+Biederman, 
1999; 
Boston, USA 
Any,  
 
but especially.social impairment 
 
 
Kiddie SADS-E from DSM III-
R , 
Social Adjustment Inventory for 
Children+Adolescents 
(SAICA) 
Any, 
especially cigarette 
smoking 
DSM III-R 
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Aggression Child Behaviour Checklist 
(CBC) – 
Aggression Scale 
Kandel et al; 1999; 
USA 
SUD; 
Anxiety; disruptive behaviour; 
Mood disorders; 
Eating, elimination and tic disorders 
NIMH-DISC-C for children and 
DISC-P for caregivers 
Alcohol; 
Marijuana; 
Other substances, 
but not tobacco. 
NIMH-DISC 
Kushner et al.,  
1999; 
USA (Midwestern Univ.) 
Anxiety disorders NIMH DIS 
DSM III 
Alcohol DIS + DSM III; 
Short Michigan Alcohol 
Screening Test (S-MAST) 
Roberts et al., 1999;  
Cape Town, SA 
Anxiety SCID Abstinent alcohol- 
dependent 
SADQ, Withdrawal 
Syndrome Scale 
Rao et al., 1999; 
USA 
Major psychiatric disorder 
 
 
Temperament 
+Personality  
Features 
Schedule for Affective 
Disorders and Schizophrenia 
-Lifetime Version. 
 
Multi-dimensional Personality  
Questionnaire (MPQ) 
Any DSM III criteria 
Johnson et al., 2000; 
NY, USA 
Agoraphobia, generalised anxiety 
disorder, panic disorder 
DISC-C Cigarette smoking DIS-C 
Dixit&Crum, 2000; 
Baltimore, USA 
Depression Diagnostic Interview Schedule 
(DIS) 
Heavy alcohol use Baseline+F-U interview 
asked “How many times 
you had >5 drinks in last 
month 
Marsden et al; 2000; 
UK 
Any Brief Symptom Inventory (BSI) Any Severity of Dependence 
Scale; 
Addiction Severity Index 
(ASI) 
McGee et al., 2000; 
New Zealand 
ADD; Conduct disorders;anxiety 
disorders; depressive disorders 
(mentalhealth assessed from age 15 
onwards). 
Mental disorders (age 18 and 21yrs) 
DIS-C 
 
 
 
DIS 
Cannabis, smoking; 
alcohol 
Self-report 
Rao et al; 2000; 
LA County, USA 
MDD; 
SUD 
SCID; 
BDI 
Any Rutgers Collegiate 
Substance Abuse 
Screening Test 
(RCSAST)=a modified 
version of MAST 
Reinherz et al., 2000; 
USA 
Lifetime Major Depression and drug 
disorders 
DIS III-R Any DIS III-R 
Rodgers et al.; 2000; 
Canberra, 
Depression; Anxiety Self-administered questionnaire Alcohol Alcohol Use Disorders 
Identification Test 
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Australia (AUDIT) 
Degenhardt et al., 2001; 
Australia 
Anxiety,  
affective disorders, psychosis 
CIDI, ICD 10, 
DSM IV 
Tobacco, 
Cannabis, 
alcohol 
Self-report 
 
Hofstra et al., 2001; 
Netherlands 
Anti-social  
behaviour,  
aggression,  
anxiety disorders, 
Mood disorders, disruptive disorders 
Child Behaviour Checklist 
(CBC) 
Alcohol misuse/ 
dependence; 
drugs 
CIDI; 
DIS 
Ferdinand et al., 2001; 
Netherlands 
Behavioural,  
emotional  
problems 
Child Behaviour Checklist 
(CBCL) 
Tobacco,  
alcohol,  
drug use 
Young Adult Self-Report 
(YASR) 
Dierker et al., 2002; 
Connecticut, USA 
Depression DSM III-R semi-stuctured 
Schedule for Affective 
disorders + schizophrenia 
(current + lifetime 
Versions) 
Tobacco 
(cigarette use) 
Diagnostic interview  
DSM III-R 
Rey et al; 2002; 
Australia  
Depression, 
ADHD, 
Conduct disorder 
Questionnaires; CHQ, CES-D; 
YRBQ; DISC-IV. Recent 
versions of DISC and CHQ, 
CBCL 
Cannabis YRBQ (Youth Risk 
Behaviour Checklist) 
Compton et al.; 2003; 
USA 
11 conditions Non-clinical psychiatric 
interview; 
DIS III-R; 
NIDA Risk Behaviour 
Assessment 
Drug dependence; 
 
Alcohol dependence. 
DIS 
Goodman et al; 2003; 
England,Scotland, 
Wales 
Any ICD-10 and DSM IV computer-
assisted interview 
Alcohol; cigarettes; 
cannabis 
ICD-10 and DDSM IV 
Shrier, et al., 2003; 
Boston, USA 
Depression;  
mania; eating disorders; delusional  
thinking; hallucinations; ADD; 
anxiety + conduct dis. 
ADI Alcohol and any 
other substance 
abuse 
Self-administered 
SubstanceUse/Abuse scale 
using POSIT + ADI for 
substance use 
Steinhausen an Metzke, 
2003; Switzerland 
Problem Behaviour Youth Self Report and other 
scales 
Alcohol Substance Use 
Questionnaire (SUQ) 
De Graaf et al., 2004; 
Netherlands 
 
Any CIDI (DSM-III-R) Any CIDI 
Grant et al.; 2004; 
USA 
Mood and anxiety disorders AUDADIS-IV Alcohol; 
8 classes of drugs 
AUDADIS-IV 
King et al., 2004; Externalising disorders (ADHD; CD; Dagnostic Interview for Tobacco, Alcohol, DICA-R 
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USA ODD); Internalising disorders 
(MDD). 
In girls, Anxiety disorders. 
Children and Adolescents- 
Revised (DICA-R), based on 
DSM-III-R. 
Cannabis 
Obando et al., 2004 
USA 
Depression Short Mood and Feelings 
Questionnaire (SMFQ) 
Any Drug Use Screening 
Inventory (DUSI) 
Fernander et al.; 2006; 
Cape Town, South 
Africa 
Depression Beck’s Depression Inventory 
(BDI) 
Smoking Self-administered 
questionnaire 
Monshouwer et al., 2006; 
Netherlands 
Any Youth Self Report (YSR) Cannabis Questionnaire 
Hayatbakhsh et al. 2007; 
Australia 
Anxiety and Depression Youth Self-Report (YSR) Cannbis Self-Report of 2 questions 
Pardini et al., 2007 
USA 
Conduct Disorder 
 
ADHD 
Depression 
 
Anxiety 
Self-Reported Delinquency 
Scale (SRD) 
DISC-P 
Short Mood and Feelings 
Questionnaire (SMFQ) 
Youth Self Report (YSR) 
Alcohol Use 
Disorders 
DIS 
Roberts et al., 2007 
USA 
Anxiety, Mood Disorders, 
Disruptive Disorders, ADHD 
DISC-IV Any DISC-IV 
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Table 3: Reviewed articles: Statistical analyses and outcomes of studies 
 
 
 
AUTHORS; 
STUDY 
LOCATION 
 
STATISTICAL 
ANALYSES 
 
 
 
 
OUTCOMES 
 
 
 
 
Anda et al., 1990, 
USA 
Cochran-Mantel-Haenszel test for  
Trend; Kaplan-Meier analysis  for incidence 
of quitting 
↑CESD=>↑smoking 
Depression=> less likely to quit smoking 
Glassman et al.,  
1990, 
USA 
Prevalences; OR’s; Lifetime prevalences Similar rates of smoking among ♂♀in depressed group. 
Gender differences among non-depressed group.  
Depressed smokers less able to quit smoking. 
MDD influences rates of smoking.  
Smoking  more common among depressed patients than in general population. 
Regier et al., 
1990, 
USA 
Prevalences, OR’s; lifetime prevalences Substance abuse in 83.6% of individuals with Anti-Social Personality Disorder (ASP).  
Greater association between Anxiety disorders and other drugs, than between anxiety and 
alcohol dependence. 
Strong association between substance abuse and affective disorder. 
Schuckit et al., 
1990; 
San Diego, USA 
Mostly descriptive statistics High prevalence of anxiety symptoms amongst alcoholics. But anxiety diagnoses 
comparable to expected population rates. 
Breslau et al., 
1991; 
Michigan, USA  
OR’s; Multivariate Logistic Regression Significant association between mild nicotine dependence and MD, OCD, phobia, and 
any anxiety disorder. 
Moderate nicotine dependence => 5 X greater likelihood of developing MD than if no 
nicotine dependence. 
Generally, any nicotine dependence =>↑ likelihood of anxiety disorder. 
Nace et al., 1991; 
USA 
t-tests with Bonferroni Correction; Chi-
squared analyses 
Subjects with personality disorders more likely to be involved in substance abuse. 
Personality disordered group had higher scores on depression, negative life changes, 
avoidance as means of coping, emotional discharge as means of coping.  
Robins and Price, 
1991; 
USA 
Receiver Operating Characteristics (ROC) 
curves 
Conduct problems more prevalent among males. 
Conduct problems predict other disorders less well than externalising disorders. 
Conduct disorders might cause externalising disorders which then cause other disorders. 
Conduct problems can lead to substance abuse and depression or anxiety or first to 
depression and then substance abuse.  
Rounsaville et al., 
1991; 
USA 
Descriptive statistics Affective disorders and alcoholism followed onset of drug abuse. 
Anxiety disorder and ASPD and ADHD preceded drug abuse. 
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Boyle et al.; 1992; 
Ontario, Canada 
Relative odds; 
Logistic Regression 
Conduct disorder was associated with use of marijuana and hard drugs but not with use 
of tobacco and alcohol. 
Small relative odds between ADHD, substance use and between emotional disorder and 
substance use. 
Deykin et al.,  
1992; 
USA 
OR’s Primary and secondary depression possible. 
Abusers have ↑ risk of depression cf community. This is possibly because of 
Berkson’s Bias. 
Breslau et al., 
1993; 
USA 
Anova; 
Dunnett’s t-test; 
Multiple regression; 
SAS General Linear models 
Nicotine dependence strongly associated with all measured psychiatric diagnoses. 
Thus nicotine-dependent smokers more vulnerable to psychopathology than non-smokers 
or non-dependent smokers. 
Breslau et al., 
1993;USA 
OR’s History of MDD =>↑ risk of first incidence MDD at FU. 
Dunn et al., 
1993; 
USA 
Correlations; Anovas; t-tests; Stepwise 
multiple regression 
Comorbid PTSD subjects more likely to score high on dissociative dysfunction. 
Blacks had higher dissociative dysfunction scores than Whites. 
Dissociative experiences common in this population. 
Henry et al., 
1993; 
New Zealand 
Logistic Regression ♂s:Conduct probs + Depressive symptoms (DP) at 11yrs predicted multiple drug use  
at 15yrs; but DP more important. 
CP + DP independently both predicted multiple Drug use. 
♀s: aged 15yrs, only CP strongly associated with substance use.  
♀s: CP + DP predicted self-medication at 15yrs. 
Kendler et al., 
1993; USA 
Bivariate twin analysis; 
Tetrachoric correlation matrices 
Highly significant comorbidity between MD and alcoholism. 
No clear indication of which disorder is the preceding one. 
Kendler et al., 
1993; 
Virginia, USA. 
Regression analyses; Co-twin control method 
to discriminate causal from non-causal 
relationships. 
Ever smokers had higher rates of MD than never smokers.  
Heavy smokers had higher rates of MD than light smokers. 
Increased risk for MD with increased levels of nicotine dependence. 
Strong association between smoking and future episodes of MD. 
Smoking did not cause MD and MD did not cause smoking. 
Lehman et al., 
1993; USA 
Description statistics; 
ANOVA; MANOVA 
Dually diagnosed patients have more adverse life circumstances than patients with single 
diagnoses, whether mental or SUD’s. 
Fals-Stewart & 
Angarano, 1994; 
NY, USA 
Approximation to Poisson Distribution to 
examine proportion differences; ANOVA; Chi 
squared 
↑prevalence of OCD as compared with population. 
OCD under-diagnosed. 
Hovens et al., 
1994; 
Burbank, LA, USA 
Student’s t; Chi squared; 
Newman-Keuls; Kruskal-Wallis 
Substance abusers had higher rates of conduct disorder; ADDH; dysthymia; MD; anxiety 
disorders; social phobia. 
Non-abusers had higher Incidence of oppositional disorders. 
Abusers had larger average number of psychiatric diagnoses; more likely to have 
multiple diagnoses. 
♀abusers more likely to have anxiety disorders; 
♂abusers more likely to have conduct disorders. 
♂s more likely to be polysubstance abusers + school dropouts. 
Drug abuse preceded MD in all cases. 
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Social phobia + ADHD preceded substance use. 
Conduct disorder before, during or after onset of substance use. 
No correlation between number or severity of drug use + severity of psychiatric 
diagnoses. Substance Use=>↑psychiatric comorbidity + ↑severity of psychopathology. 
Merikangas et al., 
1994; 
USA 
Proportional Hazards model. 
Co-transmission analysis used trivariate 
multifactorial threshold model 
Anxiety disorders preceded alcoholism in 65% of persons with both anxiety and 
alcoholism. Does not seem that alcoholism leads to anxiety. 
But alcoholism and anxiety appear to share some underlying transmissible factors. 
Sonne et al; 1994 
South Carolina, 
USA 
Mostly descriptive statistics; 
Chi squared 
Substance users had greater morbidity associated with their mood disorders than non-
substance users. 
Substance users had earlier onset of mood disorders and were more likely to have onset 
of mood disorders before age 20yrs. 
Most common comorbid non-substance use diagnosis = PTSD in substance users. 
Araujo&Monteiro, 
1995; Brazil 
t-test; chi squared Alcoholics more likely to have 2 or more additional psychiatric diagnoses, and to have 
a family history of depression. 
Biederman et al.; 
1995; 
USA 
ANOVA; Chi squared; Logistic Regression Presence of ADHD =>higher lifetime risk of drug or alcohol abuse or dependence. 
positive association between number of comorbid disorders and risk for SUD’s in both 
ADHD  and normal comparison subjects. 
Anti-social disorders are important risk factors for SUD’s in non-ADHD patients. 
Association between SUD’s and depression and anxiety. 
Brook et al., 1995; 
NY, USA 
Correlations; hierarchical  
regression 
Childhood personality ttributes assoc with adolescent personality traits. Personality 
traits related to drug use. 
Grilo et al, 1995; 
USA  
Chi squared; descriptive statistics Early CD associated with ↑risk of SUD in later adolescence. 
Study data contradicted findings of some other community and inpatient studies. 
Riggs et al, 1995; 
USA 
Chi squared; t-tests; Pearsons correlations Depression associated with increased substance use. Patients with CD had earlier onset 
of depression. Boys with depression had earlier onset of CD. Depression group had 
higher prevalence of ADHD and anxiety disorders. 
Schmidt,  1995; 
California, USA 
Logistic regression Inpatients more likely than outpatients to report having been drinking during event that 
precipitated psychiatric admission. 
Admitted patients more likely to have been drinking more heavily than patients not 
admitted. 
Inpatients more likely to have drunk more than outpatient admissions. 
Patient self-reports appear to be contradictory, namely, some say they drink because of 
emotional problems; others say substance abuse causes their mental problems. 
Triffleman et al; 
1995; San 
Francisco,USA 
Correlations Childhood trauma exposure strongly positively associated with substance dependence 
disorders. 
But study cautions that relationship might be more complicated, eg with other factors  
increasing risk for trauma and subsequent substance abuse. 
 
Brook et al., 1996; 
NY, USA 
Latent variable structural equation modeling Childhood aggression related to drug use and delinquency. 
Brown et al., 
1996; 
X 
2
; Discriminant Function Analysis; Analysis 
of Covariance; 
CD highly prevalent Amongst abusers in Rx. 
♂ abusers engage in more CD behaviour than ♀abusers. CD associated with poorer 
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SanDiego, 
California, USA 
Anova’s prognosis after treatment for abuse. 
CD secondary to abuse. Primary CD => ↑ risk of poor abuse outcome and↑ risk of 
progression to ASPD. 
King et al., 1996; 
Urban, USA 
Ancova;  
Mancova; Discriminant  
Function Analysis 
In ♀s depression=>alcohol abuse.  
 
Comorbid alcohol abuse+depression=>♀s psychosocial adjustment problems + more 
likely  to engage with ♂s 
Fergusson et al., 
1996; 
New Zealand 
Logistic regression, log-linear modeling Strong comorbidity between depression and nicotine dependence at 16yrs, and did not 
vary significantly for ♂ and ♀. 
Novins et al.,1996; 
USA 
Bivariate analyses High prevalence of SUD + psychiatric comorbidity. High drop-out from treatment. 
 
Grilo et al., 
1996; 
New Haven, 
Connecticut, USA 
Mostly descriptive statistics Substance use disorders coexist more often with conduct disorder in absence of ADHD. 
Patients with CD had earlier age at 1
st
 psychiatric contact than patients with coexisting 
CD and SUD. 
Anxiety disorders more common in conjunction with CD and comorbid SUD, than with 
SUD alone 
Kessler et al., 
1996; USA 
OR’s; Logistic Regression; 
Age-of-onset curves;  
Balanced Repeated Replications 
All the mental disorders are consistently more associated with dependence rather than 
abuse. Mental disorders usually occur first (preceding addictive disorders) except in men 
with affective disorders and alcohol use disorders. 
Rohde et al.; 1996; 
Oregon, USA; 
 
Descriptive statistics; 
Multiple Regression 
Other psychiatric disorders=>alcohol disorder; 
Early age onset of alcohol Disorder=>↑chance of comorbidity; 
Depression, disruptive behave disorders, drug, tobacco use strongly comorbid with 
alcohol use disorders. 
Alcohol Use disorder=>psychopathology 
↑alcohol problems=>↑likelihood of psychiatric disorder. 
Breslau et al.; 
1997; USA 
Cox Proportional Hazards models for 
censored survival data 
Significant association between PTSD and lifetime occurrence of MD, any anxiety 
disorders, alcohol abuse or dependence. 
PTSD increased risk for first onset MD and alcohol abuse or dependence. 
Brooner et al; 
1997; 
Baltimore, Md; 
USA 
Prevalence rates with OR’s; ANOVA’s; 
Descriptive discriminant analyses 
MD and ASPD most common lifetime diagnoses. 
39% comorbidity mostly involved personality disorders. Most had substance use other 
than opioid dep. 
♀s more likely to have Axis I diagnoses. 
♂s more likely to have personality disorders 
Kandel et al, 1997; 
USA; Puerto Rico 
Logistic regression Frequent substance users had higher prevalence of psychiatric disorders. 
↑use associated with ↑risk of psychiatric disorder. 
Kessler et al., 
1997; USA 
Logistic  regression, Bivariate survival models Earlier disorders are stronger predictors of alcohol dependence than alcohol abuse. This 
prediction is stronger in ♀s. 
Clark et al., 1997; 
Pittsburgh, USA 
Configural Frequency Analysis Alcohol dependence=>↑prevalence rates of other mental disorders, especially major 
depression+PTSD. 
MD+PTSD preceded or followed alcohol use disorders. 
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Biederman, et al., 
1997; USA 
Bivariate  
descriptive tests 
Conduct+bipolar disorders=>psychoactive SUD independently of ADHD status. 
Anxiety+Depression weakly=>PSUD 
Deykin+Buka, 
1997; 
USA 
X 
2 ; OR’s ↑ risk of PTSD amongst abusers of substances. 
♀s have greater risk of PTSD due to greater susceptibility to high risk trauma. 
In ♂s abuse well-established before PTSD onset. Reverse applied to ♀s.  
Horner&Scheibe, 
1997; USA 
Correlations, Mann-Whitney U; 2x2 Anovas There is an over-representation of ADHD among adolescent substance abusers in 
treatment. 
ADHD subjects have more severe substance use than controls. 
Moscato et al., 
1997; 
Erie County, NY, 
USA 
Logistic regression Sample had higher proportion of ♀s with depressive symptoms at baseline + FU. 
Higher proportion of ♂s had alcohol problems at baseline+ FU. 
♂♀ initial levels of depressive symptoms predicted subsequent levels of depressive 
symptoms. 
♀♂ prior alcohol problems predicted subsequent alcohol problems. 
♀ depressive symptoms predicted subsequent alcohol problems over 3 and 4 yr period, 
but not over 7yr period. 
♂alcohol problems did not predict depressive symptoms. 
No evidence that alcohol problems predict depressive symptoms in ♀s. 
Ross & Shirley, 
1997; 
Ontario, Canada 
Multiple regression; 
Chi squared 
Problem drinkers with comorbidity more likely to drink heavily; be current daily 
smokers; to have used tranquillizers or anti-depressants. 
Cannabis associated with problem-drinking with or without psychiatric comorbidity. 
Comorbid problem drinkers more likely to be diagnosed with alcohol abuse or 
dependence, and develop alcohol-related problems at a younger age. 
Binge drinking more common in problem-drinkers with psychiatric comorbidity. 
Breslau, et al., 
1998; 
Michigan, USA 
Hazards ratios Early conduct problems assoc with ↑risk for progression to daily smoking. 
Early conduct problems =>↓smokers’ potential for cessation o smoking. 
Early conduct problems =>↑risk of 1st onset MD. 
Da ly smoking =>↑ risk for 1st onset MD. 
Prior alcohol use disorder not significant in any of the models used. 
Escobedo et al., 
1998; USA 
Multivariate analyses Females more likely than males to report depressive symptoms. 
Depressed adolescents more likely to initiate smoking. 
Increase in frequency of depressive symptoms associated with increased rates of smoking 
initiation in males and females. 
McGee et al., 
1998; 
New Zealand 
OR‘s; Logistic Regression, Chi-squared Mental health only weakly predictive of smoking 
Miller-Johnson et 
al, 1998;USA 
Anova (repeated measures) Earlier CD assoc with risk for increased levels of substance use. Early substance use 
assoc with/predicts later use.↑ substance use in youth with comorbid CD and depression. 
Patton, et al., 1998; 
Australia 
Multiple logistic regression,  
Cox proportional hazards model 
Smoking did not predict mental health problems, but depression + anxiety predicted  
smoking initiation.  
↑psychiatric morbidity=>↑risk for smoking initiation if peers were mostly smokers. 
Brook, et al., 1998; 
NY, USA 
Chi squared +Fisher’s Exact Adolescent drug use=>depressive+disruptive disorders in young adulthood. 
↓drug use might later ↓psychiatric disorders.  
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No correlation between level of substance use + rates of anxiety disorder.  
Tobacco most strongly   related to depression. 
Troisi et al., 1998; 
Italy. 
Fisher’s Exact; 
Univariate and Multivariate analyses 
Users had difficulty in identifying or expressing emotions.  
Increase in Cannabis use leads to increase in psychiatric disabilities. 
Breslau and Klein, 
1999; Michigan, 
USA 
Cox Proportional Hazards Models for 
censored survival data, with daily smoking as 
a time-dependent covariate. 
Daily smoking associated with increased risk for first time occurrence of panic attack.  
Risk of panic attack higher in active than in past smokers. 
Chong et al.; 1999; 
Taiwan 
(PAST study) 
OR’s; 
Mmultivariate logistic regression 
Among SUD cases disruptive behaviour disorders (incl CD and ADHD) most common 
comorbid psychiatric disorders, followed by anxiety and depressive disorders. 
Other diagnoses, including psychoses, very rare. 
Adolescents with psychiatric disorders at risk for SUD’s. 
Clark+Parker, 
1999; 
Pittsburgh, USA 
Survival analysis ADHD not associated with substance .related problems. 
Negative affect disorders not associate with SUDs. 
Costello et al., 
1999; 
North Carolina, 
USA 
Generalised Estimating Equation modelling Early onset substance use=>↑likelihood of later substance use. 
No association between anxiety disorders or ADHD +likelihood of substance use. 
Most psychiatric disorders preceded substance use. 
Anxiety disorders=>earlier onset of later substance use/abuse. 
♀s: strong association between CD + substance use. 
♂s: strong association between Depression + substance use. 
Costello et al., 
1999; USA 
Prevalences Depression strongly associated with substance use and abuse. 
Depressed boys more likely to abuse substances than non-depressed boys. 
Presence of psychiatric disorder meant earlier or same time onset of substance use when 
compared with  those who did not have a psychiatric disorder. 
Psychiatric illness preceded substance use. 
Disney et al.; 1999; 
Minneapolis, USA 
Hierarchical Logit analysis Presence of ADHD or conduct disorder => largest rates of substance use and abuse in 
both ♂♀s. 
ADHD not significantly associated with substance use or abuse except in presence of 
comorbid conduct disorder. 
ADHD is a possible risk factor for nicotine dependence. 
Conduct disorder = strong risk factor for substance use or abuse across genders. 
Greene+ 
Biederman, 1999; 
USA 
Logistic Regression Social impairment predicts smoking and less severe SUDs. 
Conduct Disorders predict more severe SUDs. 
Kandel et al; 1999; 
USA 
WALD statistics for ORs Current SUD more likely to co-occur with another psychiatric disorder. This disorder is 
most likely to be a disruptive behaviour disorder or an anti-social personality disorder for 
both adolescents and adults. 
Adolescents with lifetime SUD are at as high a risk for psychiatric disorders as are 
adults. 
Comorbidity of SUD and psychiatric disorders highest among 15-24 yr olds. 
Kushner et al.,  
1999; 
Odds ratios; Logistic Regression; 
Path analysis 
Having anxiety disorder or alcohol abuse/dependence=>↑likelihood of developing the 
other diagnosis concurrently. 
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USA (Midwestern 
Univ.) 
Anxiety disorders predicted alcohol abuse but not vice versa. 
But anxiety disorder increased risk of new alcohol abuse disorder and vice versa. 
Roberts et al., 
1999; 
Cape Town, SA 
Correlations,  
Non-parametric tests 
Anxiety symptoms temporary, related to intoxication + withdrawal.  
Delay making diagnosis of anxiety after abstinence and only do so if symptoms persist. 
Rao, et al., 1999; 
USA 
Student, t; Anova;  
All 2-tailed tests 
Depressed adolescents had earlier onset of SUD.  
Comorbid depression + SUD assoc with Psychosocial morbidity. 
Johnson et al., 
2000; 
NY, USA 
Bivariate associations, 
Logistic regression 
Anxiety disorders not assoc. with later smoking.  
Cig smoking may ↑ risk for later anxiety disorders. 
Dixit&Crum, 
2000; 
Baltimore, USA 
Logistic regression to predict heavy drinking 
at F-U from baseline depression 
History of depression=>risk of heavy alcohol use. 
↑depressive symptoms=>↑risk of heavy alcohol use 
Marsden et al; 
2000; 
UK 
Cluster Analysis; 
Cluster profiles described single chi- squared 
and Anova; Multiple Linear Regression 
Psychiatric symptoms on admission seemed related to nature of substance use. 
Prevalent psychiatric Rx and more severe depression => more severe psychiatric 
symptoms 
McGee et al., 
2000; 
New Zealand 
OR’s; Logistic regression; Chi-squared In males aged 15yrs, mental disorder and earlier substance use predicted later substance 
use.  
Earlier smoking and cannabis use predicted later cannabis use and mental disorder for 
ages 18 and 21 yrs, especially in males.  
Smoking at age 18yrs increased risk for anxiety-depressive disorders + alcohol 
dependence 
Rao, et al; 2000; 
LA County, USA 
Descriptive statistics; Survival analysis; 
Multiple Regression 
SUD before study=>SUD at FU. 
More ♀s with MDD had lifetime SUD. 
Baseline MDD=>SUD at FU. 
MDD before study did not=> SUD at FU; but SUD before study =>more likely MDD at 
FU. 
FU SUD=>worst BDI score. 
Lifetime SUD=>depression more likely. 
SUD=>school dysfunction. 
Reinherz et al., 
2000; 
USA 
Multiple Regression models Sibling’s drug or alcohol use ↑ risk of both depression and drug disorders. 
In ♀s, those who were anxious or depressed at age 9 yrs were more likely to develop 
depression or SUD. 
Mothers’ assessment of early behaviour. Difficulties not predictive of drug disorders. 
Early attention problems predictive of drug disorders. 
Early aggressive behaviour => ↑ risk of SUD’s in ♀♂s. 
♂s more likely to develop SUD’s and ♀s more likely to develop depression. 
Rodgers et al.; 
2000; Canberra, 
Australia 
Logistic Regression Non-drinkers had higher depression and anxiety cores than low-consumption drinkers. 
But, non-drinkers included EX-Drinkers which could have pushed up the scores. 
Heavy drinkers reported more symptoms than light drinkers. 
Possible U-shaped assoc. between drinking and psychopathology. 
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Degenhardt et al., 
2001; 
Australia 
Bivariate regression, 
Multiple logistic regression 
 
Tobacco, cannabis ↑ mental health problems.  
Cannabis not associated with anxiety + affective disorders. 
Tobacco, cannabis, alcohol use => ↑ other substance use problems 
Hofstra et al. 2001; 
Netherlands 
Correlations between Time1 and Time 6; 
Linear Regressions 
Aggressive behaviour in childhood predicted alcohol misuse/dependence in adult ♀but 
not in ♂. 
Ferdinand et al., 
2001; 
Netherlands 
Fisher’s Exact; Logistic Regression; OR’s 
 
Adolescent behavioural + emotional problems related to substance use in young 
adulthood 
Dierker et al., 
2002; USA 
Logistic regression; 
Chi-squared 
Only alcohol use disorders were significantly associated with regular heavy smoking. 
Rey et al; 2002; 
Australia  
Descriptive an Logistic Regression Use of cannabis increased the chances of having emotional and behavioural problems.  
Increased depression scores increased the chances of having used cannabis. 
ADHD doe not seem to increase risk of cannabis use. 
Compton et al.; 
2003; 
USA 
Descriptive statistics; 
Multivariate regression models 
Comorbid substance use and ASPD increased the chances of worse Rx outcome. 
Generalised anxiety disorder also led to worse outcome. 
Comorbidity generally leads to worse RX outcome in ♂s. Not so clear cut in ♀s. 
Goodman et al; 
2003; 
England,Scotland, 
Wales 
Logistic Regression Having a psychiatric disorder was assoc. with increased risk of regular smoking. 
Existence of a depressive disorder doubled risk of regular dinking and lifetime cannabis 
use. Increased risk for psychiatric diagnosis if a regular smoker or drinker, or had used 
cannabis. 
Shrier et al., 2003; 
Boston, USA 
Chi squared; Anova;  
Multivariate Logistic Regression 
♀s greater no. of symptom types; more likely to report depression, eating disorders. 
Anxiety symptoms most common in ♀s; not assoc with SUDs. 
♂s↑severity substance use=>↑conduct disorder 
↑SUD’s=>↑likelihood psychiatric symptoms+ no. of symptoms. 
Steinhausen an 
Metzke, 2003; 
Switzerland 
Qualitative and Multivariate Analysis of 
Covariance (MANCOVA) 
Abstainers were mainly female. 
Females drank less than males. Disproportionate number of males among heavy drinkers. 
Problem drinkers more likely to have emotional and behavioural problems. 
The older the person, the more likely that s/he was to have emotional and/or behavioural 
problems. 
De Graaf et al., 
2004; Netherlands 
 
Descriptive statistics and Logistic Regression Males were more likely to develop substance use comorbid with mood disorders than 
were females. Only gender was associated with comorbidity. 
Appears that rapid comorbidity is triggered not so much by previous life events as by life 
events that occur during the first disorder. 
Grant et al.; 2004; 
USA 
Cross-tabulations; 
OR’s 
 
All mood and anxiety disorders were more strongly related to alcohol and drug 
dependence than to drug abuse. 
Mania most strongly associated with SUD’s   than any other mood or anxiety disorder. 
King et al., 2004; 
USA 
Generalised Estimating Equations (GEE); 
Prevalence rates; 
OR’s, Chi squared; 
Log-Linear analyses. 
Externalising psychopathology increases risk for early initiation of alcohol, nicotine and 
cannabis use, and predicts higher level of SU. 
ADHD weakest predictor of SU. 
Males and females at similar risk for SU in early adolescence, but internalising pathways 
for SU might operate from later adolescence. 
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Obando et al., 2004 
USA 
Descriptive statistics and Logistic Regression Depressive symptoms contribute significantly to overall substance involvement. 
But there are risk factors that differ for school children vs youth in Rx vs street youth. 
Fernander et al., 
2006; 
Cape Town, South 
Africa 
Logistic Regression Depression associated with smoking in ♀s only. 
Monshouwer et al., 
2006; Netherlands 
Multivariate Linear Regression Cannabis use strongly associated with delinquent and aggressive behaviour.  
Association stronger with more recent use and with increased frequency of use. 
Association with thought problems in regular users of cannabis. 
Hayatbakhsh et al., 
2007; Australia 
Logistic Regression Smoking at 14yrs increased risk of anxiety/depression in young adulthood. 
Cannabis use in adolescence significantly associated with anxiety/depression in young 
adults, but anxiety/depression in adolescence did not predict early cannabis use. 
Pardini et al., 2007 
USA 
Regression analyses Early adolescent CD symptoms leads to increased alcohol use disorder symptoms and 
alcohol dependence by early adulthood. 
Increased depressive symptoms combined with high CD symptoms increased the risk for 
alcohol use disorders in adolescent males. 
Early adolescent psychopathology only modestly related to alcohol abuse in the absence 
of dependence.  
Increased CD symptoms led to increased risk for later alcohol use problems. 
Increased anxiety/withdrawal in early adolescence led to decreased risk for alcohol use 
disorders in adulthood. 
Roberts et al., 2007 
USA 
Logistic regression Comorbidity between SUDs and othe psychopathology vary i.t.o. substance of use, abuse 
vs dependence, and type of psychiatric disorder. 
Strong association between substance use (especially dependence) and multiple 
comorbid disorders. 
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CHAPTER 3 
Association between psychopathology and substance use 
among school-going adolescents in Cape Town, South 
Africa 
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Abstract 
Background. Limited information exists regarding the association between psychopathology and specific substance use in 
young people both globally and locally. We examined the association between psychopathology and substance use in high 
school students to determine the nature of the associations and the role of demographic factors in these associations. 
Method.  Grade 8 (N = 480) and Grade 11 (N = 459) students from 39 high schools in Cape Town, South Africa, completed 
a self-administered questionnaire. Psychopathology information was obtained from total scores on the Harvard Trauma 
Questionnaire, Beck Depression Inventory and the Zung Self-Rating Anxiety Scale. Lifetime prevalence rates were 
calculated for tobacco, alcohol, cannabis and inhalant use. Associations between psychopathology and substance use were 
determined using regression analyses and structural equation modeling. Results.  On adjusting for demographic 
characteristics, significant associations were found between PTSD and all substance use, between depression, alcohol, 
cannabis and inhalant use, and between anxiety and cannabis use. The associations of PTSD and depression with alcohol 
and cannabis use, and between anxiety and cannabis use, were moderated by grade. Conclusions.  Although 
psychopathology and substance use were associated with each other, these associations occurred in accordance with 
substance and grade. Roles for gender, age and ethnicity emerged in the associations, but further investigation is 
recommended to examine these.  
 
Keywords - psychopathology, substance use, comorbidity, adolescents 
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The association between psychopathology and substance use has been extensively researched, particularly within the 
last three decades. There is consensus that psychiatric problems and substance use are almost inextricably associated with 
one another, and that such comorbidity is as common in adolescents and children as it is in adults (Angold et al. 1999; 
Saban & Flisher 2009).  
However, limited information is available on the association between psychopathology and specific types of substance 
use (such as alcohol, cannabis and inhalants) in children and young people (Roberts et al. 2007) despite evidence for 
extensive comorbidity particularly among adolescents. In addition, information is lacking regarding the association between 
psychiatric disorder and substance use disorders. Few studies have been completed in South Africa on the association 
between psychopathology and substance use or substance use disorder, despite the problems experienced here with both 
psychiatric disorder and substance use, particularly among adolescents (Flisher et al. 2002; Taylor et al. 2003; Flisher et al. 
2003).   
This study examined the extent and nature of psychopathology and substance use among Grade 8 and Grade 11 
students in Cape Town, South Africa, to determine the associations between psychopathology (specifically PTSD, 
depression and anxiety) and substance use (specifically tobacco, alcohol, cannabis and inhalants), and to establish the role 
of age, school grade, gender and racially classified social group (RCSG) in these associations.  
 
METHODS 
Study design and participants 
The sample consisted of 939 Grade 8 and Grade 11 students, of whom 782 had sufficient data recorded to enable 
the selected analyses. The sample was randomly drawn from 2779 students selected from public (non-private) high schools 
in Cape Town (Flisher et al. 2003) in a multi-stage cluster sampling procedure. The latter involved selecting 39 schools, 
using a sampling frame of all high schools in Cape Town, stratified by four-digit postal (zip) codes, the first two digits of 
which define the geographical area which, in Cape Town is relatively homogeneous with respect to both social class and 
RCSG. The number of schools selected in each stratum was directly proportional to the number of students in that stratum, 
while the probability of a school being selected was directly proportional to the number of students in that school. In each 
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participating grade, two classes were randomly selected. The students in these classes were combined to form a single list 
from which forty students were randomly selected. To accommodate possible absentees, five additional students were 
selected, thus replacing a maximum of five absentees on the day.  
Measurement tools 
The instrument used was a self-administered questionnaire which elicited data regarding, demographic 
characteristics, substance use and psychopathology (PTSD, depression and anxiety). The demographic characteristics were 
school grade, gender, age (in years), and racially classified social group (RSCG). The RCSGs were Asian, White, Coloured 
and Black, as defined in the repealed Population Registration Act of 1950, with the category “Coloured” referring to mixed 
ancestry consisting of any combinations of Asian, European, African or other heritage. Substance use was defined as 
lifetime use of cigarettes, alcohol, cannabis and inhalants. Students were asked whether they had ever smoked a whole 
cigarette, ever had more than a few sips of alcohol, ever smoked cannabis alone or ever used inhalants such as glue, petrol 
or paint thinners. Test-retest reliability data were good with kappas and 95% confidence intervals of 0.85 (0.80-0.91) for 
ever having smoked a whole cigarette, 0.78 (0.71-0.85) for ever having had more than a few sips of alcohol and 0.80 (0.72-
0.88) for ever having smoked cannabis alone (Flisher et al. 2003). Psychopathology was defined as the total scores obtained 
on the Harvard Trauma Questionnaire (modified to assess traumatic experiences in a local context), the Beck Depression 
Inventory, and the Zung Self-Rating Anxiety Scale (Ward et al. 2004). The questionnaire was available in English, 
Afrikaans and Xhosa, the major Cape Town languages. The English questionnaire was translated into Afrikaans and Xhosa 
and then back-translated by Afrikaans and Xhosa first language users respectively. The translation of the questionnaires was 
carefully scrutinized for reliability across the three languages, enabling all the students to answer the questions confidently 
in their preferred language.  
Procedure 
Ethical clearance was obtained from both the University of Cape Town Health Sciences Faculty Research 
Committee as well as from the Western Cape Education Department. Students were informed that they could refuse to 
answer questions with no risk of negative consequences to themselves or anyone else. Only members of the research team 
were present during the completion of the questionnaires. Confidentiality of the responses to the questions was preserved by 
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allowing the students to complete the questionnaires anonymously and under examination conditions. Once completed, each 
questionnaire was inserted into an envelope that was then sealed  
 
Statistical analysis 
The original sample of 939 students was found to have large swathes of missing and unreported data for 157 
(16.7%) students, rendering statistical analyses of data for these students meaningless or inappropriate. These students were 
excluded from the study, resulting in a sample size of 782 students. Of the latter, the three Asian students were excluded 
because of their small number and their being present in Grade 8 only, while others were further excluded when their data 
relevant to the required analyses were found to be inadequate. 
In analyzing the data, attempts were always made to optimize the sample size. However, missing data occurred 
across the sample, necessitating selected exclusions of students for the various statistical analyses, resulting in differing 
sample sizes for the different analyses. 
Mean psychopathology scores (with 95% confidence intervals), and prevalence rates for lifetime use of cigarettes, 
alcohol, cannabis and inhalants (with 95% confidence intervals), were calculated and used to compare the Grade 8 and 
Grade 11 students (both within grades and across grades) in terms of gender, RCSG and age. Where the confidence intervals 
did not overlap, a statistically significant difference was concluded as existing between the selected groups (p<0.05). In 
cases where the confidence intervals overlapped to the extent that the percentage prevalence rate of one group was located 
within the confidence interval of the other group, the two groups were regarded as not statistically significant (p>0.05). In 
those cases where the confidence intervals overlapped, but not to the extent that the prevalence rate of one group was 
located within the confidence interval of the other group, the comparison was regarded as inconclusive. 
Logistic regression, using survey design analyses, was performed to assess the association between 
psychopathology (PTSD, anxiety and depression total scores) and substances of use (cigarettes, alcohol, cannabis and 
inhalants). These analyses were adjusted for the sampling design with the data stratified according to the geographical 
location of the schools as defined by postal code, and weighted in terms of the number of students in each school and in 
each grade per school, and the number of students selected from each grade. The results of these analyses were expressed in 
terms of unadjusted odds ratios, 95% confidence intervals, and p-values. These regression analyses were then repeated, 
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taking into account the role of demographic factors in the associations, providing adjusted odds ratios, 95% confidence 
intervals and p-values. Substance use, through its component factors, was retained as the dependent variable throughout the 
analyses, while the components of psychopathology, and the sociodemographic factors, were the independent variables 
where required. 
The results of the regression analyses were used to inform the selection of variables for the structural equation 
modeling (SEM) (Kline 1998). Gender and RCSG were selected to fit two separate multi-group models for the SEM. 
However, the RCSG model could not solve, resulting in a model stratified by gender only. For the males and females 
configural invariance and metric invariance (equal factor loadings), were achieved, thereby demonstrating that the 
calibration of the latent variables was comparable for males and females.  
The data were analysed using STATA (Version 9) (STATA Release 9 2008) for descriptive statistics and 
multivariate analyses (in the form of regression modeling), taking into account the clustering of the schools. LISREL 
(Version 8.72) (Joreskog & Sorbom 1996) was used for the structural equation modeling.  
RESULTS 
  The 157 students who were excluded from the sample were found to differ significantly (p=0.0001) from 
the 782 included students with respect to grade and RCSG. In particular, 78% of the excluded sample was in Grade 8 
compared with 55.8% in the included group, 21.7% of the exclusions were in Grade 11 compared with 44.2% of the 
included students, 51.7% of the exclusions were male compared with 43.6% of the inclusions, 46.7% of the exclusions were 
female compared with 54.5% of the inclusions, 46.2% of the exclusions were Black compared with 20.9% of the inclusions, 
7% of the exclusions were White compared with 25.4% of the inclusions, and 39.6%  of the exclusions were Coloured 
compared with 50.3% of the inclusions. 
As indicated in Table 1, there were more females than males in both Grade 8 and Grade 11. Coloured students 
were in the majority in both grades, reflecting the ethnic composition of the area from which the sample was selected. 
Females had significantly higher mean scores for all the measures of psychopathology compared with males. Barring 
depression in Grade 11, Black students had the highest mean psychopathology scores of all ethnic groups. No significant 
differences in psychopathology mean scores were identified among the selected age groups.  
Table 2 lists the prevalence of lifetime substance use, stratified by grade, gender, ethnicity and age. 
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In the adjusted models, PTSD was significantly associated with cigarette, alcohol, cannabis and 
inhalant use, depression was significantly associated with alcohol, cannabis and inhalant use, and anxiety 
was significantly associated with cannabis use. The significant associations for PTSD and depression with 
alcohol and cannabis use, and between anxiety and cannabis use, and between depression and inhalant use, 
were moderated by grade (Table 3). In particular, Grade 8 students had a 1.8% increased risk of alcohol use 
with every one point increase in PTSD total score. The Grade 8 students had a 4.2% decreased risk of 
cannabis use with every one point increase in PTSD total score, while the Grade 11s had a 2.3% increased 
risk of cannabis use with every one point increase in the PTSD total score. Grade 8 students had a 5% 
increased risk of alcohol use, and an 8% increased risk of cannabis use, with every one point increase in the 
depression total score, while the Grade 11s had a 4.7% decreased risk of inhalant use with every one point 
increase in the depression total score. The associations between PTSD and alcohol use in Grade 11, 
between depression, alcohol and cannabis use in Grade 11, and between depression and inhalant use in 
Grade 8, were not statistically significant. 
In the SEM structural model, though the Satorra-Bentler chi-squared value (88.04) was found to 
be significant (0.00003), its ratio with the related degrees of freedom (df = 41) provided evidence of 
adequate fit (Kline, 1998). The Global Goodness of Fit Statistics values obtained were above the generally-
accepted threshold for reasonable fit, with the RMSEA value of 0.0547, and NFI=0.971, NNFI=0.978, 
PNFI=0.711; CFI=0.984; IFI=0.984; RFI=0.960. Thus, it can safely be concluded that the specified model 
provides a reasonable fit to the data. 
In the males, weak evidence was found for an association between psychopathology and substance 
use (p=0.067) when adjusting for the effects of age. In females, there was also weak evidence for a 
statistically significant association between psychopathology and substance use (p=0.058) when adjusting 
for the effects of age. However, while neither of the effects for each gender was strongly statistically 
significant, there was slightly more evidence for an effect in the females than was found in the males. In 
addition, as illustrated in Figure 2, a statistically significant association (p=0.05) was found between age 
group and substance use in females, but not in males. 
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DISCUSSION 
The results obtained are characterised by several major findings that have previously been limited 
or unknown in this population. These include firstly, that there is an association between psychopathology 
and lifetime substance use; secondly, that the association between psychopathology and substance use is 
more likely to occur between certain types of psychopathology and substances; thirdly, the association 
between psychopathology and substance use is influenced by demographic factors; and fourthly, that 
school grade in particular impacts on the association between psychopathology and substance use.  
The specific associations that have been identified are between PTSD and all the selected 
substances of use (namely cigarettes, alcohol, cannabis and inhalants), between depression, alcohol, 
cannabis and inhalants, and between anxiety and cannabis. These findings reflect the trends in associations 
between psychopathology and substance use that have been illustrated elsewhere. For example, substance 
users have been found to be at greater risk of PTSD (Deykin & Buka 1997; Breslau et al. 1997), and have 
PTSD as the most common non-substance use diagnosis (Sonne et al. 1994). Furthermore, evidence has 
been provided for associations between PTSD and alcohol abuse (Breslau et al. 1997), between depression 
and general substance use (Hovens et al. 1994), between depression and specifically smoking (Anda et al. 
1990; Glassman et al. 1990; Regier et al. 1990; Breslau et al. 1994)  and alcohol use [Regier et al. 1990; 
Araujo & Monteiro, 1995; Rohde et al. 1996; Moscato et al. 1997; Dixit & Crum, 2000; Reinherz et al. 
2000; Goodman et al. 2003), and between anxiety and both general substance use as well as specifically 
smoking, alcohol and cannabis use (Sonne et al. 1994;Hovens et al, 1994; Breslau et al. 1991; Rounsaville 
et al. 1991; Costello et al. 1999; Kushner et al. 1999; Johnson et al. 2000; McGee et al. 2000; Grant et al. 
2000; Fernander et al. 2006). These results emphasize the specificity of associations between 
psychopathology and substance use, and have important implications for the planning of interventions 
geared at the prevention or treatment of comorbidity (Swendsen et al., 2010). 
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The results also provide evidence for the impact of demographic factors on the association 
between psychopathology and substance use. For example, age was found to influence cannabis use, and 
males were more likely to have used alcohol and cannabis compared with females. But this influence is not 
evident across all substances and psychopathology. Similarly, though the association between 
psychopathology and substance use appears stronger in females than males as indicated by the SEM, the 
influence of gender has not been clear. These results reflect trends in the literature. For example, Schwinn 
et al. (2010) have highlighted the paucity of studies that have examined the influence of gender on 
comorbidity, and emphasize the ‘mixed results’ that have been obtained from these studies. Racially 
classified social grouping (RCSG) was also significantly associated with some substances of use, with 
Black students being less likely to have used any of the selected substances while White students were 
more likely to have used alcohol and inhalants, as compared with Coloured students. These results concur 
with those of Wallace et al. (2003) who found that substance use was widespread among adolescents, and 
low specifically among Blacks compared with Native American, Hispanic or White adolescents. It must be 
noted that, in the South African context, RCSG has historically been defined almost exclusively in terms of 
skin colour and thus fundamentally has no intrinsic meaning. But, as a consequence of Apartheid policies, 
RCSG does reflect economic discrepancies, with the majority of the poorer South Africans being Black. 
However, in the current study, RCSG did not significantly influence the association between 
psychopathology and substance use.  Class grade had the most significant impact on the association 
between psychopathology and substance use. In particular, Grade 8 students had an increased risk of 
alcohol use with increased PTSD and depression scores, and an increased risk of cannabis use with increase 
in depression scores. In contrast, Grade 11 students had a decreased risk of cannabis use and inhalant use 
with increase in anxiety and depression scores respectively. 
There might be a tendency for the Grade 8 students who experience traumatic events to develop 
PTSD and use illicit (age-restricted) substances, and echo the findings of Breslau (Breslau et al. 1997) that 
PTSD increases the risk for first onset of major depression and alcohol abuse or dependence. However, in 
the Grade 11 students, it appears that increase in anxiety and depression scores decreases the risk of 
cannabis and inhalant use respectively. Thus, while PTSD and depression seem to be risk factors in illicit 
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substance use among the Grade 8 students, anxiety and depression appear to be protective factors in the 
Grade 11 students. It is possible that, in the Grade 11 students, the presence of anxiety and/or depression 
might limit the social interaction of the students, thereby limiting their exposure to illicit substance use.  
The results obtained did not reflect some trends in associations that have been found elsewhere. 
For example, the literature demonstrates an almost undisputed association between depression and 
smoking. But this study found similar associations only in the absence of the effects of demographic 
factors. Considering that a previous local study (Fernander et al. 2006) had found an association between 
depression and smoking in females, a likely explanation for the absence of this and other associations in 
this study could involve a combination of methodological and conceptual factors that distinguish this group 
from others that have similarly been investigated elsewhere. The results obtained here might reflect a 
sampling bias introduced by the exclusions that were largely from Grade 8, male and Black; all 
demographic factors (namely grade, gender and RSCG) that have featured prominently in the associations 
between psychopathology and substance use. The results could also have been influenced by the conceptual 
framework of this study. For example, psychopathology was assessed in terms of a summed total score on a 
particular day. Substance use was defined as ever having used any of the selected substances, regardless of 
recency, frequency or amount. Neither of these definitions constitutes a definitive clinical diagnosis of 
psychopathology or substance use disorder, abuse or dependence, and these definitions provide no measure 
of severity of disorder or frequency of substance use. The elicited associations thus do not lend themselves 
to equivalent comparison with studies that have identified lifetime comorbidity of psychiatric or more 
severe substance use or disorders by other means.  
However, despite these and the well-known limitations presented by self-administered 
questionnaires (such as, relying on the honesty of the respondents, missing data), the value of this study lies 
in its ability to provide comprehensive evidence for an association between psychopathology and substance 
use, and its concomitants, in a community sample where these details have previously been lacking. These 
findings, together with the fact that few similar studies have been conducted in this region, should inspire 
the need to conduct further and related research with a view to verifying and elaborating on the established 
associations. 
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TABLE 1 
Psychopathology scores stratified by standard, gender, age and ethnicity (Mean scores and 95% CI) 
 
Demographics                                                   
 
Grade 8 
Male  
 
Female  
 
Asian  
 
Black  
 
Coloured  
 
White  
 
Age (years)  <14  
                     
                    14-<16  
                     
                    16-<18  
                     
                    18+  
 
 
 
 
 
N (%)                                 
 
 
152 (43.4) 
 
206 (54.7) 
 
3 (0.85) 
 
74 (19.5) 
 
188 (53.4) 
 
91 (23.1) 
 
152 (41.1) 
 
187 (51.1) 
 
24 (6.8) 
 
1 (0.3) 
 
 
 
 
 
PTSD                         
 
 
45.5 (42.9; 48.2) 
 
51.5 (49.3; 53.6) 
 
53.3 (29.6; 77.0) 
 
54.4 (51.0; 57.9) 
 
47.4 (45.0; 49.9) 
 
48.1 (43.7; 52.4) 
 
45.7 (43.6; 47.9) 
 
50.8 (47.7; 53.9) 
 
55.1 (47.5; 62.8) 
 
68.1 (38.0; 98.2) 
 
 
 
 
 
 Anxiety                         
 
 
30.5 (28.8; 32.2) 
 
34.0 (32.6; 35.3) 
 
35.7 (23.4;48.0) 
 
37.9 (35.6; 40.3) 
 
30.6 (29.2; 32.0) 
 
31.7 (30.1; 33.4) 
 
31.1 (29.7; 32.4) 
 
32.6 (31.4; 33.7) 
 
38.3 (32.5; 44.2) 
 
55.2 (42.2; 68.3) 
 
 
 
 
 
 Depression 
 
 
28.0 (26.4; 30.0) 
 
32.8 (31.3; 34.3) 
 
45.5 (18.8; 72.2) 
 
32.7 (29.8; 35.5) 
 
30.4 (28.5; 32.4) 
 
29.9 (27.0; 32.8) 
 
29.8 (28.0; 31.8) 
 
31.1 (29.6; 32.6) 
 
34.2 (27.1; 41.3) 
 
37.6 (24.3; 51.0) 
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Grade 11 
Male  
 
Female  
 
Black   
 
Coloured  
 
White  
 
Age (years)  14-<16  
                      
                     16-<18  
                      
                     18+  
 
 
 
 
171 (43.8) 
 
237 (54.2) 
 
91 (22.8) 
 
212 (46.3) 
 
102 (28.4) 
 
7 (2.0) 
 
290 (69) 
 
2 (0.3) 
 
 
 
51.8 (48.9; 54.6) 
 
60.7 (57.2; 64.1) 
 
63.5 (57.8; 69.1) 
 
58.1 (55.1; 61.2) 
 
49.1 (45.4; 52.9) 
 
65.5 (50.7; 80.4) 
 
55.0 (51.3; 58.6) 
 
59.9 (56.1; 63.6) 
 
32.6 (31.3; 33.8) 
 
36.6 (35.0; 38.3) 
 
39.1 (36.4; 41.7) 
 
34.2 (32.9; 35.6) 
 
32.7 (32.0; 33.5) 
 
36.4 (31.1; 41.7) 
 
34.0 (33.0; 35.1) 
 
37.1 (34.2; 40.0) 
 
 
 
31.7 (30.2; 33.0) 
 
37.7 (35.3; 39.7) 
 
35.7 (32.7; 38.6) 
 
36.7 (34.4; 39.0) 
 
31.7 (29.4; 34.1) 
 
33.3 (25.3; 41.3) 
 
34.6 (32.2; 37.0) 
 
36.0 (33.6; 38.4) 
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TABLE 2 
Lifetime substance use prevalence stratified by grade, gender, ethnicity and age (n; (%); 95% CIs) 
 
 
Demographics 
 
Cigarettes 
 
Alcohol 
 
Cannabis 
 
Inhalants 
 
Grade 8 
Male 
 
 
Female 
 
 
Asian 
 
 
Black 
 
 
Coloured 
 
 
 
66 (43.4) 
[34.4; 53.0] 
 
81 (39.3) 
[32.0; 48.7] 
 
1 (34.8) 
[4.1; 87.0] 
 
9 (13.2) 
[6.9; 23.9] 
 
92 (49.1) 
[39.9; 58.3] 
 
 
60 (39.5) 
[30.2; 47.0] 
 
77 (37.40) 
[27.8; 45.1] 
 
1 (34.8) 
[4.1; 87.0] 
 
13 (16.2) 
[8.7; 28.1] 
 
71 (36.8) 
[29.8; 44.5] 
 
 
7 (4.6) 
[2.1; 9.6] 
 
7 (3.4) 
[1.3; 7.3] 
 
0 
 
 
2 (1.2) 
[0.12; 1.0] 
 
6 (3.9) 
[2.0; 7.6] 
 
 
6 (3.9) 
[1.6; 8.2] 
 
16 (7.8) 
[3.7; 15.8] 
 
0 
 
 
0 
 
 
10 (5.2) 
[2.7; 9.7] 
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White 
 
 
 
Age (years)  <14 
 
 
                    14-<16 
 
 
                    16-<18 
 
 
                    18+ 
 
 
 
Grade 11 
Male 
 
 
Female 
 
 
Black 
 
 
Coloured 
 
 
 
44 (48.9) 
[34.8; 63.2] 
 
 
54 (35.5) 
[27.2; 44.7] 
 
88 (48.8) 
[41.6; 56.2] 
 
7 (24.9) 
[8.8; 53.3] 
 
1 (41.4) 
[3.8; 92.7] 
 
 
 
101 (59.1) 
[49.6; 66.0] 
 
108 (45.6) 
[37.1; 54.1] 
 
21 (21.8) 
[11.3; 37.9] 
 
131 (62.9) 
[54.6; 70.4] 
 
 
52 (56.4) 
[42.1; 69.8] 
 
 
50 (32.2) 
[24.5; 41.0] 
 
81 (42.0) 
[31.8; 53.0] 
 
9 (33.3) 
[16.0; 56.7] 
 
0 
 
 
 
 
117 (68.4) 
[58.6; 77.5] 
 
117 (49.4) 
[39.9; 56.7] 
 
29 (32.0) 
[23.8; 41.5] 
 
133 (62.8) 
[51.6; 72.7] 
 
 
6 (5.9) 
[2.1; 15.5] 
 
 
4 (2.4) 
[0.8; 7.6] 
 
10 (5.3) 
[2.6; 10.4] 
 
0 
 
 
0 
 
 
 
 
46 (26.9) 
[19.0; 36.2] 
 
35 (14.8) 
[9.5; 19.8] 
 
9 (9.2) 
[4.5; 17.9] 
 
48 (23.2) 
[16.3; 31.8] 
 
 
12 (13.6) 
[7.9; 22.5] 
 
 
9 (5.7) 
[2.7; 11.7] 
 
13 (7.0) 
[3.3; 14.2] 
 
0 
 
 
0 
 
 
 
 
28 (16.3) 
[1.3; 7.6] 
 
11 (4.6) 
[2.2; 10.1] 
 
3 (3.6) 
[0.9; 13.0] 
 
23 (13.0) 
[7.6; 21.3] 
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White 
 
 
Age (years) 14-<16 
 
 
                    16-<18 
 
 
                    18+ 
 
 
58 (56.8) 
[43.1; 69.5] 
 
1 (10.9) 
[1.7; 46.6] 
 
161 (56.3) 
[49.8; 62.7] 
 
52 (42.8) 
[29.4; 57.3] 
 
72 (70.0) 
[56.3; 80.8] 
 
3 (41.5) 
[10.9; 80.5] 
 
178 (61.5) 
[52.1; 70.2] 
 
55 (47.5) 
[38.1; 57.0] 
 
23 (21.4) 
[14.6; 30.4] 
 
1 (10.9) 
[1.7; 46.6] 
 
53 (18.1) 
[13.4; 24.0] 
 
27 (23.3) 
[14.7; 34.8] 
 
14 (15.2) 
[10.2; 21.9] 
 
1 (19.8) 
[2.6; 69.8] 
 
30 (12.1) 
[7.4; 19.3] 
 
9 (8.3) 
[4.0; 16.6] 
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TABLE 3   
The association between psychopathology and substance use 
a
 
 
 
Psychopathology 
and demographic 
factors 
Substance use 
 
 
 
 
 
Cigarettes 
 
 
 
 
 
Alcohol 
 
 
 
 
 
 
Cannabis 
 
 
 
 
 
 
Inhalants 
 
 
 
 
 
 
Unadjusted 
 
 
 
 
Adjusted 
 
 
 
Unadjusted 
 
 
 
Adjusted 
 
 
 
Unadjusted 
 
 
 
Adjusted 
 
 
 
Unadjusted 
 
 
 
Adjusted 
 
 
 
 
 
PTSD 
 
1
1.010 
2
(0.998;1.023) 
3
0.101 
 
 
1.016 
(1.004;1.028) 
0.010 
 
1.005 
(0.997;1.014) 
0.208 
 
b
Gr. 8: 
1.018 
(1.000;1.037) 
0.053 
 
Gr. 11: 
0.998 
(0.977;1.019) 
0.839 
 
 
1.013 
(0.995;1.031) 
0.161 
 
bGr. 8: 
0.958 
(0.920;0.998) 
0.040 
 
Gr. 11: 
1.023 
(1.003;1.043) 
0.027 
 
1.035 
(1.012;1.058) 
0.004 
 
1.050 
(1.019;1.081) 
0.002 
 
 
Depression 
1.024 
(1.004;1.046) 
0.022 
1.014 
(0.992;1.035) 
0.199 
1.030 
(1.010;1.050) 
0.004 
b
Gr. 8: 
1.050 
(1.011;1.091) 
0.014 
1.022 
(0.991;1.054) 
0.156 
b
Gr. 8: 
1.080 
(1.007;1.159) 
0.032 
0.990 
(0.956;1.026) 
0.580 
 
Gr. 8: 
1.001 
(0.948;1.057) 
0.969 
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Gr. 11: 
1.011 
(0.979;1.045) 
0.487 
 
Gr. 11: 
0.999 
(0.967;1.031) 
0.934 
 
 
Gr. 11: 
0.953 
(0.909;0.999) 
0.044 
 
 
Anxiety 
 
0.966 
(0.942;0.991) 
0.009 
0.986 
(0.961;1.012) 
0.274 
0.967 
(0.945;0.994) 
0.007 
0.981 
(0.956;1.008) 
0.164 
0.965 
(0.936;0.995) 
0.023 
b
Gr. 8: 
1.035 
(0.963;1.112) 
0.342 
 
Gr. 11: 
0.955 
(0.919;0.993) 
0.021 
 
0.982 
(0.946;1.020) 
0.334 
 
1.003 
(0.954;1.054) 
0.908 
 
         
 
CI = Confidence Interval  OR = Odds 
Ratio 
a 
Models adjusted for grade, age, gender, 
ethnicity 
b
Associations indicating statistical 
interactions 
1,2,3
OR, CI and p-values respectively 
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Depression 
Anxiety 
PTSD 
Cigarettes 
Alcohol 
Cannabis 
Inhalants 
Psychopathology 
Substance Use 
Age Group Age 
Group 
0.53 
1.09 
0.63 
0.45 
0.38 
0.29 
0.54 
0.00 
0.31 
0.28 
1.0
0 
1.00 
0.76 
1.07 
1.00 
1.06 
1.13 
0.91 
0.06 
 Chi Square = 88.04, df = 41, p-value = 0.0003, RMSEA = 0.055 
 
Figure 1.   Structural Equation Model: The association between psychopathology and substance use in males 
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Depression 
Anxiety 
PTSD 
Cigarettes 
Alcohol 
Cannabis 
Inhalants 
Psychopathology 
Substance Use 
Age Group Age 
Group 
0.82 
0.95 
0.66 
0.32 
0.24 
0.13 
0.43 
0.00 
0.37 
0.05 
1.0
0 
1.00 
0.76 
1.07 
1.00 
1.06 
1.13 
0.91 
0.14 
Chi Square = 88.04, df = 41, p-value = 0.00003, RMSEA = 0.055 
 
Figure 2.  Structural Equation Model: The association between psychopathology and substance use in females 
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CHAPTER 4 
The association between psychopathology and substance use: 
adolescent and young adult substance users in inpatient treatment 
in Cape Town, South Africa 
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Abstract 
Introduction and Aims. Evidence suggests that comorbid psychopathology can negatively affect 
treatment outcomes in substance users. In South Africa, limited information is available regarding the 
prevalence, nature and contributing factors of the comorbid non-substance use psychopathology of 
substance users in treatment for their substance use. This study aimed to determine the frequency of 
occurrence and nature of comorbid non-substance use psychopathology, and its association with 
specific substance use, in adolescent and young adult substance users who received treatment for their 
substance use in Cape Town, South Africa. Design and Methods. Between December 2008 and 
December 2009, male and female inpatient substance users (n=95; ages 17-30 years) were sampled 
consecutively in order of admission from three substance use treatment facilities in Cape Town. An 
interview schedule was administered to elicit patients’sociodemographic and substance use history 
details. The computer-assisted Diagnostic Interview Schedule DSM IV (C-DIS IV) was administered 
to screen patients for current psychiatric disorders. Results. The sample was largely male, Coloured, 
Muslim and single. Cannabis (51.6%) and crystal methamphetamine (17.9%) were the most common 
first substances of use. Heroin (53.7%) and crystal methamphetamine (33.7%) were the most common 
substances for which treatment was sought (primary substances). The most common comorbid 
psychopathologies were anti-social personality disorder (ASPD 87.4%), conduct disorder (CD 
67.4%), oppositional defiant disorder (33.7%), major depression (25.3%), specific phobia (15.8%) 
and post-traumatic stress disorder (PTSD 14.7%). Regression analyses found a marginally significant 
association between specific phobia and first use of cannabis, but overall indicated no statistically 
significant associations between psychopathology and substance use. Discussion and Conclusions. 
The results demonstrated a high proportion of previously unidentified comorbid psychopathology in 
inpatient substance users. Further research is needed to investigate the prevalence and nature of such 
comorbid psychopathology in inpatient substance users, taking into account the context and 
heterogeneity of substance users in treatment.  
 
Key words: comorbidity, psychopathology, substance use treatment. 
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Introduction 
In psychiatry, the phenomenon where non-substance use psychopathology and problematic 
substance use coexist is a common form of comorbidity [1]. The comorbid conditions may 
co-exist simultaneously (concurrent), in tandem (sequential) or separately at any time in the 
patient’s life (lifetime) [2].  Comorbidity is sometimes referred to as “dual diagnosis’ or ‘co-
occurring disorders’, and can involve the co-occurrence of two or more disorders. [3,4]. The 
comorbidity might involve pathology that meets the criteria for diagnosis of a disorder, or 
might refer to the presence of symptoms of a disorder [5] 
Various suggestions have been proposed to explain relationships between comorbid 
psychopathology and substance. These include i) that the comorbidity might occur when 
people with psychiatric illness attempt to alleviate their discomfort by self-medicating with 
substances, leading to problematic use of the substances or to substance use-related disorders 
[2], ii)  that the substance use could lead to mental illness [2], iii) that certain individuals 
might be genetically predisposed to either psychiatric illness and/or substance use resulting in 
comorbid conditions [2], iv) that in some cases, either condition could influence, or effect a 
change in, the course of the other [2], and v)  that the substance use and psychopathology 
share a common neural substrate [4].  
Community and hospital-based studies have provided evidence for an increased 
likelihood of comorbid psychiatric disorder in substance users [5], with a greater likelihood 
of such comorbidity as the severity of the substance use increases [6]. Psychological and 
psychiatric problems that have been associated with substance use include cognitive 
impairment, poor scholastic performance, personal and relationship problems [7], depression, 
anxiety [8] and PTSD [9]. Disruptive behaviour disorders like antisocial personality disorder 
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[10] and conduct disorder [11] have been found to be very common in patients who receive 
treatment for substance use [12].   
However, the evidence for associations between specific forms of psychopathology 
and the use of specific substances has not been clear or consistent. For example, the review of 
community studies by Armstrong and Costello [6] indicated that, except for cannabis, 
associations between psychiatric disorders and the use of specific substances was not specific 
to either the psychiatric disorders or the substances of use. In the National Comorbidity 
Survey (NCS), anxiety disorders and conduct disorder/adult anti-social behaviour disorder 
were found to precede and predict later alcohol dependence, but such consistency in  
chronicity was not duplicated with the same certainty with regards to other mental disorders 
or substances of use [13].  
In treatment populations, comorbidity is known to be characterised by heterogeneity 
[14]. For example, co-occurring substance use and psychopathology differ with respect to the 
types of substances and psychiatric problems, the temporality of the comorbid conditions 
[14], and the possible influence of sociodemographic factors such as age [15], gender or 
race/ethnicity in the associations [6]. 
Comorbid substance use and psychiatric disorder has also commonly been associated 
with poor treatment outcomes for either or both conditions, including increase in the use or 
abuse of substances and increased psychosocial impairment, compared with outcomes of 
treatment when either substance use or psychiatric disorder occur individually [16] [5]. The 
diagnosis of psychiatric comorbidity in substance users, and of substance use disorders in 
psychiatric patients, is thus an important component in the development of strategies for 
treatment [17].  
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More information is available on comorbid psychiatric disorders and substance use in 
adults than in children, adolescents and young adults [6] [18]. In South Africa, the prevalence 
of substance use is a cause for concern, with an increase in the use of substances such as 
crystal methamphetamine (locally known as ‘tik’) and diacetyl morphine (heroin) [19], and 
evidence for increased use of substances in general, and cannabis in particular, in adolescents 
and young adults [20]. Globally, substance use and psychiatric disorders are managed largely 
independently. Reasons for this include treatment facilities being historically specialised as 
either substance use treatment centres, or centres for the treatment of psychiatric disorders, 
with limited numbers of suitably-trained professionals to treat comorbidity [21]. The trend is 
similar in South Africa. As a result, patients with comorbid psychopathology and problematic 
substance use usually attend either a psychiatric or a substance use treatment facility 
depending on the problem deemed by the patient or his/her family as the one most urgently in 
need of attention.  
In many substance use treatment centres comorbid psychopathology might be 
suspected in patients, but it is often not assessed or addressed. The reasons for this are usually 
a lack of expertise, capacity, time or opportunity at the treatment centres [21]. Consequently, 
if the substance use treatment results in the patient behaving more socially-appropriately, 
concurrent psychopathology will receive little attention unless the patient’s behaviour 
becomes disruptive or dysfunctional. Since these behavioural problems are often 
accompanied by substance use [22], the cycle can be repeated endlessly. Individuals with 
comorbid psychopathology and substance use can thus repeatedly enter and exit either 
psychopathology and/or substance use treatment depending on which problem is regarded as 
the “most problematic’’ at any one time.  
The examination of comorbid psychopathology and substance use in both clinical and 
community populations of substance users is important particularly because these groups may 
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differ with respect to the nature of the comorbidity [6]. For example, morbidity might be 
more severe, and comorbidity rates might be higher, in clinical samples compared with 
community samples. Patients might be more likely to seek treatment for certain disorders (for 
example, disruptive behaviour disorders) than for others (for example, depression), resulting 
in clinical samples having a predominance of disorders that are more likely to precipitate 
admission to treatment [6]. Results from clinical samples might thus not be generalisable to 
community samples and, conversely, the information obtained from community samples 
might not apply to clinical populations. Examination of both community and clinical samples 
is, therefore, needed to ascertain the prevalence of comorbidity in general, and to determine 
the likelihood of associations between comorbid conditions. 
As previously mentioned, research evidence indicates increased substance use 
amongst young people in South Africa [20][23]. Information from the South African Stress 
and Health (SASH) study provides evidence for high prevalence rates of mental disorders in 
particularly the urban areas of South Africa [22]. However, there has been only limited 
investigation of the occurrence and nature of comorbid psychiatric diagnoses in substance 
users in South Africa, and the factors that impact on this comorbidity, for both community 
[20] and treatment samples [23] of substance users.  
As part of a series of studies on comorbidity in young people, this study aimed to 
determine the frequency and nature of non-substance psychopathology in adolescent and 
young adult substance users who were receiving inpatient treatment for their substance use, 
and to examine the association between psychopathology and substance use in these patients, 
adjusting for social and demographic factors.  
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Methods 
Sample: Ninety-five inpatient substance users were sampled from three privately-
funded inpatient substance use treatment centres in Cape Town, South Africa. The treatment 
centres were selected from the list of Cape Town substance use inpatient treatment centres 
affiliated to the South African Community Epidemiology Network on Drug Use 
(SACENDU) [23] for the surveillance of substance use trends across South Africa. The 
inpatient treatment centres that had the largest number of admissions over the previous six 
months were shortlisted as possible study sites to ensure obtaining the selected sample size 
within the study period. Since the Cape Town area is geographically still largely divided in 
terms of racially classified social groups (RCSGs, as defined by the Population Registration 
Act of 1950, and consisting of the categories White, Coloured, Black and Indian/Asian) and 
economic class, three clinic study sites were selected (from the shortlist of treatment centres) 
from three different suburbs of Cape Town, in an attempt to gain information from as broad a 
racial and economic spectrum of inpatients within the research period. These were i) a 
predominantly White upmarket residential-cum-commercial area, and followed a medical 
model of treatment ii) a middle-class residential area of largely White, Coloured and Indian 
communities, and followed a treatment modality that included homeopathy, spirituality and 
Ayurvedic medicine, and iii) an area which included largely Coloured and Black 
communities, brick homes, informal dwellings, smallholdings and farmland, and provided 
custodial care, and encouraged spirituality, accompanied by administration of vitamins, 
massage, periods in a sauna, motivational talks and group therapy.  
Sampling of patients was completed over the period December 2008 to December 
2009. The estimated required sample size for a precision of 0.05 and an anticipated 
proportion of 98% (the approximate proportion of patients that were found to be positive for 
psychopathology while sampling), was 45 and thus very small. As such, it was decided to aim 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
134 
 
for a sample of 100 patients, thus more than doubling the estimated required sample size. A 
minimum sample size of 46 would also be required for logistic regression analyses with 6 
predictor variables (excluding the constant), a precision of 0.05, 80% power, and a large 
effect (f2=0.35 or model r2=0.26), while a minimal sample size of 97 would be required for a medium 
anticipated effect (f
2
=0.15, or model r
2
=0.13). We assumed the latter effect being most likely in this 
study, given previous findings in the literature. A total of 95 adolescents (n=1) and young adults 
(n=94), constituting all admissions aged 30 years and younger, and admitted for inpatient 
treatment of their problematic substance use, had been sampled by the end of the data 
collection period.  Instruments: An Interview Schedule was designed for the study to elicit 
demographic, social, substance use history and recent substance use information. The 
demographic and social information elicited included age, gender, racially classified social 
group (RCSG), religious denomination, highest educational level, referral source, marital 
status, living arrangements and employment status. The substance use information elicited 
included age of onset, the first substance of use (other than tobacco), the most frequently used 
substance, the substance for which treatment was sought, the frequency and quantity of 
substance use, and previous treatment for substance use. The most frequently used substance 
was invariably the substance for which treatment was sought and will alternatively be 
referred to in this paper as the primary substance of use.  The computer-assisted Diagnostic 
Interview Schedule (DIS) for Diagnostic and Statistical Manual (DSM) IV (C-DIS IV) [24] 
was administered to screen for any current (12-month) psychiatric disorders. The C-DIS is a 
computerised version of the paper-and-pencil DIS-IV. The instrument was designed to allow 
administration by non-clinically experienced examiners who are trained to use the instrument, 
and does not need corroborating details from alternative sources, such as hospital records, to 
make diagnoses. The responses from interviewees are directly coded and captured, reducing 
possible error, and providing study data immediately via the diagnostic report using the SAS 
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computer programme. The C-DIS is considered to be more accurate than the pencil-and-
paper version because it automatically counts symptoms for diagnostic criteria, checks dates 
to ensure accuracy of onset and remission of symptoms. The questions are designed to be 
specific, thus the responses to questions can be reliably recorded by a variety of interviewers. 
The C-DIS can be used in both treatment and community settings, has the option of being 
used in either a limited screening version or full version, with the screen version providing 
information about the presence or absence of a disorder without details regarding the 
symptoms, course or severity of the disorder. The C-DIS can be self-administered with the 
proviso of training for the respondent. The instrument also allows the interviewer to skip 
certain diagnostic modules, thus tailoring the interview to the diagnoses of interest.  
Instructions for use of the C-DIS [24] suggest that full versions of the instrument be 
used to assess disorders with early onset (such as attention deficit hyperactivity disorder, 
separation anxiety, oppositional disorder and conduct disorder) since these disorders might be 
risk factors for disorders of later onset. However, it is also recommended that full and 
screened versions for making diagnoses not be combined in interviews. Thus, to ensure parity 
in the mode of administration throughout the study, it was elected to use the screened version 
of the instrument for all interviews to minimize the duration of the interviews, and to include 
all the C-DIS modules in the interviews.  
It was felt that the study would not be compromised with use of the screened version 
of the C-DIS with respect to early onset diagnoses because the study sample consisted largely 
of young adults. All the interviews were conducted by a trained DIS interviewer (primary 
author). Procedure: Admitted patients who were aged 30 years and under were considered for 
selection in the sample after completing the detoxification programme (a period ranging from 
one to two weeks, as determined by the treatment centre managers) offered at each clinic. 
This was done to ensure that patients selected for interviewing had largely overcome the 
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discomfort and agitation associated with withdrawal from substance use, and were more 
amenable to interviewing. This delay also allowed for the symptoms of substance-induced 
psychiatric symptoms to be minimized, where present. Each identified potential study subject 
was approached to obtain written informed consent for participating in the study. The one 
patient under the age of 18 completed assent forms, and written parental consent was 
obtained before interviewing this patient. All interviews were conducted by the primary 
author, at the clinics, and in private, with only the interviewer and patient present. Each 
interview was completed in one session, with the duration of each session approximating 90 
to 120 minutes. The study was approved by the Research Ethics Committee of the University 
of Cape Town (REC REF: 340/2007). 
Data analyses 
The data were analysed using STATA Version 10 [25]. Percentages were estimated 
for demographic factors, substance use, and psychiatric diagnoses. The demographic factors 
selected for analyses in this study were: age, gender, racially classified social grouping 
(RCSG), religious denomination (none, Christian, Muslim, Jewish, other), highest 
educational level (none, primary, secondary, tertiary), marital status (never married or other), 
employment (employed, unemployed or student), and living arrangements (alone, with 
immediate family). Substance use data were recorded in terms of the first substance of use 
(other than tobacco), the age at which the first substance of use was initiated, and the most 
frequently used substance (which was always the substance for which treatment was sought, 
listed in the tables as primary substance of use).  
Bivariate associations [to compare the distribution of patients across the clinics 
sociodemographically (Table 1), by substance use (Table 2), and by current psychopathology 
(Table 3)] were assessed using Fisher’s Exact tests in those cases where the cell sizes were 
less than or equal to 5, and chi-squared tests where the cell sizes were  greater than 5. The 
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percentage of psychopathology and first and primary substances of use (Table 4), and the 
percentage of first and primary substance use with respect to the most commonly-occurring 
forms of psychopathology (Table 5) were calculated. Bivariate associations between 
psychopathology and substance use were calculated using Fisher’s Exact and chi-squared 
analyses (Tables 6 and 7). Multiple logistic regression analyses (Table 8) were conducted to 
determine associations between type of psychiatric disorder (selected from the most 
commonly-occurring psychiatric diagnoses) and a) the first substances of use, and b) the most 
frequently used (primary) substances. First substance of use was coded as either cannabis, 
crystal methamphetamine, or other, based on the most common substances first used;  most 
common primary substance of use was coded as crystal methamphetamine , heroin or other, 
based on the most common substances for which patients were admitted for treatment. For 
these, odds ratios and 95% confidence intervals were calculated, unadjusted and adjusted for 
the treatment centres, and sociodemographic factors including age, gender, religious 
denomination, racially classified social group and treatment centre. In all the relevant 
analyses, substance use (in the form of first and primary substances of use) was the dependent 
variable, and the sociodemographic characteristics and psychopathology diagnoses were the 
independent variables. Forced statistical modelling was used for the logistic regression. The 
independent variables were not formally tested for multicollinearity and singularity since the 
statistical programme (STATA 10)[25] used for the analyses automatically tests for tolerance, 
and excludes variables which have insufficient tolerance. Statistical significance was 
indicated by p<0.05 while p-values between 0.05 and 0.10 were regarded as reflecting 
marginal effects. 
Results 
Table 1 shows the demographic characteristics of the sample at the three treatment 
centres(clinics). The total sample consisted of 95 inpatients [ages 17-30 years, with a mean 
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age of 23 years (SD = 2.9)]. The sample consisted predominantly of males (89.5%), 
individuals of Coloured origin (88.4%), and Muslim religious denomination (68.4%). Eighty-
six percent of the patients had some secondary school education, 77.9% had never been 
married, 91.6% lived with immediate family, and 61.1% had entered treatment on their own 
volition. More than half the sample (54.7%) was unemployed, while nearly a third had 
fulltime employment, at the time of entering treatment. The proportions of patients at the 
three clinics differed with respect to two demographic variables - religious denomination (p 
<0.001), with Clinics 2 and 3 having 90% and 75% Muslim patients respectively, while 
Clinic 1 had 88.2% Christian patients, and RCSG (p=0.066), with Clinics 2 and 3 having 
more than 90%  Coloured patients while 17.7% of the patients at Clinic 1 were White. 
 A total of 51.6% of the sample had commenced substance use between the 
ages of 10 and 14 years (Table 2) while 85.3% (n=81) had started using substances by age 17 
years, with a mean age of substance use onset of 14.7 years (SD=2.4).  The most common 
first substances of use were cannabis (51.6%) and crystal methamphetamine (tik) (17.9%). 
The most common substances for which treatment was sought (i.e. primary substances of 
use) were heroin (53.7%) and crystal methamphetamine (33.7%). The large majority of 
patients used substances every day (90.5%), and used as much as they could obtain (58.9%) 
or afford to buy (38.9%). All except two of the patients smoked cigarettes every day, did not 
count how many cigarettes they smoked, and did not regard their cigarette smoking as a 
problem (not listed in Table 2). There was a statistically significant difference in the 
proportion of patients at the three clinics with respect to the primary substance of use. Heroin 
was the primary substance of use in more than 60% of the patients at Clinics 2 and 3, 
compared with 11.8% at Clinic 1. At Clinic 1, more than 40% of the patients had crystal 
methamphetamine as their primary substance of use compared with 26.7% and 35.4% at 
Clinics 2 and 3 respectively. Forty-four percent of the patients were in substance use 
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treatment for the first time at the time of the study. Of those who had had previous treatment 
for their substance use (n=53), 68% (n=36) had been between the ages of 15 and 20 years 
when they had their first treatment.  However, the proportion of patients at each clinic was 
marginally different with respect to their previous history of substance use treatment 
(p=0.081), with the majority of patients at Clinic 1 (64.7%) being in substance use treatment 
for the first time. 
Table 3 lists the proportions of patients at each of the clinics with respect to their 
diagnosis of current psychopathology. In the study all the C-DIS IV modules were 
administered, but only the most common psychiatric diagnoses are listed in Table 3. In total, 
95.8% of patients had some form of psychopathology; only three patients had no non-
substance use psychiatric diagnosis. Some patients had more than one current psychiatric 
disorder. Sixty patients (63.2%) had at least two non-substance use psychopathology 
diagnoses, and 27 patients (28.4%) had at least three non-substance use psychopathology 
diagnoses. Of the 92 patients with psychopathology, only four patients had previously been 
diagnosed with a non-substance use psychiatric disorder (Table 3). There was no statistically 
significant difference in the proportions of patients at each clinic who had never previously 
been diagnosed with a psychiatric disorder. The most common current psychiatric diagnoses 
were substance dependence (91.6%), anti-social personality disorder (ASPD) (87.4%), 
conduct disorder (CD) (67.4%), oppositional defiant disorder (33.7%) and major depression 
(25.3%). The proportion of patients differed significantly at the three clinics with respect to 
mania (p=0.007), with one patient at Clinic 2 having had a manic episode in the last 12 
months compared with six and five patients at Clinics 1 and 3 respectively. The numbers of 
patients diagnosed with substance dependence differed significantly across the treatment 
centres (p=0.007), with Clinics 2 and 3 having more than 95% of patients dependent on 
substances compared with 70.6% of patients with substance dependence at Clinic 1.  The 
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Clinics also differed marginally with respect to generalised anxiety disorder (p=0.059) and 
post-traumatic stress disorder (PTSD) (p=0.065) although the numbers of patients with these 
diagnoses were generally relatively small. 
Table 4 presents the frequency of psychopathology by first substance of use and 
primary substance of use. There was no statistically significant difference in the proportions 
of any psychopathology by either first substance of use or by primary substance of use.  
Table 5 presents the percentage of patients with the most common first and primary 
substances of use in terms of the most commonly-occurring non-substance use 
psychopathology. These results indicate that a statistically significant proportion of those who 
were positive for conduct disorder had started out using cannabis (p=0.048) compared with 
those who were not positive for conduct disorder. The proportion of patients who had anti-
social personality disorder and had used cannabis as their first substance was marginally 
higher than the proportion of patients who were positive for the other commonly-occurring 
disorders and used cannabis as their first substance of use. The difference in the proportions 
of the other psychopathologies by substance use were not statistically significant. 
Tables 6 and 7 list the percentage of the most common first and primary substances of 
use by the most common psychopathology, and the percentage of the most common 
psychopathology by the most common first and primary substances of use respectively. 
These tables thus essentially list the same frequency of occurrences in terms of row and 
column totals. Significantly more patients (p=0.049) who were found to be positive for 
conduct disorder, compared with those who were not diagnosed with conduct disorder, had 
used cannabis as their first substance. Marginally more patients (p=0.0654) who were found 
to be positive for antisocial personality disorder, compared with those who were not positive 
for antisocial personality disorder, had their substance use debut with cannabis.  
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Table 8 documents the results of the regression analyses which were conducted to 
determine associations between different forms of non-substance use psychopathology and 
different forms of first substance used and primary substance use, listing odds ratios, 95% 
confidence intervals and p-values for these associations.  Odds ratios are presented both 
unadjusted and adjusted for age, gender, religion, racially classified social group, and 
treatment centre (clinic).  
The marginal unadjusted association (p=0.061) found between anti-social personality 
disorder and cannabis as the first substance of use on bivariate comparisons (Table 8) was 
lost on adjustment for age, gender, religion, treatment centre and racially classified social 
group (p=0.117). 
Similarly, the apparent association between conduct disorder and cannabis as the first 
substance of use which was statistically significant (p=0.031) before adjustment for age, 
gender, education, treatment centre and RCSG, became statistically not significant after 
adjustment (p=0.103). 
The unadjusted odds ratio for the association between specific phobia and cannabis as 
the first substance of use was not statistically significant before adjustment (p=0.479) but 
approached statistical significance on adjustment (OR=4.74; 95% CI 0.99-22.66, p=0.051). 
The unadjusted odds ratio for the association between oppositional defiant disorder 
and crystal methamphetamine as the primary substance of use was marginally significant 
(p=0.087) but became not statistically significant on adjustment for age, gender, treatment 
centre and racially classified social group. 
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Discussion 
This study aimed to determine the frequency and nature of non-substance use 
psychopathology in young adult substance users in inpatient treatment for their substance use, 
and to identify demographic, social and substance use factors that influenced the association 
between psychopathology and substance use. 
The results obtained indicate a large proportion of inpatient substance users who had 
not previously been diagnosed with a psychiatric disorder (95.8%) (Table 3). A large number 
of patients was diagnosed with a current (12-month) non-substance psychiatric disorder in 
this study (n=92; 96.8%), demonstrating a high percentage of comorbid psychopathology in 
these inpatients in Cape Town, with a percentage that exceeds the prevalence of these 
psychiatric diagnoses reported for the general adult community but using a different 
instrument, namely the Composite International Diagnostic Interview (CIDI) which also 
provides DSM IV diagnoses [22].  
The high percentage of previously-undiagnosed psychopathology in these inpatient 
substance users, despite many of the patients having been in treatment for their problematic 
substance use previously, suggests a need for substance users to be assessed for co-occurring 
psychopathology as part of the rehabilitation from either the substance use or 
psychopathology. It might also be necessary to recognize the demographic and social 
heterogeneity of these patients, and to tailor their treatment according to their individual 
needs.  
It is, however, likely that the study sample was vulnerable to Berkson’s Bias [26] in 
that there would be an increased likelihood of patients seeking treatment for their substance 
use problems because they experienced a co-existing non-substance use psychiatric disorder. 
The presence of disruptive behavior disorders (noted by the high prevalence of diagnoses 
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such as anti-social personality disorder, conduct disorder and oppositional defiant disorder) 
could also have played a role in treatment-seeking by causing social conflict in the lives of 
the substance users [7], precipitating admission for substance use treatment. It is also possible 
that the percentage of psychopathology in this substance use treatment group differed from 
that in community substance users because of differences in the severity of the extant 
conditions in the two groups [6]. In other words, substance users in the community might 
experience symptoms related to the same psychiatric diagnoses as those of patients in this 
study, but these psychiatric symptoms might be less severe and not yet meet the criteria for 
diagnoses and hence might not yet play a role in treatment-seeking behavior.  
While there is debate on whether substance use (in the form of problematic substance 
use, or abuse or dependence) may be regarded as a dysfunctional or antisocial behaviour, 
constituting part of a psychiatric disorder, or a psychiatric disorder itself [8], there is little 
doubt about the predominance of disruptive behavior disorders in clinical samples of 
substance users compared with the prevalence of other non-substance use psychopathology 
[7] (as was found in this study), and the role that  disruptive behaviour disorders might play 
in treatment-seeking. 
The presence of a comorbid disruptive behavior disorder might also be more likely to 
precipitate treatment- seeking for substance use problems than would a co-occurring anxiety 
disorder [6], possibly accounting for the low proportions, or absence, in the present study, of 
those comorbid psychiatric diagnoses (for example, depression [8] anxiety [7] and 
posttraumatic stress disorder [6]) that have commonly been associated with substance use, 
abuse or dependence in the community [7; 8] and in patients who receive treatment for their 
substance use [5].  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
144 
 
The proportions of patients with the most common psychiatric diagnoses did not show 
statistically significant differences by either the first or primary substances of use (Table 4). 
However, a significantly greater proportion of patients who were diagnosed with conduct 
disorder had also initiated their substance use with cannabis (59.4%) (Table 6) compared with 
the proportion of patients in whom conduct disorder was absent (p=0.049). Similarly, a 
marginally larger proportion of patients with antisocial personality disorder had cannabis as 
their first substance of use (55.4%) (Table 6), compared with those patients in whom 
antisocial personality disorder was absent (p=0.065). It is thus possible that cannabis was 
indeed a notable first substance of use in those who were diagnosed with conduct disorder or 
antisocial personality disorder. Further multivariate investigation of the association between 
psychopathology and substance use (Table 8) indicated a (marginally) statistically significant 
association only between specific phobia and cannabis as the first substance of use (OR=4,74 
95%CI 0.99-22.68; p=0.051). It is, however, important that the marginal results obtained in 
this study be interpreted with caution. 
There might be other factors that also play a role in the nature, prevalence and 
associated substance use of psychopathology amongst inpatient substance users. For example, 
when examining the psychiatric symptoms of patients in the National Treatment Outcome 
Research Study, Marsden et al. [7], found that the relationship between psychiatric symptoms 
and substance use was not a direct relationship but rather a relationship that was conditional 
on the types of substance use. For example, these authors reported that depressive symptoms 
were less likely or less severe in opiate users in treatment, than in users of stimulants who 
were in treatment. They also found that, in substance users who receive treatment, the 
frequency and severity of psychiatric symptoms were predicted by poor physical health, 
previous psychiatric treatment, gender, and personal relationships characterized by high 
levels of conflict. It is thus possible that factors such as these, of which physical health, 
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previous psychiatric treatment and personal relationships were not assessed in relation to 
comorbidity in the present study, contributed to the findings of the present study by 
influencing psychiatric symptoms and disorders, and, indirectly, the association between 
psychopathology and substance use.  
The distribution of the Western Cape province (of which Cape Town is the capital 
city) treatment population during the study period, in terms of racially classified social 
grouping, indicates that Coloured patients who presented for substance use treatment 
constituted 54% of the treatment population, with Whites, Blacks and Indians consisting of 
18%, 27% and 1% respectively [27]. The study sample, with comparative RCSG figures of 
88.4% Coloured, 4.2% White, and 7.4% Indian, thus reflects the population preponderance of 
Coloured substance use patients relative to White and Indian patients. The complete absence 
of Black patients from this sample is, however, surprising, particularly considering the close 
proximity to Clinic 3 of a largely Black informal settlement. This finding could possibly be a 
result of a combination of factors that involved financial constraints and/or the nature of the 
treatment offered at the treatment centres selected for sampling.    
The sample contained few females. However, the proportion of males (90%) to 
females in the sample, appears to be consistent with the gender distribution of the substance 
using population that sought treatment, from which the sample was drawn [27], and with 
samples of similar studies [28, 29]. On examining possible reasons for the uneven gender 
distribution of substance use inpatients, Green et al. [30] found that in females, a comorbid 
psychiatric diagnosis predicted a failure of treatment initiation, while in males a low 
educational level predicted a failure of treatment initiation. It is possible that comorbid 
psychopathology might have played a role in the treatment initiation of some females, but 
this association was beyond the design of the present study, as was the role of low 
educational level in potential male substance use inpatients in treatment initiation. 
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However, the paucity of females in this study sample could also be indicative of 
females possibly facing more obstacles to entering inpatient treatment [for example, social 
stigma and treatment beliefs [30], or financial constraints [31] compared with males.  
Further investigations could be geared at identifying and minimising the obstacles that 
females face with regards to attending inpatient treatment facilities.  Based on the findings of 
Green et al. [32], it might thus be useful to emphasise assessment of females for psychiatric 
disorder prior to suggesting inpatient admission. Such assessment, coupled with treatment for 
psychiatric disorder and counselling, might aid admission of females where this is deemed 
appropriate and potentially beneficial. Similar support for males with low educational levels 
might also prove helpful in aiding initiation of treatment for substance use. 
The high percentage of cigarette smoking amongst this group of substance users in 
treatment might be cause for concern. Only two patients in the sample did not smoke 
cigarettes. The other patients smoked cigarettes every day, did not count the number of 
cigarettes they smoked, did not regard cigarettes as another substance of use, and viewed 
their cigarette smoking as more socially acceptable and with a smaller impact on their lives 
than their use of other substances. There is thus the possibility that cigarette smokers who 
receive treatment for use of other substances could potentially face a future of compromised 
health as a result of their cigarette smoking, irrespective of whether or not they attain 
abstinence from their other substance use.  
It is notable that few of the patients were in treatment for problem-drinking of alcohol 
when alcohol is still the most common substance of abuse for which treatment is sought in 
the area [27]. The preponderance of Muslim patients in this sample could have accounted for 
this result since alcohol consumption is forbidden in Islam and is considered a social taboo in 
Muslim communities, even among users of other substances. However, alcohol generally 
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appears to be an unlikely substance of use for which treatment is sought in young people, 
particularly when there are other (usually illicit) substances of use available [33]. The most 
likely reason for the small number of patients in treatment for alcohol use in this sample 
might thus be that patients in treatment for alcohol use were usually older [27] and thus not 
eligible for selection in the study.  
The present study did not elicit information regarding the mode of substance use. 
Hence information on intravenous versus other drug administration is absent. Injecting 
substances like heroin is known to be associated with increased Severity of Dependence 
scores compared with smoking heroin [34], while increased severity of dependence on 
substances has been associated with increased risk of psychopathology [13]. Thus, in the 
absence of information regarding mode of drug administration, its relevance for associations 
between substance use, substance use severity and psychopathology cannot be commented 
on. However, smoking appears to be the most common means of non-alcohol substance 
administration in this community [27] so it would be appropriate to assume that, where 
relevant, substances in this sample were smoked rather than injected. 
It is important that the implications of these study findings also be considered in light 
of the small sample size and its role in limiting the study power. There is the possibility that 
the multiple comparisons could have produced differences between groups that might be 
chance findings, while, with the relatively small sample size, real differences between groups 
might have been missed.  
In addition, the lack of a representative sample precludes generalisability of the 
results beyond the study sample, while the cross-sectional design of the study limits 
inferences regarding temporality, causality, and gateway pathways to comorbid substance use 
and psychopathology, even in those cases where statistically significant associations 
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emerged. Further investigations in the form of longitudinal studies that i) examine the risk for 
substance use in individuals diagnosed with psychiatric disorder, and ii) examine the risk for 
psychiatric disorder in substance users, are needed to provide information regarding temporal 
associations between the psychopathology and substance use. In addition, further 
investigations of both treatment and community samples might provide additional insights, 
particularly as regards differences in comorbid non-substance use psychopathology. 
The use of the C-DIS to diagnose psychiatric and substance use disorders in this 
population could have placed limitations on this study. Testing the validity of the DIS has 
been a complicated and difficult task because of the absence of suitable benchmarks against 
which to measure the instrument [24].  The reliability of the computer-assisted version of the 
DIS compared with the pencil-and-paper version of the instrument has also not been tested, 
although the DIS reflects 79%-96%  agreement with diagnoses assisted by clinical judgement 
[35]. In addition, the instrument has not been standardized for use with the South African 
population.  
The screening version of the C-DIS [24] might also have influenced the results by 
limiting information about the duration and impairment of psychiatric disorders, and about 
the sequence or temporality of non-substance use and substance use disorders. Furthermore, 
use of the screen version for disorders with early onset (such as attention deficit disorder, 
separation anxiety, oppositional defiant disorder and conduct disorder) might have 
compromised the percentage of these disorders that could be identified, as well as the 
percentage of the disorders they preempt [such as antisocial personality disorder being 
regarded as the adult version (> 18 years) of conduct disorder (< 18 years)]. Lastly, errors 
with respect to the diagnoses of the earlier and later disorders could have occurred because of 
the manner in which the C-DIS codes assessment of the diagnostic criteria for these disorders 
[24]. However, the DIS is one of few available recognized diagnostic instruments that are 
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regarded as sufficiently reliable for use by lay interviewers [35], that shows high concordance 
with clinically-derived diagnoses [35], and provides the opportunity to screen for current 
diagnoses when the interviewing time is limited [24]. 
This study has highlighted that psychopathology is common in substance using young 
people who received inpatient treatment for their substance use. The study has illustrated the 
need for psychiatric assessment of comorbid psychopathology in substance users who receive 
treatment for their substance use in Cape Town, South Africa, with the suggestion that 
integrated service models be developed for the treatment of mental illness and substance use. 
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Table 1.  Demographic characteristics of the sample in the three treatment centres (n; %) 
 
 
 
Demographic variable 
 
Clinics 
 
Clinic 1 
 
Clinic 2 
 
Clinic 3 
 
Total 
 
p-value 
 
n =17 
 
n = 30 
 
n = 48 
 
n = 95 
 
 
Mean Age 
SD 
 
21.7 
3.5 
 
23.2 
3.0 
 
23.4 
2.6 
 
23.0 
2.9 
 
 
0.111
†
 
 
Gender Male 
 
16 (94.1) 
 
24 (80.0) 
 
45 (93.8) 
 
85 (89.5) 
 
0.151
††
 
 
Racially Classified Social Group 
 White  
 Coloured 
 Indian 
 
 
3 (17.7) 
13 (76.5) 
1 (5.9) 
 
 
1 (3.3) 
27 (90.0) 
2 (6.7) 
 
 
0 
44 (91.7) 
4 (8.3) 
 
 
4 (4.2) 
84 (88.4) 
7 (7.4) 
 
 
 
 
0.066
††
 
 
Religion 
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 Muslim 
 Christian 
None 
2 (11.8) 
15 (88.2) 
0 
27 (90.0) 
3 (10.0) 
0 
36 (75.0) 
11 (22.9) 
1 (1.1) 
65 (68.4) 
29 (30.5) 
 
 
<0.001
††
 
 
Highest educational level 
 Primary school 
 Secondary school 
 Tertiary 
 
 
1 (5.9) 
16 (94.1) 
0 
 
 
0 
24 (80.0) 
6 (20.0) 
 
 
2 (4.2) 
42 (87.5) 
4 (8.3) 
 
 
3 (3.2) 
82 (86.3) 
10 (10.5) 
 
 
 
 
0.176
††
 
 
Referral source 
 Self 
 Family 
 Other 
 
 
10 (58.8) 
3 (17.6) 
4 (23.5) 
 
 
18 (60.0) 
11 (36.7) 
1 (3.3) 
 
 
30 (62.5) 
13 (27.1) 
5 (10.4) 
 
 
58 (61.1) 
27 (28.4) 
10 (10.5) 
 
 
 
 
0.250
††
 
 
Marital status 
 Never married 
 Other 
 
 
15 (88.2) 
2 (11.8) 
 
 
22 (73.3) 
8 (25.7) 
 
 
37 (77.1) 
11 (22.9) 
 
 
74 (77.9) 
21 (22.1) 
 
 
 
0.488
††
 
 
Living arrangements 
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 Live alone 
 Live with immediate family 
 Other 
0 
16 (94.1) 
1 (5.9) 
0 
29 (96.7) 
1 (3.3) 
2 (4.2) 
42 (87.5) 
4 (8.3) 
2 (2.1) 
87 (91.6) 
6 (6.3) 
 
 
0.819
††
 
 
Employment status 
 Unemployed 
 Casually employed 
 Permanently employed 
Other 
 
 
7 (41.2) 
1 (5.9) 
7 (41.2) 
2 (11.8) 
 
 
18 (60.0) 
2 (6.7) 
7 (23.3) 
3 (10.0) 
 
 
27 (56.3) 
4 (8.3) 
17 (35.4) 
0 
 
 
52 (54.7) 
7 (7.4) 
31 (32.6) 
5 (5.3) 
 
 
 
 
 
0.186
††
 
 
Usual employment 
 Professional 
 Skilled 
 Unskilled 
 None/student/scholar 
Other 
 
 
0 
6 (35.3) 
4 (23.5) 
7 (41.2) 
0 
 
 
0 
10 (33.3) 
10 (33.3) 
8 (26.7) 
2 (6.7) 
 
 
1 (2.1) 
18 (37.5) 
16 (33.3) 
8 (16.7) 
5 (10.4) 
 
 
1 (1.1) 
34 (35.8) 
30 (31.6) 
23 (24.2) 
7 (7.4) 
 
 
 
 
 
 
0.635
††
 
†
Comparisons between clinics based on Kruskal-Wallis testing for age, and on chi-squared tesing for other sociodemographic variables 
††
 Fisher’s Exact testing for expected frequencies <5 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
157 
 
 
 
 
 
 
Table 2. Distribution of substance use and related variables at the three treatment centres (n; %) 
 
 
 
Substance use variable 
 
Clinics 
 
Clinic 1 
 
Clinic 2 
 
Clinic 3 
 
Total 
 
p-value 
 
n = 17 
 
n = 30 
 
n = 48 
 
n = 95 
 
 
Age of first substance use (years) 
 10 – 14 
 15 – 17 
 18 – 20 
 21 – 24 
 
 
13 (76.5) 
3 (17.6) 
0 
1 (5.9) 
 
 
13 (43.3) 
11 (36.7) 
5 (16.7) 
1 (3.3) 
 
 
23 (47.9) 
18 (37.5) 
7 (14.6) 
0 
 
 
49 (51.6) 
32 (33.7) 
12 (12.6) 
2 (2.1) 
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 Mean (SD) 13.6 (2.4) 15.1 (2.6) 14.8 (2.3) 14.7 (2.4) 0.127
†
 
 
First substance of use 
 Alcohol 
 Cannabis 
 Ecstasy 
 Heroin 
 Methaqualone (mandrax) 
 Crystal methamphetamine (tik) 
 Multiple 
 
 
4 (23.5) 
8 (47.1) 
0 
1 (5.9) 
0 
4 (23.5) 
0 
 
 
0 
16 (53.3) 
5 (16.7) 
2 (6.7) 
2 (6.7) 
3 (10.0) 
2 (6.7) 
 
 
3 (6.3) 
25 (52.1) 
4 (8.3) 
3 (6.3) 
0 
10 (20.8) 
3 (6.3) 
 
 
7 (7.4) 
49 (51.6) 
9 (9.5) 
6 (6.3) 
2 (2.1) 
17 (17.9) 
5 (5.3) 
 
 
 
 
 
 
 
 
0.163
††
 
Primary substance of use 
 Alcohol 
 Cannabis 
 Heroin 
 Crystal methamphetamine (tik) 
Methaqualone (mandrax) 
 Multiple 
 
3 (17.6) 
4 (23.5) 
2 (11.8) 
7 (41.2) 
0 
1 (5.9) 
 
0 
0 
20 (66.7) 
8 (26.7) 
1 (3.3) 
0 
 
0 
1 (2.1) 
29 (60.4) 
17 (35.4) 
0 
1 (2.1) 
 
3 (3.2) 
5 (5.3) 
51 (53.7) 
32 (33.7) 
1 (1.1) 
2 (2.1) 
 
 
 
 
 
 
<0.001
††
 
Frequency of use of primary substance      
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 Daily 
 Few times a week 
Sometimes 
15 (88.2) 
1 (5.9) 
1 (5.9) 
28 (93.3) 
2 (6.7) 
0 
43 (89.6) 
3 (6.3) 
2 (4.2) 
86 (90.5) 
6 (6.3) 
3 (3.2) 
 
 
0.844
††
 
Intensity/Volume of primary substance use 
 As much as I can obtain 
 As much as I can afford to buy 
Other 
 
11 (64.7) 
6 (35.3) 
0 
 
14 (46.7) 
15 (50.0) 
1 (3.3) 
 
31 (64.6) 
16 (33.3) 
1 (2.1) 
 
56 (58.9) 
37 (38.9) 
2 (2.1) 
 
 
 
0.509
††
 
Previous treatment for substance use  
 None 
 Once in past year 
 More than once in past year 
 More than a year ago 
 
11 (64.7) 
3 (17.6) 
0 
3 (17.6) 
 
12 (40.0) 
2 (6.7) 
5 (16.7) 
11 (36.7) 
 
19 (39.6) 
8 (16.7) 
12 (25.0) 
9 (18.8) 
 
42 (44.2) 
13 (13.7) 
17 (17.9) 
23 (24.2) 
 
 
 
 
0.081
††
 
Age of first treatment for substance use 
(yrs)  
 10 – 14 
 15 – 17 
 18 – 20 
 
n=6 
1 (16.7) 
0 
5 (83.3) 
0 
 
n=18 
2 (11.1) 
4 (22.2) 
7 (38.9) 
3 (16.7) 
 
n=29 
0 
7 (24.1) 
13 (44.8) 
9 (31.0) 
 
n=53 
3 (5.7) 
11 (20.8) 
25 (47.2) 
12 (22.6) 
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 21 – 24 
 >24 
 Mean (SD) 
0 
17.5 (3.3) 
2 (11.1) 
18.9 (3.9) 
0 
19.3 (2.6) 
2 (3.8) 
19 (3.1) 
0.139
††
 
0.454
†
 
†
Comparisons between clinics based on Kruskal-Wallis testing for age, and on chi-squared testing for other sociodemographic variables 
††
 Fisher’s Exact testing for expected frequencies <5 
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Table 3. Distribution of psychopathology at the three treatment centres (n; %) 
 Clinics 
  
Clinic 1 
 
Clinic 2 
 
Clinic 3 
 
Total 
 
p-value
††
 
 
Psychopathology 
 
n = 17  
 
n = 30 
 
n = 48 
 
n = 95 
 
 
No previous diagnosis of psychopathology 
 Generalised anxiety disorder 
 Post-traumatic stress disorder (PTSD) 
 Depression 
 Mania 
 Schizophrenia 
 Obsessive Compulsive Disorder (OCD) 
 Eating disorder 
 Separation anxiety 
 Oppositional defiant disorder 
 Conduct disorder 
 
15 (88.2) 
3 (17.6) 
3 (17.6) 
6 (35.3) 
6 (35.3) 
0 
2 (11.8) 
0 
1 (5.9) 
7 (41.2) 
10 (58.8) 
 
29 (96.7) 
1 (3.3) 
5 (16.7) 
9 (30.0) 
1 (3.3) 
2 (6.7) 
1 (3.3) 
2 (6.7) 
2 (6.7) 
10 (33.3) 
18 (60.0) 
 
47 (97.9) 
1 (2.1) 
6 (12.5) 
9 (18.8) 
5 (10.4) 
0 
1 (2.1) 
2 (4.2) 
2 (4.2) 
15 (31.1) 
36 (75.0) 
 
91 (95.8) 
5 (5.3) 
14 (14.7) 
24 (25.3) 
12 (12.6) 
2 (2.1) 
4 (4.2) 
4 (4.2) 
5 (5.3) 
32 (33.7) 
64 (67.4) 
 
0.298 
0.059 
0.065 
0.291 
0.007 
0.128 
0.298 
0.656 
0.848 
0.771 
0.263 
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 Antisocial personality disorder 
 Pain disorder 
 Specific phobia 
 Substance dependence 
 Substance abuse 
14 (82.4) 
3 (17.7) 
4 (23.5) 
12 (70.6) 
4 (23.5) 
26 (86.7) 
4 (13.3) 
5 (16.7) 
29 (96.7) 
5 (16.7) 
43 (89.6) 
3 (6.3) 
6 (12.5) 
46 (95.8) 
6 (12.5) 
83 (87.4) 
10 (10.5) 
15 (15.8) 
87 (91.6) 
15 (15.8) 
0.657 
0.330 
0.565 
0.007 
0.606 
††
 Fisher’s Exact testing for expected frequencies <5 
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Table 4. Frequency of psychopathology by substance use 
  
Psychopathology (n; row%) 
 
Substances of use 
 
Conduct Disorder 
 
Oppositional Defiant 
Disorder 
 
Major Depression 
 
Anti-Social 
Personality Disorder 
 
Total n=95 
(column%) 
 
First substance of use 
 Alcohol 
Cannabis 
Ecstasy 
Heroin 
Methaqualone (mandrax) 
Crystal methamphetamine (tik) 
p-value
†
 
 
 
4 (57.1) 
38 (77.6) 
3 (33.3) 
3 (50.0) 
2 (100.0) 
11 (64.7) 
0.130 
 
 
2 (28.6) 
20 (40.8) 
0 
2 (33.3) 
1 (50.0) 
4 (23.5) 
0.136 
 
 
4 (57.1) 
14 (28.6) 
1 (11.1) 
2 (33.3) 
0 
2 (11.8) 
0.297 
 
 
6 (85.7) 
46 (93.9) 
7 (77.8) 
4 (66.7) 
2 (100.0) 
14 (82.4) 
0.194 
 
 
7 (7.4) 
49 (51.6) 
9 (9.5) 
6 (6.3) 
2 (2.1) 
17 (17.9) 
 
Most common primary substance of use 
Heroin 
 
 
19 (37.2) 
 
 
9 (17.6) 
 
 
8 (15.7) 
 
 
29 (56.9) 
 
 
51 (53.7) 
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Crystal methamphetamine 
p-value
†
 
15 (46.9) 
0.352 
10 (31.3) 
0.199 
3 (9.4) 
0.117 
16 (50.0) 
0.366 
32 (33.7) 
†
 Fisher’s Exact testing for expected frequencies <5 
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Table 5. Frequency of most common first and primary substances of use by most common psychopathology diagnoses 
 
  
First substance of use 
 
Most common primary substance of use 
 
Psychopathology 
 
Cannabis 
 
p-value
†
 
 
Crystal Methamphetamine 
 
p-value
†
 
 
Heroin 
 
p-value
†
 
 
Crystal Methamphetamine 
 
p-value
†
 
 
Conduct disorder 
Anti-social personality disorder 
Major depression 
Oppositional defiant disorder 
 
38 (59.3) 
46 (55.4) 
14 (58.3) 
20 (62.5) 
 
0.048 
0.065 
0.486 
0.192 
 
11 (17.2) 
14 (16.9) 
2 (8.3) 
4 (12.5) 
 
0.782 
0.445 
0.223 
0.405 
 
19 (29.7) 
29 (34.9) 
8 (33.3) 
9 (28.1) 
 
0.170 
1.000 
1.000 
0.371 
 
15 (23.4) 
16 (19.3) 
3 (12.5) 
10 (31.1) 
 
0.592 
0.271 
0.385 
0.111 
†
Chi-squared testing when expected frequencies >5 and Fisher’s Exact testing when expected frequencies <5 
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Table 6. Prevalence of most common substance use by most common psychopathology* 
 
  
First substance of use n (%) 
 
Primary substance of use n (%) 
 
 
Most common psychopathology (n) 
 
Cannabis 
(Total = 49) 
 
p 
 
Crystal Methamphetamine 
(Total = 17) 
 
p Heroin  
(Total = 33) 
 
p Crystal Methamphetamine  
(Total = 20) 
p 
Conduct disorder 
 Present: 64 
 Absent: 31 
 
38 (59.4) 
11 (35.5) 
 
0.049 
 
11 (17.2) 
6 (19.4) 
 
0.796 
 
19 (29.7) 
14 (45.2) 
 
0.209 
 
15 (23.4) 
5 (16.1) 
 
0.587 
Oppositional defiant disorder 
 Present: 32 
 Absent: 63 
 
20 (62.5) 
29 (46.0) 
 
0.193 
 
4 (12.5) 
13 (20.6) 
 
0.405 
 
9 (28.1) 
24 (38.1) 
 
0.461 
 
10 (50.0) 
10 (15.9) 
 
0.141 
Major depression 
 Present: 24 
 Absent: 71 
 
14 (58.3) 
35 (49.3) 
 
0,596 
 
 
2 (8.3) 
15 (21.1) 
 
0.223 
 
8 (57.1) 
25 (35.2) 
 
0.867 
 
3 (21.4) 
17 (23.9) 
 
0.385 
Anti-social personality disorder         
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 Present: 83 
 Absent: 12 
46 (55.4) 
3 (25.0) 
0.064 14 (16.9) 
3 (25.0) 
0.445 29 (34.9) 
4 (33.3) 
1.000 16 (34.8) 
4 (33.3) 
0.271 
 
*Chi squared tests were used to calculate p-values when cell sizes were >5 and Fisher’s Exact was used when cell sizes were <5 
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Table 7. Prevalence of psychopathology by most common substances of use* 
 
 
Substance use 
 
Psychopathology n (%) 
Conduct disorder  
Total=64 
p Oppositional defiant 
disorder  
Total=32 
p Major depression 
Total=24 
p Anti-social 
personality disorder 
Total=83 
p 
 Most common first substance 
of use 
Cannabis 
 Present: 49 
Absent: 46 
 
Crystal methamphetamine 
 Present: 17 
Absent:  78 
 
38 (77.6) 
26 (56.5) 
 
 
11 (64.7) 
53 (67.9) 
 
0.049 
 
 
 
0.796 
 
20 (40.8) 
12 (26.1) 
 
 
4 (23.5) 
28 (35.9) 
 
0.193 
 
 
 
0.405 
 
14 (28.6) 
10 (21.7) 
 
 
2 (11.8) 
22 (28.2) 
 
0.596 
 
 
 
0.223 
 
 
46 (93.9) 
37 (80.4) 
 
 
14 (82.4) 
69 (88.5) 
 
0.065 
 
 
 
0.445 
Most common primary 
substance of use 
Heroin 
 Present: 33 
Absent: 62 
        
 
19 (57.6) 
45 (72.6) 
 
0.209 
 
 
9 (27.3) 
23 (37.1) 
 
0.461 
 
 
8 (24.2) 
16 (25.8) 
 
0.867 
 
 
29 (87.9) 
54 (87.1) 
 
1.000 
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Crystal methamphetamine 
 Present: 20 
Absent: 75 
 
 
15 (75.0) 
49 (65.3) 
 
 
0.581 
 
 
 
10 (50.0) 
22 (29.3) 
 
 
0.141 
 
 
3 (15.0) 
21 (28.0) 
 
 
0.385 
 
 
16 (80.0) 
67 (89.3) 
 
 
0.271 
 
*Chi-squared tests were used to calculate p-values for cell sizes >5 and Fisher’s Exact was used for cell sizes < 5 
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Table 8. Association between psychopathology and substance use (OR, 95% CI and p-value)
†
 
 
  
First substance of use 
 
Most common primary substance of use 
  
Cannabis 
 
Crystal methamphetamine 
 
Heroin 
 
Crystal methamphetamine 
 
Psychopathology 
 
Unadjusted 
 
Adjusted 
 
Unadjusted 
 
Adjusted 
 
Unadjusted 
 
Adjusted 
 
Unadjusted 
 
Adjusted 
 
Anti-social personality    OR 
                                        95%CI 
                                        p-value 
Conduct disorder 
 
 
Oppositional defiant 
 
 
 
3.730 
0.942-14.773 
0.061 
2.657 
1.092-6.464 
0.031 
1.954 
0.818-4.666 
0.131 
 
3.228 
0.745-13.975 
0.117 
2.256 
0.847-6.006 
0.103 
1.920 
0.749-4.917 
0.174 
 
0.609 
0.146-2.537 
0.495 
0.865 
0.287-2.605 
0.796 
0.549 
0.163-1.847 
0.333 
 
0.644 
0.136-3.047 
0.579 
0.722 
0.213-2.443 
0.600 
0.503 
0.139-1.824 
0.296 
 
1.074 
0.298-3.872 
0.913 
0.513 
0.211-1.246 
0.140 
0.636 
0.253-1.601 
0.336 
 
1.496 
0.326-6.857 
0.604 
0.413 
0.139-1.229 
0.112 
0.670 
0.232-1.939 
0.460 
 
0.478 
0.128-1.785 
0.272 
1.592 
0.520-4.870 
0.415 
2.409 
0.879-6.599 
0.087 
 
0.424 
0.100-1.800 
0.245 
1.895 
0.553-6.493 
0.309 
2.192 
0.752-6.385 
0.150 
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PTSD 
 
 
Major depression 
 
 
Specific phobia 
 
 
Pain disorder 
0.929 
0.299-2.888 
0.898 
1.440 
0.565-3.670 
0.445 
1.500 
0.488-4.607 
0.479 
1.144 
0.324-4.040 
0.834 
1.571 
0.388-6.363 
0.527 
1.669 
0.537-5.183 
0.376 
4.739 
0.990-22.677 
0.051 
1.077 
0.276-4.199 
0.915 
0.313 
0.038-2.568 
0.279 
0.339 
0.072-1.608 
0.173 
0.286 
0.035-2.337 
0.243 
1.022 
0.200-5.221 
0.979 
0.334 
0.030-3.753 
0.375 
0.586 
0.111-3.083 
0.528 
0.417 
0.045-3.857 
0.441 
1.609 
0.269-9.634 
0.602 
2.115 
0.672-6.659 
0.200 
0.920 
0.346-2.448 
0.867 
1.309 
0.422-4.060 
0.641 
0.675 
0.166-2.737 
0.582 
2.207 
0.482-10.116 
0.308 
1.014 
0.296-3.467 
0.983 
1.665 
0.382-7.249 
0.497 
0.677 
0.124-3.699 
0.652 
0.251 
0.031-2.045 
0.197 
0.454 
0.120-1.710 
0.243 
0.926 
0.235-3.660 
0.913 
1.478 
0.354-6.174 
0.592 
0.245 
0.025-2.385 
0.226 
0.569 
0.131-2.479 
0.453 
1.098 
0.230-5.237 
0.906 
1.812 
0.354-9.263 
0.475 
†
Adjusted for age, gender, racially classified social group, religion and treatment centre 
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INTERVIEW SCHEDULE FOR TREATMENT CENTRE STUDY 
 
 
Treatment Centre……………………………………………. 
 
 
Patient/Subject number……………………………………... 
 
 
Folder/File number…………………..  DATE……………………………… 
 
Patient/Subject name……………………………………………………………………... 
Address……………………………………………………………………………………. 
Telephone numbers i)……………………  ii)……………………… iii)……………… 
 
I would like to start by asking you a few questions about yourself, your home-life, and your past. I would like you to 
answer each question as honestly and openly as you can. If any question makes you feel uncomfortable, please feel 
free to tell me. No-one, other than I will know that the information you give me has come from you. I will, however, 
need to inform the treatment centre staff of things that might be harmful to yourself or someone else. 
 
A. DEMOGRAPHIC FACTORS 
AI. Kind of patient 
1. Inpatient 
2. Outpatient 
3. Daypatient 
4. Other    Specify……………………………………………. 
 
A2. Home language 
1. English 
2. Afrikaans 
3. Xhosa 
4. Other    Specify……………………………………………... 
 
A3. Age 
Date of birth………………………………………………………………………………. 
Actual age…………years 
1. 14-16 years 
2. 17-19 years 
3. 20-24 years 
4. 25-29 years 
 
A4. Gender 
1. Male 
2. Female 
 
A5. Racial classification 
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1. Black 
2. Coloured 
3. Indian 
4. White 
5. Other    Specify……………………………………………... 
 
A6: Religious denomination 
1. None 
2. Christian 
3. Muslim 
4. Jewish 
5. Other    Specify…………………………………………… 
 
A7. Highest educational level 
Highest standard passed/diploma/degree………………………………………………… 
1. None 
2. Primary school 
3. High school 
4. Tertiary   Specify…………………………………………… 
 
A8. Referral source 
1. Self 
2. Family 
3. Friend 
4. Doctor/other professional 
5. Employer 
6. Correctional services 
7. Other    Specify……………………………………………. 
 
 
Now I want to ask you a few questions about your home-life and work situation. 
 
B. SOCIAL FACTORS 
 
B1. Current marital status 
1. Never married 
2. Married with children 
3. Married, no children 
4. Divorced 
5. Separated 
6. Widowed   Comments………………………………………….. 
 
B2. Living arrangements 
1. Live alone 
2. Live with immediate family 
3. Live with extended family 
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4. Live with non-relatives 
5. Other    Specify…………………………………………….. 
 
B3. Employment status 
1. Employed (permanent) 
2. Casual 
3. Unemployed 
4. Part-time/Student/Scholar 
5. On leave of absence 
6. Other    Specify/Comments…………………………………. 
 
B4. Nature of usual employment 
1. None/Student/Scholar 
2. Unskilled 
3. Skilled 
4. Managerial 
5. Professional   Specify……………………………………………... 
 
 
I would now like to ask you a few questions about your being here and your use of substances. 
Please remember that the information you give me will be treated confidentially. Please feel free 
to tell me if any question makes you feel uncomfortable. 
 
C. HISTORY OF SUBSTANCE USE 
 
C1. Age of first use 
Actual age of first use……………………years 
1. < 10 years  
2. 10-14 years 
3. 15-17 years 
4. 18-20 years 
5. 21-24 years 
6. > 24 years 
 
C2. First substance of use 
Actual first substance of use……………………………………………………………….. 
1. Cigarettes/Tobacco 
2. Alcohol 
3. Cannabis 
4. Methamphetamine (Tik) 
5. Other    Specify……………………………………………... 
Comments………………………………………………………………………………….. 
 
C3. Substance currently consumed most frequently 
1. Cigarettes/Tobacco 
2. Alcohol 
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3. Cannabis 
4. Methamphetamine (Tik) 
5. Heroin 
6. Cocaine 
7. Other    Specify……………………………………………... 
Comments………………………………………………………………………………….. 
 
C4. Frequency of use 
1. Daily 
2. Few times a week  Specify…………………………………………….. 
3. Weekends only 
4. Sometimes   Specify…………………………………………….. 
5. Other    Specify……………………………………………... 
 
C5. Intensity of use 
Actual amount consumed at any one time…………………………………………………. 
 
C6. What other substances do you use currently (in descending frequency)? 
Specify other substances of use 
 1. Tobacco 
2. Alcohol 
3. Cannabis 
4. Methamphetamine 
5. Other   Specify…………………………………………….. 
Comments………………………………………………………………………………….. 
 
C7. How often do you use each of these substances? 
 1. Tobacco 2. Alcohol 3. Cannabis 4. Tik 5.Other  
1.Daily      
2.Few times/wk      
3.Weekends only       
4.Seldom/Sometimes      
5. Never      
 
Specify other…………………………………………………………………………….
  
C8. Previous treatment for substance use 
Have you ever received treatment for your substance use? 
1. None/Never 
2. Once in past year  Specify details……………………………………… 
3. More than once in past year Specify details……………………………………… 
4. More than a year ago  Specify details……………………………………… 
Comments………………………………………………………………………………….. 
 
C9. Actual age of first Rx for substance use problem………………………… 
1. < 10 years  
2. 10-14 years 
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3. 15-17 years 
4. 18-20 years 
5. 21-24 years 
6. > 24 years 
 
 
C10. What was the nature of your substance use treatment in the past? 
1. Inpatient    Specify details where, when, how long…………… 
2. Outpatient    Specify details where, when, how long…………… 
3. Daypatient    Specify details where, when, how long…………… 
4. Other    Specify details where, when, how long…………… 
Comments…………………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………… 
 
C11. EXPECTATIONS 
What do you expect from the treatment you will be receiving/have received at this visit? 
………………………………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………… 
Specify nature of current Rx if known……………………………………………………... 
 
I will now ask you a few questions relating to other treatment that you might have 
received in the past. 
 
D: HISTORY OF PSYCHIATRIC PROBLEMS 
D1. Have you ever been diagnosed with a psychiatric problem? 
1. Yes 
2. No 
 
If no, that will be the end of this part of our session. I will now ask you a few questions 
relating to your general health and other treatment you might have received in the past. 
(Proceed to DIS) 
 
D2. If yes, what was the diagnosis for your psychiatric problem(s)? 
1. 
2. 
3. 
4. 
 
D3. Who made the diagnosis of your psychiatric problem made? 
1. 
2. 
3. 
4. 
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D4. Where was this diagnosis made? 
1. 
2. 
3. 
4. 
 
D5. How old were you when you were first diagnosed with a psychiatric problem? 
Actual age of first psychiatric diagnosis………………………………………. 
1. < 10 years  
2. 10-14 years 
3. 15-17 years 
4. 18-20 years 
5. 21-24 years 
6. > 24 years 
 
D6. Did you ever receive treatment for a psychiatric problem? 
1. Yes 
2. No 
 
D7. If YES, how long ago did you receive treatment the first time? 
Specify actual date of first treatment…………………………………………………. 
1. In the last month 
2. In the last year 
3. More than a year ago 
4. More than 2 years ago 
 
D8. Actual age of first Rx for psychiatric problem……………………………………. 
1. < 10 years  
2. 10-14 years 
3. 15-17 years 
4. 18-20 years 
5. 21-24 years 
6. > 24 years 
 
 
 
D9. Where did you receive treatment for your psychiatric problem the first time? 
Specify where…………………………………………………… 
1. 
2. 
3. 
 
D10. What treatment did you receive the first time? 
Specify………………………………………………………………………….. 
1. 
2. 
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3. 
 
D11. How many times have you received treatment for that first psychiatric problem? 
Specify exactly how many times……………………………. 
1. 
2. 
3. 
4. 
 
D12. When was the last time that you received treatment for a psychiatric problem? 
Specify date of last treatment……………………………………… 
1. In the last month 
2. In the last year 
3. More than a year ago 
4. More than 2 years ago 
 
D13. Was the last treatment you received for the same psychiatric problem or for a 
different psychiatric problem? 
1. Same 
2. Different    Specify…………………………………… 
 
D14. What treatment did you receive the last time? 
Specify…………………………………………………………………………………… 
1. 
2. 
3. 
4. 
 
D15. Where were you last treated for your psychiatric problem? 
Specify where……………………………………………………………………….. 
1. 
2. 
3. 
4. 
 
That will be the end of this part of our discussion. I will now ask you a few more questions relating to your 
health and substance use. Some questions will have been asked before, but I will need to ask them again, so 
just bear with me and try to answer each question as accurately as possible. Don’t worry if you cannot 
remember what you answered when I first asked you the question. (Proceed to DIS) 
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CHAPTER 5 
Comorbid psychopathology, substance use and treatment 
outcomes: a follow-up of inpatient substance users in Cape 
Town, South Africa 
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ABSTRACT 
Comorbid psychopathology in substance users is thought to be associated with poor substance use 
treatment outcomes. This study followed up 95 substance users after inpatient treatment for substance 
use. Males, and patients who were single, were more likely to complete treatment. Females were more 
likely than males to relapse, or not complete treatment. No statistically significant associations were 
found between comorbid psychopathology, substances of use, and treatment outcomes. Primary users 
of crystal methamphetamine were marginally more likely than primary users of other substances not 
to complete treatment (OR=0.291; p=0.062). Major depression was marginally associated with 
decreased odds of relapse (OR=0.346; p=0.076). Further investigation is needed to explore the 
factors that influence treatment completion and relapse in female inpatients. 
 
KEYWORDS comorbid psychopathology, substance use treatment, inpatients 
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INTRODUCTION 
Comorbid psychopathology appears to occur in the majority (70% – 80%) of substance users 
in treatment (Kaminer, Connor and Curry, 2007). Evidence seems to indicate that the presence of 
comorbid psychopathology could play a role in i) increasing patients’ risk of dropout from substance 
use treatment and relapse (Compton et al., 2003; Kaminer, Connor and Curry, 2007), ii) increasing the 
risk of increased frequency and intensity of substance use after treatment for substance use (Brooner,  
King, Kidorf, Schmidt (Jr), & Bigelow, 1997), and iii) exacerbating psychopathology symptoms after 
treatment (Brooner,  King, Kidorf, Schmidt (Jr), & Bigelow, 1997; Armstrong  & Costello, 2002; 
Schuckit, 2006). For example, relapse after substance use treatment has been associated with pre-
treatment depression (Mc Carthy et al., 2005; Greig et al., 2006) and externalising disorders 
(Tomlinson et al., 2004), with comorbid substance users being more likely than substance use-only 
individuals to resume substance use treatment subsequent to discharge (Tomlinson et al., 2004).  
The developmental pathway to adulthood is often characterised by factors that have been 
identified as possible risks for substance use. For example, adolescents in treatment for problematic 
substance use have commonly been found to have a history of behavioural problems such as 
aggressiveness, impulsivity, poor frustration tolerance, to have experienced problems at school (such 
as learning disabilities, attention deficit),  psychiatric disorders (such as oppositional defiant disorder), 
or family problems (such as abuse or neglect) (Riggs, 2003). These factors could adversely affect 
intellectual and psychosocial development, with the possibility of lifelong difficulties for the 
individuals involved. Evidence has indicated that when psychiatric problems and substance use co-
occur, there is an increased risk of poorer psychosocial outcomes than when substance use occurs 
alone (Greig et al., 2006; Tomlinson et al., 2004). Early identification of risk factors for substance use 
thus provide opportunities for earlier intervention and management of the individuals involved to 
increase their chances of improved future development. 
Yet, even though evidence indicates that comorbid psychopathology might influence 
substance use treatment outcomes  (Compton et al., 2003; Kaminer, Connor and Curry, 2007), and, 
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while the effectiveness of substance use treatment has not been demonstrated unequivocally (Singh et 
al., 2008),  relatively few studies have examined associations between psychiatric disorder and 
outcome from substance use treatment (Chi and Weissner, 2008; Lubman et al., 2007) among 
adolescents and young adults (Lubman et al., 2007). Hence, information regarding the impact of 
psychiatric disorder on the outcomes of substance use treatment, particularly in adolescents and young 
adults, is sparse (Chi and Wessner, 2008). 
Globally (including in South Africa), understanding of how comorbid psychopathology and 
substance use is treated, and what the substance use treatment outcomes in patients with comorbidity 
are, and how these are managed, remains limited (Lichtenstein et al., 2010). The limited reporting of 
treatment outcomes in substance-using inpatients with comorbid psychopathology might be a 
consequence of general difficulties experienced with the follow-up of substance using patients 
(Desmond et al., 1995). These include the cost associated with follow-up (Kleschinsky et al., 2009), 
and difficulties encountered in engaging or retaining substance users in treatment research (McHugo, 
Drake, Brunette et al., 2006) or locating substance use patients after treatment  (Desmond et al., 
1995).  
In addition, psychiatric and substance use treatment facilities are commonly separate facilities 
(McHugo, Drake, Brunette et al., 2006), and this appears to be the case in South Africa as well.  
Problematic substance users with comorbid psychopathology might thus be referred for substance use 
treatment, where they might not be assessed or treated for comorbid psychopathology (Lichtenstein et 
al., 2010), possibly because the treatment emphasis would be on the substance use as the primary 
problem. Thus, while substance use in patients referred for psychiatric disorders is likely to be 
addressed within a psychiatric treatment facility, substance use treatment institutions frequently do not 
have the capacity to assess or treat comorbid psychopathology (Riggs, 2003).  
This study examined  the post-substance use treatment status of adolescent and young adult 
substance users, sampled from three substance use treatment centres in Cape Town between 
December 2008 and December 2009, on average six months after they had been discharged from an 
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inpatient substance use treatment programme. The study aimed to examine the association between 
comorbidity identified on admission for substance use treatment, and post-treatment status as defined 
by relapse, and treatment completion.  
 
METHODS 
Sample 
At baseline (December 2008 to December 2009), 95 substance users aged 17 to 30 years (Mean 23 
SD 2.9) were sampled consecutively in order of admission for inpatient substance use treatment at 
three  privately-funded substance use treatment centres in Cape Town, South Africa.  
Each patient was followed up on average six months after discharge from the baseline 
inpatient treatment programme. Nine patients could not be located for a follow-up interview, even 
after several attempts to contact them. These nine patients were considered officially lost to follow-
up, resulting in a follow-up sample of 86 patients. 
Study sites 
Three inpatient treatment centres (sometimes referred to as clinics in the study) in Cape Town, South 
Africa, were selected from the South African Community Epidemiology Network on Drug Use 
(SACENDU) (Pluddemann et al., 2009; 2010) list of treatment centres that are regularly monitored as 
part of a programme that tracks substance use trends in the country.  
One clinic (Clinic 1) was the dedicated chemical dependency unit in a private hospital, 
located in an upmarket and predominantly White  [racially classified social group (RCSG) as defined 
by the population Registration Act of 1950, and including, White, Coloured, Indian and Black] 
residential-cum-commercial suburb of Cape Town, and offered a 21-day substance use treatment 
programme based on a medical model, and largely admitting patients with medical insurance. The 
second clinic (Clinic 2) was a house in a middle-class residential suburb that had a mix of White, 
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Coloured and Indian  residents. The treatment at this clinic was an eclectic mix of psychology, 
spirituality and Asian medicine, offered in an environment where Muslim principles predominated, 
with a duration of 28 days and the possibility of patients’ having extended treatment either as 
daypatients, outpatients or inpatients. The third clinic (Clinic 3) was a large house on a 
farm/smallholding in an underdeveloped and largely Coloured residential area, bordering on an 
informal settlement of makeshift shacks that housed a mix of Coloured and Black residents. This 
treatment centre offered custodial care in a Muslim environment, coupled with motivational talks, 
group therapy and the administration of vitamins and massages. The duration of the inpatient 
programme was 28 days, with patients having the option of extending their stay indefinitely as either 
inpatients or daypatients, and of remaining resident at the treatment centre while being employed 
elsewhere. The inpatient treatment programme at all three treatment centres included a 7-day 
detoxification period, and had abstinence as a prerequisite for inpatient admission, and maintenance of 
abstinence as the primary treatment goal.  
Instruments 
At baseline, an interview schedule, designed for the study, was administered to elicit 
sociodemographic (Table 1a) and substance use information (Table 1b). The sociodemographic 
factors that were assessed included age, gender, racially classified social group (RCSG), religious 
denomination, marital status, highest educational level, employment status and referral sources. 
Substance use information included the first substance(s) used (other than cigarettes), age of onset of 
substance use, the substance(s) for which inpatient treatment was sought (also referred to as the 
primary substance of use), and history of substance use treatment. 
The interview schedule was followed by administration of the computer-assisted Diagnostic 
Interview Schedule for Diagnostic and Statistical Manual (DSM) IV (C-DIS IV) (Robins, Cottler, 
Bucholz, Compton, North & Rourke, 2002), by a trained C-DIS IV interviewer (the primary author), 
to screen for current (12-month) psychopathology. The C-DIS is a computerised version of the pencil-
and-paper DIS, and was designed for use by trained lay interviewers to make psychiatric diagnoses 
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that match the capabilities of the pencil-and-paper DIS. The C-DIS, however, has greater flexibility 
than the pencil-and-paper version in that it is possible to administer the C-DIS in Full mode (the Full 
version mimics the complete pencil-and-paper version), in Screen mode (the Screen version allows 
current diagnoses to be made in a shorter time than the duration of the Full version). It is also possible 
to exclude DIS diagnostic modules that might not be of interest to a particular study. The DIS was 
designed for use with treatment and community populations, and has ‘reasonably satisfactory’ 
reliability with clinical diagnoses, with an overall agreement of 90% with diagnoses based on clinical 
judgement for most diagnoses (Helzer et al., 1985:665). 
In this study, all the diagnostic modules of the DIS were administered at baseline, and all the 
modules were administered using the Screen version. The decision to administer all the DIS 
diagnostic modules in Screen mode was made to reduce the duration of the baseline interviews. The 
reasons for electing to economise on the duration of interviews included being able to complete all the 
interviews within the projected timeline of the project, and to minimise the burden on patients in 
terms of attention  and time. All the baseline DIS interviews followed the instrument recommendation 
of not combining Full and Screen versions of the instrument in one interview (Robins et al., 2002). 
Follow-up  information was obtained by administering a follow-up questionnaire designed 
specifically for the study. The follow-up questionnaire elicited information about patient’s completion 
or non-completion of the inpatient programme, and whether the patient had returned to treatment or, 
when electing to and being allowed to (as offered at Clinics 2 and 3), continued to remain in treatment 
after discharge from the initial inpatient programme. Substance use-related questions referred to 
whether the patient had relapsed with respect to substance use at any time during or after completion 
of the inpatient programme, whether or not the patient was using substances on the day of the follow-
up interview, and what substances, if any, had been used after treatment discharge.  
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Procedure 
The baseline interviews were conducted in private at the treatment centres, with only the patient and 
interviewer present. All the interviews were conducted by the same trained interviewer (primary 
author) and had a duration of approximately 90-120 minutes.  
  Admitted patients were identified for selection on admission, and interviewed after 
completing the detoxification period to decrease the likelihood of substance-use induced symptoms of 
psychopathology. No admitted eligible patients that met the study inclusion criteria of being aged 30 
years or younger, refused study participation or were excluded from selection.  
  All study participants completed informed consent forms at baseline for both the baseline and 
follow-up interviews, and granted permission for their possible DIS diagnoses to be shared with their 
professional treatment managers if requested  For the one patient who was aged 17, an assent form 
was completed by the patient, and written informed consent was obtained from a parent. The informed 
consent forms also contained contact details for patients’ parent(s) or guardian whom patients 
consented to being contacted in their absence, particularly since patients had their mobile telephones 
confiscated while in treatment and were usually unable to provide reliable future mobile telephone 
contact details.  
Patients were followed up after they had been discharged from the inpatient programme. The 
reasons for discharge from the programme were completion of the programme, premature discharge 
for any reason (for example, bringing substances such as cannabis, methamphetamine onto the 
treatment centre premises, or using substances such as these while at the treatment facility), or 
absconding from the programme for any reason before its completion. All patients were followed up 
in the year after their discharge from the inpatient programme. Follow-up of patients was initiated  
from 5 weeks after discharge. However, because it was not always possible to locate the patients for 
follow-up interviews immediately, these interviews were conducted as soon as the patients were 
available for the interviews. This resulted in a range in the time interval from discharge to successful 
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patient follow-up (5 weeks to 9 months; Mode = 3 months), with, a mean of six months elapsing after 
discharge from the inpatient treatment.  
Some follow-up patients were resident at the clinic where they had completed the inpatient 
programme. In these cases the patients had usually elected to continue treatment because they felt 
they needed more assistance with their substance use-related problems, or to remain within the 
therapeutic environment because they did not feel sufficiently equipped to cope without the support of 
the clinic staff and fellow patients. These patients paid a rental for their stay, funded by family, or 
themselves if they were employed outside the clinic during this time. Some patients had moved in 
with family (usually their parents) after discharge. Others did not feel comfortable to move in with 
family, or had been rejected by their families on discharge.  
On follow-up, patients were interviewed (by the same interviewer, and in all cases, the 
primary author) in person if they were still in treatment or resident at the treatment centre, or 
telephonically (via landline or mobile telephones) if they lived elsewhere. In cases where the patient 
was repeatedly inaccessible by telephone and could not be located for an interview, the interviewer 
consulted the director of the clinic (for 10 cases) or the patient’s parent or guardian (two cases) 
personally or by telephone to obtain the required information where possible. In cases where the clinic 
director or a parent were interviewed, the questions asked were restricted to whether it was known if 
the patient had completed the inpatient programme (also obtainable from clinic records), whether it 
was known if the patient had relapsed since discharge, and whether it was known if the patient was 
back in a treatment programme. The interviewees answered these questions to the best of their 
knowledge. Where follow-up information was obtained from a parent, guardian or clinic director, 
abstinence was assumed where there was no known use of substances other than cigarettes. Details 
about the patients were  kept to the minimum three questions (answering Yes or No with respect to 
treatment completion, relapse and treatment resumption) so as not to breach patient confidentiality, 
while still obtaining the most important required follow-up information for the study.  
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The study was approved by the Research Ethics Committee of the Health Sciences 
Faculty, University of Cape Town (REC REF: 340/2007). 
 
Operational definitions 
Relapse was defined as ever having used any substances, other than cigarettes, since the baseline 
interview, irrespective of whether or not the treatment programme had been completed in its entirety. 
Completion of treatment was defined as remaining in the programme for which the patient was 
admitted  until the conclusion of the programme.   
 
DATA ANALYSES 
The data were analysed using STATA Version 10 (2007).  
At baseline (Tables 1, 2 and 3): The demographic factors recorded for analysis were age, 
gender, racially-classified social group (RCSG), religious denomination (none, Christian, Muslim, 
Jewish, other), highest educational level (none, primary, secondary, tertiary), marital status [(never 
married (single), partnered/married], employment (employed, unemployed, student), and living 
arrangements (alone, with immediate family, other). The psychopathology variables consisted of the 
most common current (12 months) DIS psychiatric diagnoses (namely, antisocial personality disorder, 
conduct disorder, oppositional defiant disorder, major depression, post-traumatic stress disorder and 
specific phobia). Substance use was recorded in terms of substance use history (substance use 
initiation age, previous treatment for substance use), the first substance of use (other than tobacco), 
and the substance use for which treatment was sought (coincided with the most frequently used 
substance, and referred to as primary substance of use).  
At follow-up: The baseline sociodemographic factors considered for the follow-up analyses 
were gender, RCSG, religious denomination and marital status. The psychopathology variables were 
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the most common DIS psychiatric diagnoses identified at baseline. The treatment outcome factors 
were treatment completion, relapse and back/still in treatment (Table 5). In all analyses, where 
relevant, the independent variables were the sociodemographic and psychopathology variables, while 
the dependent variables were the treatment outcome variables. 
Percentages of patients were calculated at follow-up and compared with prevalence at 
baseline in terms of the selected sociodemographic variables (Table 4). Bivariate analyses were 
completed using Chi squared tests when cell sizes were five or larger, and Fisher’s Exact tests when 
cell sizes were smaller than five to i) compare the distribution of sociodemographic, psychopathology 
and substances variables, by treatment outcomes (Table 5), ii) to compare the distribution of 
sociodemographic, psychopathology and substance use variables by loss to follow-up status, and iii) 
to compare the the distribution of sociodemographic, psychopathology and substance use variables by 
whether the patients were interviewed personally or by proxy.  Multivariate logistic regression 
analyses were used in two distinct models to determine associations between baseline 
psychopathology, first substance of use and primary substance of use, respectively, and treatment 
outcome variables [ completion of treatment (Table 6), relapse (Table 7)], adjusting for baseline 
factors (namely, age, gender, RCSG, religion and treatment centre/clinic). Separate multivariate 
analyses were conducted to determine associations between each of the most common forms of  
psychopathology and treatment outcomes, adjusting for age, gender, RCSG, religion, and treatment 
centre/clinic, and including primary substance of use as independent variables in the regression 
predicting outcomes (Tables 6 and 7), as well as previous substance use treatment. Additional 
bivariate analyses were completed to examine the association between time elapsed, between baseline 
and follow-up, and treatment outcomes. The follow-up (outcome) variables were dichotomous 
(Yes/No), making logistic regression analyses appropriate, and forced modelling was used for the 
regression analyses. Baseline sociodemographic, psychopathology and first and primary substance use 
variables were tested for multicollinearity, with STATA automatically excluding any variables with 
insufficient tolerance from the analyses. Odds ratios, 95% confidence intervals, and p-values were 
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calculated for these associations. Statistical significance was assumed if p < 0.05 while marginal a p-
value between 0.05 and 0.10 was regarded as marginal. 
 
RESULTS 
Tables 1, 2 and 3 present the distribution of the sample at baseline in terms of sociodemographic, 
substance use and psychopathology factors. The baseline sample was predominantly male (89.5%), 
Coloured (88.4%), Muslim (68.4%) and with some secondary school education (86.3%). A large 
proportion of the baseline sample had never been married (77.9%) and lived with their immediate 
family (91.6%). The first substance of use was cannabis in more than half of the baseline sample 
(51.6%), and crystal methamphetamine was the first substance of use in 17.9% of the sample. Heroin 
was the substance for which treatment was sought in 53.7% of the sample, while 33.7% of the sample 
sought treatment for use of crystal methamphetamine. 
Table 4 lists the numbers of patients sampled at baseline and the percentage reached for 
follow-up with respect to selected demographic factors. This table indicates that 86 patients were 
followed up (90.5%), with an approximate attrition of 10% at a mean of six months after discharge 
from inpatient treatment, and the characteristics of patients in the follow-up sample reflecting the 
characteristics of the baseline sample (Table 1). The follow-up sample was thus also largely male 
(89.4%), Coloured (89.3%), Muslim (93.8%) and single (87.8%). All the White, Indian, and partnered 
or married patients were located for interviews at follow-up. Bivariate analyses indicated that there 
were no statistically significant differences, in terms of sociodemographic, psychopathology and 
substance use factors between those who were lost to follow-up and those patients who were located 
for follow-up. However, those who were located for follow-up were marginally more likely (n=3; 
3.4%) to have been diagnosed with current (12-month) generalised anxiety disorder (p=0.069), 
compared with those who were lost to follow-up (n=2; 22%).  The cell sizes for these analyses were, 
however, very small.  Patients lost to follow-up were also marginally more likely to have used crystal 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
184 
 
methamphetamine as their primary substance of use (n=5; 55%; p=0.092) than were those patients 
who were located for follow-up (n=27; 31%).  
Table 5 presents the percentage of patients who completed treatment  or who had relapsed, in 
terms of the sociodemographic factors, psychopathology and substance use details examined. In this 
table, 70 patients (64 males and 6 females) had completed the inpatient treatment programme, 46 (38 
males and 8 females) had relapsed by the time the follow-up interview was conducted.  
In addition, at follow-up,  38 patients (32 males and 6 females) were found to have resumed 
treatment for their substance use.  
The proportions of patients who completed the inpatient programme differed statistically 
significantly by marital status (p=0.002), while the proportion of patients who relapsed differed 
marginally by gender (0.097). It appeared that females (80.0%) in this sample were more likely than 
males (50%) to relapse, while single patients (92.3%) were more likely than married or partnered 
patients (47.6%) to complete their treatment.  There was no statistically significant difference in the 
proportions of patients who completed treatment compared with those who did not,  or relapsed 
compared with those who did not, in terms of the other factors examined (Table 5). 
Tables 6 and 7 present the results of multivariate logistic regression analyses between 
psychopathology (independent variable) and treatment completion, and relapse (dependent variables)  
respectively, after discharge from treatment, adjusted for age, gender, religion, RCSG, first, and 
primary, substance use, treatment centre (clinics in Tables 1, 2 and 3) and previous substance use 
treatment.  
Table 6 shows no statistically significant associations between comorbid psychopathology at 
baseline, and completion of the inpatient treatment programme.  There was a marginal association 
(p=0.062) between crystal methamphetamine as the primary substance of use, and treatment 
completion. Thus primary users of crystal methamphetamine appeared to be 71% more likely than 
primary users of other substances to drop out of the inpatient treatment programme.  
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Table 7 indicates that there were largely no statistically significant associations between 
psychopathology or substance use, and relapse. However, there was a marginal association between 
having crystal methamphetamine as the first substance of use and relapse (p=0.080). Those patients 
who used crystal methamphetamine as their first substance of use had 67% decreased likelihood of 
relapsing compared with those patients who had cannabis as their first substance of use.  Thus first 
users of crystal methamphetamine were less likely than first users of cannabis to relapse. 
On adjustment for sociodemographic and substance use factors (Table 7), there was a 
marginal association between current (12-month) major depression and relapse (p=0.076), with 
patients diagnosed with current depression appearing to have a 65% decreased odds of relapse 
compared with those who were not diagnosed with depression (Table 7). These results thus indicate 
that, on adjustment for both sociodemographic and substance use factors, patients diagnosed with 
current (12-month) major depression had decreased odds of relapse, and, on further analyses, that 
these patients also had increased odds of resuming treatment after discharge. 
In addition, no statistically significant associations were found between time elapsed to 
follow-up and treatment outcomes (relapse and treatment resumption). Similarly, bivariate analyses 
indicated no statistically significant associations between previous substance use treatment and 
treatment outcomes, and the association between psychopathology and treatment outcomes was not 
altered when previous treatment for substance use was added to the completed models. 
 
DISCUSSION 
The primary objectives of this study were to determine whether patients, who had been in inpatient 
substance use treatment, had completed the inpatient treatment programme, or had relapsed, and 
whether these outcomes were associated with psychopathology or substance use factors identified at 
baseline. No statistically significant associations were found between comorbid psychopathology, 
controlled for substance use and sociodemographic variables, and the treatment outcome factors.  
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 Overall, this study had a low attrition rate in the five-week to nine-month period after 
inpatient treatment for substance use. This could be the result of the relatively short follow-up period 
(mean 6 months), and patients in the sample having retained some form of contact with their treatment 
managers or fellow inpatients. The finding  that patients who were lost to follow-up were more likely 
to have been diagnosed with generalised anxiety disorder, and more likely to have had primary use of 
heroin or crystal methamphetamine  might be an indication of lost patients with generalised anxiety 
disorder and/or primary use of crystal methamphetamine having moved from their baseline places of 
residence, or that their anxiety disorder might have made them less likely to want to continue 
participation in the study. These reasons for loss to follow-up, however, are speculative since reasons 
for the loss to follow-up were not specifically investigated. 
Treatment completers were largely single and male, possibly reflecting the increased time 
available to these patients to complete the treatment due to reduced domestic responsibilities 
compared with married or female substance users. For example, Grella (2003) found that, compared 
with males, prospective female patients for substance use treatment were more likely to require 
assistance related to family needs and trauma while, in a study of females who were pregnant or 
entered residential treatment for substance use with their children, treatment completion was 
associated with having completed high school, having no arrests in the six months preceding 
admission, and having friends who were less deviant (Knight et al., 2001). A recent review of the 
literature regarding treatment entry, retention and outcome in women (Greenfield et al., 2007) 
indicated that gender differences played a role in treatment entry, with males being more likely to 
enter treatment, but that gender was not a statistically significant predictor of treatment retention, thus 
echoing the findings of the present study.  Similarly, recent studies with adolescents and young adults 
have indicated that fixed client factors such as age, gender and ethnicity were not significantly 
associated with completion of treatment (Schroder et al., 2009). Instead, it was found that retention in 
treatment was more likely to be a function of so-called dynamic patient factors such as patients’ 
experiences in the treatment process, the degree to which patients are motivated to attend treatment, 
and their expectations about the treatment offered. It is thus possible that unmeasured factors [for 
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example, patients’ readiness to change their behaviour (Saban et al., 2001), patients’ experience of the 
treatment programme and their relationship with treatment staff (Schroder et al., 2009)] were 
operative in dropout from treatment, relapse, and possibly resumption of treatment in the present 
study. It has also been suggested that gender might moderate the relationship between comorbid 
psychopathology in substance users and treatment outcome (Compton et al., 2003), but this was not 
assessed in this study.  
There was a marginal association between primary use of crystal methamphetamine and 
treatment completion (p=0.062) (Table 6), with crystal methamphetamine users being 71% less likely 
to complete treatment (OR=0.291) than were primary users of substances other than crystal 
methamphetamine. Methamphetamine is the primary substance of use in 47% of all individuals (and 
51% of individuals under 20 years of age) who present for treatment in the Western Cape area of 
South Africa (including Cape Town) (Pluddemann, et al., 2010).  It might, thus, be useful for further 
investigations to examine the suggestion that crystal methamphetamine might play a role in non-
completion of inpatient treatment.  
Initiating substance use with of crystal methamphetamine was marginally (p=0.080) and 
inversely (OR=0.331; CI 0.096-1.143) associated with relapse, suggesting that users of crystal 
methamphetamine as a first substance might be less likely than first users of other substances, such as 
cannabis, to relapse. Evidence indicates that initiation of substance use appears to be a function of 
factors such as environmental and economic stressors (Brook et al., 2006), while choice of debut 
substance is subject to availability and affordability (Anderson, 2006). However, initiating crystal 
methamphetamine use specifically has been found to be associated with factors such as age, ethnicity, 
earlier criminal behaviour and sensation-seeking in substance users in treatment for their substance 
use (Brecht et al., 2007). It might thus be of value to investigate further the association between 
crystal methamphetamine (versus other substances) as a first substance of use, and treatment 
outcomes such as relapse, particularly since comparable information on the Cape Town inpatient 
substance using population is currently not available.    
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Overall, no clear-cut statistically significant associations were found between comorbid 
psychopathology and treatment outcome. The  results of the current study also indicated that patients 
diagnosed with current (12-month) depression were less likely than those who were not diagnosed 
with depression to relapse. These findings of continued engagement in substance use treatment 
amongst patients who were depressed, even if they did not relapse, might reflect the recognition by 
these patients of a need for some assistance, but associating the need with problems relating to 
substance use rather than a psychiatric disorder. Thus, since the study sample had largely previously 
undiagnosed psychiatric disorders, it is possible that the affected patients were unaware of their 
mental health status and its possible role in either their discomfort or their substance use or need for 
substance use.  In addition, Miller et al. (1999), in examining substance users in private outpatient 
treatment for their substance use, had previously found that post-treatment factors  such as a lack of 
peer support groups and continuing care, played a larger role in the prediction of relapse than did pre-
treatment factors such as lifetime depression. It is possible that parts of the sample for the present 
study lacked such continuing care and support, and that the absence of continued support accounted 
for, for example, relapse in the female patients.  
The results of this study, however, need to be considered in light of possible study limitations 
imposed by the study design, sample size, and diagnostic instrument.  
The sample was a consecutively-selected clinical sample obtained from three purposively 
selected treatment centres in Cape Town, South Africa. The sample was not selected from a 
representative sample of inpatient treatment centres, and was not selected randomly. The sample was 
thus not representative of Cape Town substance users in inpatient treatment for their substance use 
even though it reflected the broader population trends for the geographical area with respect to some 
demographic factors (such as gender and RCSG). As such, the results obtained are not generalisable 
beyond the selected sample, and comparisons with the results of similar studies have to be made with 
caution. It is also possible that the sample size might have limited the study power, and the kinds of 
statistical analyses that could be performed, with the baseline sample size being slightly smaller than 
the anticipated minimal sample size and subsequent attrition on follow-up. However, it is also likely 
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that the finding that nearly all the inpatients had a psychiatric disorder reduced the gradient for 
looking at associations between psychiatric disorder and treatment outcomes. If  the exceedingly large 
proportion of patients of patients with psychiatric disorder had been anticipated, a larger sample size 
could have been estimated, but the large proportion of patients with psychiatric disorder in this sample 
was unexpected based on the literature (Kaminer et al., 2007). 
Considering that substance use and psychopathology treatment facilities are usually separated 
(Kaminer, Connor &Curry, 2007), it is possible that patients with more severe psychopathology had 
not been represented in this sample of patients in treatment for substance use if patients with more 
severe psychopathology were more likely to be in psychiatric institutions. Severity of comorbid 
psychopathology was not assessed in the sampled patients because using the C-DIS in screen mode 
assesses presence or absence of a diagnosis, and does not indicate severity of diagnoses (Robins et al., 
2002). Thus if the psychopathology in the sample was of varying severity or possibly less severe than 
in patients who receive treatment for psychiatric disorder, and the degree of psychopathology severity 
influenced treatment outcomes, it is possible that omission of a psychopathology severity factor could 
have influenced the associations between psychopathology and treatment outcome in the present 
study. 
The frequency with which comorbid psychopathology occurred in this sample could also have 
been influenced by use of the C-DIS IV since this instrument had not been standardised for use with 
the sample. Generally, validation studies of the DIS have proven difficult, because of the lack of an 
absolute standard that covers the full range of the DSM diagnoses with which to compare it (Robins et 
al., 1981). Furthermore, though the DIS has been found to have satisfactory concordance with 
diagnoses based on clinical judgement (Helzer et al., 1985) this comparison assumes clinical 
judgement to be the appropriate yardstick against which to measure the skills of lay interviewers 
(Robins et al., 1981). The C-DIS also elicited patient information via self-reports, the reliability of 
which was not verified from other sources. Thus, if patients over- or under-reported information 
relevant to the study, the results of the study could have been affected.  
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Furthermore, the variability in the time period between baseline and follow-up interviews 
could have influenced the findings related to outcome. For example, patients who had their follow-up 
interview after a few weeks might have had different outcomes with regards to relapse or treatment 
resumption compared with patients who had their follow-up interviews several months after the 
baseline interviews. 
In addition, resumption of substance use treatment (after discharge from the initial inpatient 
substance use treatment programme) was considered as a treatment outcome measure since comorbid 
psychiatric disorder has been found to be associated with increased rates of re-entry into substance use 
treatment (Arendt et al., 2007). However, this treatment outcome measure proved to be problematic in 
the present study when it was found that some patients elected to continue their inpatient substance 
use treatment programme after discharge, irrespective of their substance use status at the time. Thus 
some patients who had resumed substance use treatment after discharge might have been abstinent, or 
might have elected to resume treatment because of relapse or the effects of a psychiatric disorder. 
Since the reasons for resumption of treatment were not elicited in the study, it would be inappropriate 
to assume that resumption of treatment in this study necessarily reflects a negative treatment outcome. 
Generally, the sample for this study did not constitute an homogeneous group. Patients had 
used different substances (both individual and multiple substances), possibly in differing amounts and 
with differing frequencies, presumably had differing social supports, differing psychosocial 
developments, and differing patterns of severity of psychiatric disorder and/or substance use. It is 
possible that, with the limited information collected at follow-up, some unmeasured sources of 
heterogeneity in the sample might have contributed to confounding, resulting in a lack of significant 
associations between comorbid psychopathology and treatment outcomes. It is also possible that 
information obtained via proxy (clinic directors or parents/guardians) might have differed from 
information obtained from the patients themselves, providing further sources of confounding. 
To identify associations between psychiatric disorder and substance use treatment outcome, it 
might thus be necessary for the heterogeneity of substance users to be considered. Furthermore, it 
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might be advantageous for patient heterogeneity to be considered in attempts to improve the efficacy 
of substance use treatment by, for example, having the treatment tailored to suit the needs of 
individuals. One suggestion has been to provide primary care in substance use treatment facilities as a 
cost-effective means of accommodating treatment for comorbidity, compared with fully integrating 
psychiatric and substance use treatment services (McKay 2005). In the longer term, this approach 
might result in improved compliance with inpatient and follow-up treatment in these patients since 
both (or all) comorbid conditions could be stabilized and monitored.  
In conclusion, similar future studies might examine treatment outcomes in a cohort of 
comorbid substance use patients versus patients with only a substance use disorder. Future studies of  
the treatment outcomes  of substance use inpatients might also have to consider assessment of patient 
factors that include severity of comorbid psychopathology, patients’ readiness to change their 
behaviour (Saban et al., 1999), coping skills, reasons for extending or resuming substance use 
treatment after discharge, and psychosocial functioning (Ciraulo et al., 2003), while treatment 
programmes might have to be supplemented with practices that ensure continuity of care after 
treatment discharge (Schaefer et al., 2008). 
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TABLE 1  Demographic characteristics of the sample in the three treatment centres (n; %) 
 
 
 
Demographic variable 
 
Clinic 1 
 
Clinic 2 
 
Clinic 3 
 
Total 
 
n =17 
 
n = 30 
 
n = 48 
 
n = 95 
 
Mean Age 
SD 
 
21.7 
3.5 
 
23.2 
3.0 
 
23.4 
2.6 
 
23.0 
2.9 
 
Gender Male 
 
16 (94.1) 
 
24 (80.0) 
 
45 (93.8) 
 
85 (89.5) 
 
RCSG 
 White  
 Coloured 
 Indian 
 
 
3 (17.7) 
13 (76.5) 
1 (5.9) 
 
 
1 (3.3) 
27 (90.0) 
2 (6.7) 
 
 
0 
44 (91.7) 
4 (8.3) 
 
 
4 (4.2) 
84 (88.4) 
7 (7.4) 
 
Religion 
 Muslim 
 
 
2 (11.8) 
 
 
27 (90.0) 
 
 
36 (75.0) 
 
 
65 (68.4) 
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 Christian 15 (88.2) 3 (10.0) 11 (22.9) 29 (30.5) 
 
Highest educational level 
 Primary school 
 Secondary school 
 Tertiary 
 
 
1 (5.9) 
16 (94.1) 
0 
 
 
0 
24 (80.0) 
6 (20.0) 
 
 
2 (4.2) 
42 (87.5) 
4 (8.3) 
 
 
3 (3.2) 
82 (86.3) 
10 (10.5) 
 
Referral source 
 Self 
 Family 
 Other 
 
 
10 (58.8) 
3 (17.6) 
4 (23.5) 
 
 
18 (60.0) 
11 (36.7) 
1 (3.3) 
 
 
30 (62.5) 
13 (27.1) 
5 (10.4) 
 
 
58 (61.1) 
27 (28.4) 
10 (10.5) 
 
Marital status 
 Never married 
 Other 
 
 
15 (88.2) 
2 (11.8) 
 
 
22 (73.3) 
8 (25.7) 
 
 
37 (77.1) 
11 (22.9) 
 
 
74 (77.9) 
21 (22.1) 
 
Living arrangements 
 Live alone 
 Live with immediate family 
 
 
0 
16 (94.1) 
 
 
0 
29 (96.7) 
 
 
2 (4.2) 
42 (87.5) 
 
 
2 (2.1) 
87 (91.6) 
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 Other 1 (5.9) 1 (3.3) 4 (8.3) 6 (6.3) 
 
Employment status 
 Unemployed 
 Casually employed 
 Permanently employed 
 
 
7 (41.2) 
1 (5.9) 
7 (41.2) 
 
 
18 (60.0) 
2 (6.7) 
7 (23.3) 
 
 
27 (56.3) 
4 (8.3) 
17 (35.4) 
 
 
52 (54.7) 
7 (7.4) 
31 (32.6) 
 
Usual employment 
 Professional 
 Skilled 
 Unskilled 
 None/student/scholar 
 
 
0 
6 (35.3) 
4 (23.5) 
7 (41.2) 
 
 
0 
10 (33.3) 
10 (33.3) 
8 (26.7) 
 
 
1 (2.1) 
18 (37.5) 
16 (33.3) 
8 (16.7) 
 
 
1 (1.1) 
34 (35.8) 
30 (31.6) 
23 (24.2) 
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TABLE 2 Frequency of substance use  at baseline (n; %) 
 
 
 
Substance use variable 
 
Clinic 1 
 
Clinic 2 
 
Clinic 3 
 
Total 
 
n = 17 
 
n = 30 
 
n = 48 
 
n = 95 
 
Age of first illicit substance use (years) 
 10 – 14 
 15 – 17 
 18 – 20 
 21 – 24 
 Mean (SD) 
 
 
13 (76.5) 
3 (17.6) 
0 
1 (5.9) 
13.6 (2.4) 
 
 
13 (43.3) 
11 (36.7) 
5 (16.7) 
1 (3.3) 
15.1 (2.6) 
 
 
23 (47.9) 
18 (37.5) 
7 (14.6) 
0 
14.8 (2.3) 
 
 
49 (51.6) 
32 (33.7) 
12 (12.6) 
2 (2.1) 
14.7 (2.4) 
 
First illicit substance of use 
 Alcohol 
 
 
4 (23.5) 
 
 
0 
 
 
3 (6.3) 
 
 
7 (7.4) 
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 Cannabis 
 Ecstasy 
 Heroin 
 Methaqualone (mandrax) 
 Crystal methamphetamine (tik) 
 Multiple 
8 (47.1) 
0 
1 (5.9) 
0 
4 (23.5) 
0 
16 (53.3) 
5 (16.7) 
2 (6.7) 
2 (6.7) 
3 (10.0) 
2 (6.7) 
25 (52.1) 
4 (8.3) 
3 (6.3) 
0 
10 (20.8) 
3 (6.3) 
49 (51.6) 
9 (9.5) 
6 (6.3) 
2 (2.1) 
17 (17.9) 
5 (5.3) 
Primary substance of use 
 Alcohol 
 Cannabis 
 Heroin 
 Crystal methamphetamine (tik) 
Methaqualone (mandrax) 
 Multiple 
 
3 (17.6) 
4 (23.5) 
2 (11.8) 
7 (41.2) 
0 
1 (5.9) 
 
0 
0 
20 (66.7) 
8 (26.7) 
1 (3.3) 
0 
 
0 
1 (2.1) 
29 (60.4) 
17 (35.4) 
0 
1 (2.1) 
 
3 (3.2) 
5 (5.3) 
51 (53.7) 
32 (33.7) 
1 (1.1) 
2 (2.1) 
Frequency of use 
 Daily 
 Few times a week 
 
15 (88.2) 
1 (5.9) 
 
28 (93.3) 
2 (6.7) 
 
43 (89.6) 
3 (6.3) 
 
86 (90.5) 
6 (6.3) 
Intensity/Volume of use 
 As much as I can obtain 
 
11 (64.7) 
 
14 (46.7) 
 
31 (64.6) 
 
56 (58.9) 
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 As much as I can afford to buy 6 (35.3) 15 (50.0) 16 (33.3) 37 (38.9) 
 
Previous treatment for substance use  
 None 
 Once in past year 
 More than once in past year 
 More than a year ago 
 
11 (64.7) 
3 (17.6) 
0 
3 (17.6) 
 
12 (40.0) 
2 (6.7) 
5 (16.7) 
11 (36.7) 
 
19 (39.6) 
8 (16.7) 
12 (25.0) 
9 (18.8) 
 
42 (44.2) 
13 (13.7) 
17 (17.9) 
23 (24.2) 
Age of first treatment for substance use 
(yrs)  
 10 – 14 
 15 – 17 
 18 – 20 
 21 – 24 
 >24 
 Mean (SD) 
 
n=6 
1 (16.7) 
0 
5 (83.3) 
0 
0 
17.5 (3.3) 
 
n=18 
2 (11.1) 
4 (22.2) 
7 (38.9) 
3 (16.7) 
2 (11.1) 
18.9 (3.9) 
 
n=29 
0 
7 (24.1) 
13 (44.8) 
9 (31.0) 
0 
19.3 (2.6) 
 
n=53 
3 (5.7) 
11 (20.8) 
25 (47.2) 
12 (22.6) 
2 (3.8) 
19 (3.1) 
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TABLE 3 Prevalence of psychopathology at baseline (n; %) 
  
Clinic 1 
 
Clinic 2 
 
Clinic 3 
 
Total 
 
Psychopathology 
 
n = 17  
 
n = 30 
 
n = 48 
 
n = 95 
 
No previous diagnosis of psychopathology 
 Generalised anxiety disorder 
 Post-traumatic stress disorder (PTSD) 
 Depression 
 Mania 
 Schizophrenia 
 Obsessive Compulsive Disorder (OCD) 
 
15 (88.2) 
3 (17.6) 
3 (17.6) 
6 (35.3) 
6 (35.3) 
0 
2 (11.8) 
 
29 (96.7) 
1 (3.3) 
5 (16.7) 
9 (30.0) 
1 (3.3) 
2 (6.7) 
1 (3.3) 
 
47 (97.9) 
1 (2.1) 
6 (12.5) 
9 (18.8) 
5 (10.4) 
0 
1 (2.1) 
 
91 (95.8) 
5 (5.3) 
14 (14.7) 
24 (25.3) 
12 (12.6) 
2 (2.1) 
4 (4.2) 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
204 
 
 Eating disorder 
 Separation anxiety 
 Oppositional defiant disorder 
 Conduct disorder (CD) 
 Antisocial personality disorder (ASPD) 
 Pain disorder 
 Specific phobia 
 Substance dependence 
 Substance abuse 
0 
1 (5.9) 
7 (41.2) 
10 (58.8) 
14 (82.4) 
3 (17.7) 
4 (23.5) 
12 (70.6) 
4 (23.5) 
2 (6.7) 
2 (6.7) 
10 (33.3) 
18 (60.0) 
26 (86.7) 
4 (13.3) 
5 (16.7) 
29 (96.7) 
5 (16.7) 
2 (4.2) 
2 (4.2) 
15 (31.1) 
36 (75.0) 
43 (89.6) 
3 (6.3) 
6 (12.5) 
46 (95.8) 
6 (12.5) 
4 (4.2) 
5 (5.3) 
32 (33.7) 
64 (67.4) 
83 (87.4) 
10 (10.5) 
15 (15.8) 
87 (91.6) 
15 (15.8) 
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TABLE 4 Percentage retention at follow-up by demographic characteristics 
 
Demographic factors 
 
Baseline (n) 
 
Follow-up (n; % of baseline) 
  
Lost to follow-up (n; % of 
baseline) 
 
Total 
 
95 
 
86 (90.5) 
 
9 (9.5) 
   
Males 
 
85 
 
76 (89.4) 
 
9 (10.6) 
  
RCSG 
  Coloured 
  White 
  Indian/Asian 
 
 
84 
7 
4 
 
 
75 (89.3) 
7 (100) 
4 (100) 
 
 
9 (10.7) 
0 
0 
 
Religion 
  Muslim 
  Christian 
 
 
65 
29 
 
 
61 (93.8) 
24 (82.8) 
 
 
4 (6.2) 
5 (17.2) 
 
Marital status 
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  Never married 74 65 (87.8) 7 (10.4) 
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Table 5 Frequency of treatment outcome by demographics, most common psychopathology, first substances of use, and primary substances of use [n, (%), p-
value] 
 
Demographic, psychopathology and 
substance use factors 
 
Completed Treatment Yes                                       
n (% of baseline) 
p-value 
Relapsed Yes                         
n (% of follow-up)  
p-value 
Back/Still in Treatment   Yes                      
n (% of follow-up) 
 p-value 
 
 
   
 
n at follow-up (% of 
baseline total n=95)  
n=70 n=86 n=86 
Age 
 
    
Mean(SD) 
 
23.0 (3.1) 22.8 (3.0)  23.2 (2.8)  
 
 0.428 0.488 0.723 
 
 
   
Gender 
 
   
Male  
 
76 (80) 64 (75.3) 38 (50.0) 32 (42.1) 
Female 
 
10 (10.5) 6 (60.0) 8 (80.0) 6 (60.0) 
 
 0.220 0.097 0.326 
 
 
  
 
 
  
 
RCSG 
 
  
 
Coloured 
 
75 (78.9) 62 (73.8) 39 (52.0) 35 (46.7) 
White/Indian 
 
11 (10.5) 8 (72.7) 7 (63.6) 3 (27.3) 
 
 0.660 0.410 0.333 
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Religious denomination 
 
   
Muslim 
 
61(64.2) 49 (75.4) 33 (54.0) 29 (47.5) 
Christian 
 
24 (25.3) 21 (72.4) 13 (54.2) 9 (37.5) 
 
 0.255 1.000 0.477 
 
 
   
 
 
   
Marital Status 
 
   
Never married 
 
65 (63.2) 60 (81.1) 36 (55.4) 30 (46.2) 
Other 
 
21(22.1) 10 (47.6) 10 (47.6) 8 (38.0) 
 
 0.002 1.000 1.000 
 
 
   
Psychopathology 
 
n at baseline 
   
Anti-social personality disorder 
 
83 61 (73.5)  41 (49.4)  31 (41.9)  
 
 0.725 0.748 0.355 
Conduct disorder 
 
64 47 (73.4)  32 (50.0)  23 (35.9)  
 
 1.000 1.000 0.168 
Oppositional defiant disorder 
 
32 23 (71.9)  17 (53.1)  12 (37.5)  
 
 1.000 0.368 1.000 
Major Depression 
 
24 19 (79.2)  9 (37.5) 12 (50.0)  
 
 0.772 0.218 0.322 
PTSD                                                       
 
 
14 10 (71.4) 
1.000 
7(58.3) 
 0.765 
6 (50.0)  
0.758 
Specific phobia                                     
 
 
 
 
 
 8 (57.1)  
1.000 
4 (28.6)  
0.248 
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15 12 (80.0)  
0.727 
 
 
  
 
 
  
 
First substance of use 
 
  
Cannabis 
 
 
49 
 
36 (73.5) 27 (55.1) 20 (40.8) 
Crystal methamphetamine 
 
17 11 (64.7) 5 (29.4) 6 (35.3) 
Other 
 
29 23 (79.3) 12 (41.3) 12 (41.3) 
 
 
0.887 0.244 0.876 
 
 
   
 
  
 
 
 
Primary substance of use 
 
   Heroin 51 23 (45.1) 20 (62.5) 18 (56.3) 
 
Crystal methamphetamine 
 
 
 
 
32 
 
 
12 (37.5) 
 
0.108 
7 (41.2) 
 
0.148 
7 (41.2) 
 
0.213 
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TABLE 6 Association, using logistic regression analyses, between psychopathology and treatment completion (OR, 95% CI, p-value)
 
 
 
                  
  
Rx Completion (Yes) 
n=70 
    
  Unadjusted   Adjusted
†
   Adjusted
††
  
Psychopathology    OR      95% CI    p     OR       95% CI    p  OR 95%CI p 
ASPD 1.118 0.272-4.598 0.878   1.361 0.266-6.956 0.711  1.225 0.230-6.531 0.812 
Conduct disorder 0.918 0.310-2.725 0.878   0.967 0.291-3.209 0.956  1.014 0.282-3.641 0.984 
Oppositional defiant 0.867 0.302-2.489 0.790   0.796 0.261-2.425 0.688  0.738 0.227-2.392 0.612 
Major depression 1.500 0.442-5.092 0.516   1.672 0.422-6.622 0.464  2.273 0.512-10.093 0.280 
PTSD 0.895 0.217-3.681 0.878 
 
1.855 0.276-12.470 0.525  1.640 0.228-11.777 0.623 
Specific phobia 2.000 0.408-9.799 0.393 
 
2.757 0.416-18.271 0.293  2.953 0.445-19.608 0.262 
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Primary substance use 
Heroin 0.500 0.181-1.380 0.181   0.705 0.233-2.127 0.534     
Crystal methamphetamine 0.467 0.147-1.481 0.196   0.291 0.080-1.065 0.062     
 
First substance of use               
    
Cannabis 1.200 0.441-3.267 0.721   1.493 0.477-4.672 0.491     
Crystal methamphetamine 0.800 0.224-2.856 0.731   0.841 0.205-3.454 0.810     
        
    
†
Adjusted for age, gender, RCSG, religion and treatment centre 
††
 Adjusted for age, gender, RCSG, religion, first substance of use, most frequently used (primary) substance and treatment centre 
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TABLE 7 Association, using logistic regression analyses,  between psychopathology and relapse (OR, 95% CI, p-value)
 
 
 
                 
  
Relapse (Yes) 
n=86 
   
  Unadjusted   Adjusted
†
  Adjusted
††  
Psychopathology           OR      95% CI          p        OR         95% CI            p OR 95%CI p 
ASPD 1.739 0.505-5.985 0.380   2.293 0.600-8.767 0.225 2.071 0.530-8.104 0.295 
CD 1.101 0.442-2.740 0.837   1.425 0.523-3.880 0.489 1.299 0.453-3.723 0.626 
Oppositional defiant 1.545 0.618-3.865 0.352   1.717 0.656-4.495 0.271 1.629 0.601-4.414 0.337 
Major depression 0.505 0.189-1.352 0.174   0.420 0.136-1.296 0.131 0.346 0.107-1.120 0.076 
PTSD 1.256 0.365-4.320 0.717 
 
0.806 0.173-3.760 0.784 0.662 0.136-3.221 0.610 
Specific phobia 1.193 0.376-3.787 0.765 
 
1.066 0.291-3.908 0.923 0.873 0.224-3.400 0.845 
 
                
 
Primary substance use 
       
   
Heroin 1.795 0.735-4.383 0.199  1.430 0.537-3.804 0.474    
Crystal methamphetamine 0.538 0.183-1.581 0.260   0.551 0.177-1.717 0.304    
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First substance of use 
       
   
Cannabis 1.571 0.669-3.690 0.300  2.108 0.797-5.576 0.133    
Crystal methamphetamine 0.366 0.113-1.181 0.093   0.331 0.096-1.143 0.080    
†
Adjusted for age, gender, RCSG, religion and treatment centre 
†† 
Adjusted for age, gender, RCSG, religion, first substance of use, most frequently used (primary) substance and treatment centre 
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FOLLOW-UP QUESTIONNAIRE FOR TREATMENT CENTRE STUDY 
 
 
Treatment Centre……………………………………………. 
 
 
Patient/Subject number……………………………………... 
 
 
Folder/File number…………………..   Date………………………………… 
 
Time lapse since baseline interview (weeks)………………. 
 
Patient/Subject name……………………………………………………………………... 
Address……………………………………………………………………………………. 
Telephone numbers i)……………………  ii)……………………… iii)………………... 
 
 
You will/might remember that I interviewed you a little while ago. At that time I 
mentioned that I will speak with you again. So now I would like to ask you a few short 
questions. 
 
A. TREATMENT 
A1. Where was treatment received since we last spoke? 
1. Horizon Halfway House 
2. Claro Clinic 
3. Other  Specify…………………………………………………………….. 
 
A2. What kind(s) of treatment did you receive? 
1. Medication  Specify…………………………………………………………….. 
2. Group psychotherapy 
3. Individual psychotherapy 
4. Alternative treatme ts (eg massage, reiki etc)  Specify…………………….. 
5. Other  Specify…………………………………………………………….. 
 
A3. Do you feel that the treatment you received was what you expected? 
1. No 
2. Yes 
3. Didn’t have expectations about Rx 
4. Don’t know 
 
A4. Do you have any suggestions about how your treatment could have been 
improved/altered? 
1. No 
2. Yes 
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A5. If YES, what changes/improvements would you suggest? 
………………………………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………… 
B. CURRENT STATUS 
B1. How would you describe how you are now compared with when we last spoke? 
1. Better 
2. Worse 
3. Same 
4. Not sure 
 
Comments…………………………………………………………………………
………………………………………………………………………………………
……………………………………………………………………………… 
 
B2. Are you using any substance(s) now? 
1. No 
2. Yes 
3. Not sure 
    
 Comments…………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………… 
 
If NO, then that is the end of this interview. Many thanks for your time. I wish you well 
and hope you don’t mind if I contact you again in the future. 
 
B3. If YES, what are you currently using? 
1. Tobacco 
2. Alcohol 
3. Cannabis 
4. Methamphetamine 
5. Heroin 
6. Cocaine 
7. Other  Specify……………………………………………………………... 
 
B4. What would you say your main current substance of use is? 
1. Tobacco 
2. Alcohol 
3. Cannabis 
4. Methamphetamine 
5. Heroin 
6. Cocaine 
7. Other  Specify……………………………………………………………... 
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B5. Is your current main substance of use different from what it was when we last 
spoke? 
1. No 
2. Yes 
3. Not sure 
 
 
 Comments…………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………… 
 
B6. How often do you use this substance? 
1. Daily 
2. Few times per week 
3. Weekends only 
4. Seldom/Sometimes 
5. Never 
 
 
 Comments…………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………… 
 
B7. How much of this substance do you consume at any one time? 
Actual amount……………………………………………………………………………… 
 
 
Thanks very much for your time and cooperation. I would like to contact you again some 
time in the future, if that will be alright with you. Meanwhile, all the best. 
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CHAPTER 6 
The association between substance use and common 
mental disorders in young adults: results from the South 
African Stress and Health (SASH) Survey 
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ABSTRACT 
Although substance use is commonly associated with mental disorders, limited data on this 
association is available from low and middle income countries such as South Africa. The South 
African Stress and Health (SASH) study is a nationally-representative random cross-sectional survey 
of South African households, and forms part of a World Health Organisation (WHO) World Mental 
Health (WMH) initiative to standardise information on the global burden of mental illness and its 
correlates. In this study,  data from a subset (n=1766; aged 18 to 30 years) of the SASH sample of 
4351 individuals were analysed. The aims of the study were i) to determine patterns of substance use 
in young adults, ii) to identify trends of common psychiatric disorders in relation to use of specific 
substances, and iii) to determine whether specific psychiatric disorders were associated with use of 
specific substances in the South African population.  The Composite International Diagnostic 
Interview Version 3 (CIDI 3.0) was used to elicit basic demographic details and information regarding 
mental illness and substance use. Multiple regression analyses, adjusted for age and gender, were used 
to identify associations between mental disorders and substance use. Results indicated significant 
associations between substance use and mood and anxiety disorders, with a particularly strong 
relationship between cannabis use and mental disorder. The data here are consistent with those from 
previous studies, and reinforce the argument that comorbid substance use and mental disorders 
constitute a major public health burden 
Key words:  SASH  comorbidity  mental disorders  substance use 
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1. Introduction 
Debilitating mental illness often places a burden on society (Teeson et al., 2009).  Mental illness 
can result in reduced economic productivity in affected individuals (Chatterji et al., 2009),  and can 
influence the quality of life for individuals and their families as a result of the disabling effects of the 
mental illness (Kessler et al., 2009). Mental illness can also increase the load on service providers 
who treat the affected individuals (Kessler et al., 1997). Similarly, problematic substance use poses a 
challenge to society because of its effects on the psychosocial functioning, productivity and general 
health of the affected individuals (Glassner-Edwards et al., 2010; Goldstein and Bukstein, 2009). It 
has been argued that individuals who suffer from mental illnesses are more likely to be or become 
dependent on substances than are individuals who do not have mental disorders (Kessler et al., 1997). 
Conversely, individuals who abuse substances appear to be more likely to develop or suffer from 
mental illnesses than are those who do not abuse substances (Buckley, 2007). Thus, when mental 
illness and problematic substance use or abuse co-occur (commonly described as comorbidity), the 
resulting problems are often compounded and more complex than when either mental illness or 
problematic substance use occurs individually (de Graaf et al., 2004), increasing the challenges posed 
to the management and treatment of the affected individuals (Kessler et al., 1997) 
Globally, many studies have examined comorbid psychopathology and substance use. However, 
more details on comorbidity are generally available for older individuals, and less regarding children, 
adolescents and young adults (Goldstein and Bukstein, 2009). Furthermore, most of these studies have 
examined samples in treatment for either substance use or psychiatric disorders (Armstrong and 
Costello, 2002) resulting in less published information on comorbidity in communities. 
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Armstrong and Costello (2002) described six important reasons for examining comorbid 
psychopathology and substance use in representative community samples. The reasons for this are 
based primarily on inherent differences between clinical and community samples and the consequent 
inappropriateness of extrapolating information from clinic-based studies to communities. Firstly, 
since individuals with more than one disorder are more likely to seek treatment for either disorder 
than are individuals with only one disorder, clinical samples are more likely than community samples 
to contain comorbid individuals. Secondly, the nature of some disorders might be more likely to 
precipitate treatment seeking. Hence, for example, a disruptive behaviour disorder (such as conduct or 
antisocial personality disorder) that co-occurs with substance use might be more likely to elicit 
treatment seeking than would an internalising disorder (such as depression), resulting in clinical 
samples possibly having a higher percentage of comorbid disruptive behaviour disorders than is 
commonly prevalent in communities.  Thirdly, community and clinical samples might differ with 
respect to the severity of occurring symptoms. Fourthly, community and clinical samples might differ 
with respect to the temporality of comorbidity. Fifthly, clinic and community samples might differ 
with respect to the risk factors for comorbid psychopathology and substance use. These differences 
can usually be assessed for diseases where most cases are treated. However, since not all comorbid 
substance users receive treatment, it would be inappropriate to assume that risk factors for 
comorbidity are the same in both treatment and community samples. Lastly, substance use treatment 
samples might reflect a different patient economic profile compared with community samples by 
containing mainly individuals who have access to finances for treatment, and thus excluding those 
individuals who might need treatment but cannot afford it.  
In South Africa, as in other developing countries, information regarding comorbid 
psychopathology and substance use, its consequences, and the implications for society, is limited by a 
paucity of published studies (Sharan et al., 2009; Saban and Flisher, 2010). Evidence has indicated 
that sociodemographic factors can play a significant role in comorbidity and its effects (Hovens et al., 
1994; Brook et al., 1995; Riggs et al., 1995; Rohde et al., 1996; Deykin & Buka, 1997; Escobedo et 
al., 1998; Costello et al., 1999; McGee et al., 2000; Shrier et al., 2003).  Findings from non-South 
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African studies have included evidence for associations between conduct disorder and substance use 
within specific developmental stages (Grilo et al., 1995; Ferdinand, Blum and Verhulst, 2001), and 
differing associations between psychopathology and substance use in males and females (Brooner et 
al., 1997; Deyken and Buka, 1997). While some findings included evidence for associations between 
depression and smoking (Escobedo et al., 1998; Ferguson et al., 1996; Kendler et al., 1993), between 
depression and alcohol use (Araujo and Monteiro, 1995), and between psychopathology in general 
and cannabis use (McGee et al., 2000), other findings have not indicated definitive associations 
between psychopathology and substance use (Boyle et al., 1992; Costello et al., 1999; Degenhardt et 
al., 2001). For example, Boyle et al. (1992) found associations between conduct disorder and cannabis 
use, but not between conduct disorder and use of tobacco or alcohol, while Costello et al. (1999) 
found no evidence for associations between anxiety and substance use. Though these findings play a 
significant role in the understanding of associations between psychopathology and substance use, their 
generalisability to the South African population cannot be assumed. In particular, these studies had 
not always used similar psychopathology assessment tools, had often examined differing substances 
of use with differing instruments, and subscribed to differing conceptual frameworks, suggesting that 
over-arching conclusions about the nature of comorbid psychopathology and substance use be drawn 
with caution.   
The World Health Organisation (WHO) World Mental Health (WMH) initiative was embarked 
upon to provide standardised information on the global burden of mental disorders and its correlates 
in 28 countries. The South African Stress and Health (SASH) survey, initiated in 1999 and 
commenced in 2002, represents the South African arm of the WHO WMH initiative. The SASH 
survey is significant in that it is a nationally representative survey of selected mental disorders in 
South Africa and in Africa (Stein et al., 2009; Herman et al., 2009).  One of the primary aims of the 
SASH survey was to address a recognised gap in knowledge regarding the prevalence and severity of 
selected mental disorders in South Africa, in a manner that was comparable with similar data from 
other parts of the world.  
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  The current study focussed on the nature of associated psychopathology and substance use in a 
previously unexamined sample of young South African adults aged 18 to 30 years. The study 
advances knowledge about comorbidity in general, and particularly in South Africa, by using a 
nationally representative community sample. 
The aim of the study was threefold. Firstly, the prevalence of substance use was calculated with 
respect to selected demographic factors (namely, age, gender, racially classified social group, highest 
educational level, marital status, employment status, income and urbanicity) to determine substance 
use patterns in young adults. Secondly, the prevalence of psychopathology (namely mood and anxiety 
disorders) amongst younger users of various selected substances was calculated, to determine 
percentage of psychopathology in relation to specific substances of use. Thirdly, and finally, the 
current study calculated associations between selected lifetime and 12-month psychopathology 
(namely mood and anxiety disorders) and substance use, adjusted for age and gender to determine 
whether specific psychopathology was associated with use of specific substances of use in young 
South African adults.  
 
 
2. Methods 
The SASH study was a nationally representative mental health survey that was conducted 
between January 2002 and June 2004 (Williams et al., 2004). The study protocol was approved by the 
Institutional Review Board of the University of Stellenbosch. All sampled individuals provided 
written informed consent for participation in the study. 
2.1. Sample 
The SASH study randomly sampled adult males and females, aged 18 years and older, from all 
the South African racially classified social groups (RCSGs). RCSGs are defined according to the 
Population Registration Act of 1950 that classified citizens largely in terms of skin colour. These 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
220 
 
RCSGs were selected because they still reflect ongoing social disparities in South Africa (Kon and 
Lackan, 2008).  The RCSGs were Asian/Indian, White, Coloured and Black, with Coloured referring 
to individuals of mixed origins including Asian, European, African or any other heritage.   A three-
stage probability sample design was used. The primary stage stratified by census enumerator areas 
(EA). A probability sample of households (that excluded prisons, hospitals and military barracks) and 
hostel quarters (single-sex migrant labour accommodation) was then selected from each EA. One 
adult was randomly selected from each household to be included in the sample. Of these, 
questionnaires were adequately completed for 98.1% of the interviewed individuals, resulting in a 
final sample size of 4351 study participants aged 18 years and older. The present study extracted data 
regarding those individuals who were aged 18 to 30 years (inclusive), with the aim of addressing 
comorbid psychopathology and substance use in young adults. This resulted in a sub-sample size of 
1766. 
2.2. Instruments 
The mental health of each selected individual was assessed using the lay-administered World 
Mental Health (WMH) Composite International Diagnostic Interview Version 3 (CIDI 3.0) (Kessler 
& Ustun, 2004), providing both Diagnostic and Statistical Manual-Version IV (DSM IV) and 
International Classification of Diseases-Version 10 (ICD-10) psychiatric diagnoses for lifetime and 
last 12-months.  Since the CIDI had not previously been used in a South African population sample, 
parallel validation interviews were conducted by a clinician who was blind to the CIDI diagnoses, on 
100 study participants (Williams et al., 2004). Some CIDI questions were modified, and additional 
questions were included, to suit the South African context. The interview questions were translated 
from English into six of the 11 official languages in South Africa, to enable respondents to 
communicate in their mother tongue.  
2.3. Procedure 
Interviewers were trained to use the CIDI and become fieldworkers, operating in conjunction with 
fieldwork supervisors to identify and select potential subjects. The scheduled face-to-face interview 
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was completed by the fieldworker, usually at the home of the participant, after informed consent had 
been obtained from the subject. Interviews were conducted in seven of the 11 official languages of 
South Africa, namely English, Afrikaans, isiXhosa, isiZulu, seSotho, Northern Sotho and seTswana. 
The duration of interviews averaged three hours. In the event of an interview not being completed in 
one sitting, a second interview was scheduled and conducted. 
2.4. Measures 
The pencil-and paper version of the CIDI was administered to all study participants. It elicited 
lifetime and 12-month occurrence for major depression (MD), panic disorder, social phobia, 
agoraphobia, generalised anxiety disorder (GAD), intermittent explosive disorder (IED), suicidality, 
substance use and post-traumatic stress disorder (PTSD), while personality disorders and psychoses 
were screened for. Anxiety disorders included panic disorder, generalised anxiety disorder (GAD) 
with hierarchy, social phobia, agoraphobia, and PTSD. A summary category was created  for ‘any 
anxiety disorder or mood disorder’. Diagnoses of mood (namely, major depression) and anxiety 
disorders were selected for analyses in the present study (Tables 2, 3 and 4), thus excluding 
intermittent explosive disorder, suicidality and those disorders that were screened for (personality 
disorders and psychoses). 
Basic sociodemographic information was elicited, including both time-fixed (age, gender and 
RCSG) and time-varying factors (highest educational level, marital status, employment, income and 
urbanicity). Income was defined as the participant’s personal earnings from employment in the past 
12 months, before taxes, and excluded income from investments or pensions. Participants also 
answered questions regarding their own substance use, including use of tobacco, alcohol, cannabis, 
extra-medical drugs (including non-medical use of sedatives, tranquilisers, stimulants, analgesics, or 
any other psychoactive over-the-counter compounds) and any other drugs (including cocaine, LSD, 
heroin, opium or glue). Tobacco smokers were defined as those who reported having smoked more 
than 100 cigarettes in their lifetime. Alcohol use was defined as ever having had a drink of alcohol. In 
cases where the latter question was unanswered and/or missing, participants who had recorded an age 
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at which they had had their first drink, were also defined as having used alcohol. Cannabis users, 
users of other drugs, and users of extra medical drugs were defined as those who answered ‘yes’ to 
ever having used those drugs. 
2.5. Data analyses 
Data were analysed using Stata Version 11.0 (2007).  All reported analyses took into account the 
survey design based on person-level weights, and incorporated sample selection, non-response and 
post-stratification factors.  All statistical tests were two-sided at α=0.05.   
Descriptive statistics were generated, providing mean age, and proportions for categorical data.  
The prevalence of the demographic and socioeconomic variables was examined and stratified, and 
presented by substance use categories (tobacco, alcohol, cannabis, other drugs, extra-medical drugs).  
Differences between the proportions were tested with the chi-squared test, and p-values reported to 
compare demographic and socioeconomic characteristics by substance use.  The prevalence and 95% 
confidence intervals of lifetime and 12-month DSM-IV disorders were stratified by substance use and 
again p-values from chi-squared tests for proportions were reported, with prevalence of comorbidity 
reported for specific forms of psychopathology in relation to specific substances of use.  To look at 
the associations between DSM-IV disorders (both lifetime and 12-month) and substance use, 
regression analyses were conducted, calculating prevalence odds ratios with p-values and 95% 
confidence intervals, including adjustment for age (as a continuous variable) and gender.  
 
3. Results 
The study sample consisted of 1766 males and females. These study participants comprised a 
subset of the SASH survey sample (n=4351), and consisted of all the SASH survey participants 
aged 18 to 30 years (Mean age 23.6 years; 95% CI 23.4-23.8). 
Table 1 summarises the prevalence of substance use in terms of the selected demographic 
factors.  This table indicates that 27.4% of the sample had smoked 100 or more cigarettes in their 
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lifetime, 38.7% had ever used alcohol, 10.7% had ever used cannabis, 2.7% had used other 
substances such as cocaine, heroin, opium, glue, LSD or peyote, and 20.6% had used sedatives, 
tranquilisers, stimulants or analgesics for non-medical use (extra-medical drugs). Significantly 
more males than females smoked cigarettes (p<0.001) and significantly fewer Blacks smoked 
cigarettes compared with the other RCSGs (p<0.001). Smokers were also more likely to be 
employed (p<0.001) and to live in urban environments (p=0.006). 
A larger proportion of males used alcohol compared with females (p<0.001),  and a significantly 
smaller proportion of Indians/Asians used alcohol compared with the other RCSGs (p<0.001). 
Significantly more alcohol users were employed (p<0.001), and lived in urban environments 
(p=0.003).  
The proportion of cannabis users differed statistically significantly by gender (p<0.001), RCSG 
(p<0.001), highest educational level (p=0.020), employment status (p=0.003) and urbanicity 
(p<0.001). Significantly more males than females used cannabis (p<0.001). A larger proportion of 
Whites had ever used cannabis compared with the other RCSGs. The highest proportions of cannabis 
users were reported for those who had no formal education (21.6%) and those who had tertiary 
education (16.8%), suggesting a bimodal distribution. A significantly larger proportion of cannabis 
users was unemployed and lived in rural environments.  
A larger proportion of males had ever used drugs such as cocaine, heroin, opium, glue, LSD, 
and/or peyote) (p<0.001) while the proportion of Blacks who used these substances was significantly 
smaller than the proportions of other RCSGs who used these substances (p=0.004). A significantly 
larger proportion of extra-medical substance users lived in urban environments (p=0.010) compared 
with the proportion who lived in rural environments. 
Table 2 lists the prevalence odds ratios of mental disorders by substance of use. In the total 
sample, the odds of any lifetime anxiety disorder were 14.7, and 19.7 for any lifetime anxiety or mood 
disorder. The  odds  of any 12-month anxiety or mood disorder were 10.3 while for the total sample, 
the odds of having any 12-month anxiety disorder was 7.1. The prevalence odds ratios of lifetime 
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anxiety disorders in the sample was lowest for panic disorder (0.7)  and highest for  
agoraphobia(11.1), while the prevalence odds of 12-month anxiety disorders was lowest for PTSD 
(0.3) and highest for agoraphobia (5.1). The prevalence odds were 8.6 for lifetime major depression 
and 4.3 for 12-month major depression.  
Compared with non-tobacco users, tobacco users had a significantly higher  likelihood of lifetime 
social phobia (OR=5.1; p=0.011), and major depression (OR=12.1; p=0.027), and had significantly 
higher prevalence odds of 12-month generalised anxiety disorder (OR=1.6; p=0.005), major 
depression (OR=7.0; p=0.037) and any anxiety or mood disorder (OR=14.7; p=0.004). Alcohol users 
differed significantly from non-alcohol users with respect to the prevalence of lifetime social phobia, 
PTSD, major depression and any anxiety or mood disorder; and  alcohol users differed significantly 
from non-alcohol users with respect to the prevalence of 12-month PTSD, major depression and any 
anxiety or mood disorder. Those who had ever used cannabis differed significantly from those who 
had never used cannabis with respect to the prevalence of lifetime social phobia, PTSD, major 
depression, and 12-month generalised anxiety disorder, PTSD, major depression and any anxiety or 
mood disorder. Users of other drugs differed significantly from non-users with respect to the 
prevalence of lifetime PTSD, major depression and any anxiety or mood disorder, and to 12-month 
major depression and any anxiety or mood disorder. The proportion of individuals who had ever used 
extra-medical substances differed significantly from that of non-users of extra-medical drugs with 
respect to the prevalence of lifetime panic disorder, major depression and any anxiety or mood 
disorder, and 12-month panic disorder. 
Table 3 presents associations between any anxiety or mood disorders and substance use in 
general. Most of these associations were significant after adjustments were made for age and gender 
(Table 4). It is evident from Tables 3 and 4 that the odds of comorbid psychopathology are increased 
in the presence of substance use compared with the odds of psychopathology in the absence of 
substance use. For example, the odds of having any lifetime anxiety or mood disorder was 1.4 with 
use of tobacco and extra-medical substance use, 1.6 with use of alcohol or cannabis, and 3.2 with use 
of other substances. The equivalent odds on adjustment for age and gender were 2.2 and 1.5 for 
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tobacco and extra-medical substance use respectively ,2.1 and 2.2 for alcohol and cannabis use, and 
4.0 for other substance use. Similarly, the odds of a 12-month mood or anxiety disorder, on 
adjustment for age and gender, were 1.4 for extra-medical substance use, 2.4 for alcohol use, 3.8 for 
tobacco use, and 4.1 and 4.7 for cannabis and other substance use respectively. 
On adjustment for age and gender, there was approximately a twofold increased likelihood of 
lifetime psychopathology, and a threefold increased likelihood of 12-month psychopathology in 
tobacco users versus non-tobacco users. Tobacco users had a six- to sevenfold increased likelihood of 
12-month panic or generalised anxiety disorder over non-tobacco users, and a 5-fold increased 
likelihood of 12-month major depression. The increased likelihood of lifetime and 12-month PTSD in 
alcohol, cannabis and other drug users, the increased likelihood of 12-month major depression in 
cannabis and other drug users, and the increased likelihood of lifetime and 12-month panic disorder in 
extra-medical users were significant. 
It is also notable that, on adjustment for age and gender, lifetime generalised  anxiety disorder 
(GAD) was not significantly associated with any of the substances of use examined, while lifetime 
agoraphobia,  panic disorder, PTSD and social phobia were associated with only some of the selected 
substances of use. Similarly, with regards to 12-month disorders, the specific disorders were 
significantly associated with certain, and not all, the selected substances of use. Both lifetime and 12-
month major depression were significantly associated with all (barring one) the selected substances of 
use.  
Overall comorbidity rates in the SASH sample were as follows (percentages adjusted for survey 
weighting with 95% CIs): For any lifetime substance use and any DSM IV disorder 21.3% (CI 18.8-
23.9); For any lifetime substance use disorder and any anxiety or depression disorder 4.0% (CI 2.6-
6.1); For any 12-month substance use and any DSM IV disorder 11.5% (CI 9.2-14.2); For any 12-
month substance use disorder and any anxiety or depression disorder 1.6% (CI 1.0-2.7). 
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4. Discussion 
The main findings of the study were  that, in young adults 1) substance users were more likely 
than non-substance users to be male, White, employed and living in urban environments, 2) lifetime 
and 12-month anxiety or mood disorder was more likely to occur in substance users than in non-users 
of substances, and 3) strengths of association between psychopathology and substances of use were 
higher in relation to specific psychopathology (for example PTSD) and specific substances of use (for 
example, cannabis and alcohol) .  
Overall, the results obtained concur with previous findings that males were more likely than 
females to smoke (McGee et al., 2000), and to have been regular users of alcohol (Steinhausen & 
Metzke, 2003) and other drugs. These results possibly reflect the stereotypical norms of male 
socialisation with regards to cigarette smoking and use of alcohol. However, recent evidence suggests 
that, as traditional gender roles start to equalise, prevalence of female substance use might approach 
that of males, with potentially similar consequences regarding substance-related morbidity (Seedat et 
al., 2009).  
Employed individuals were more likely to use substances, possibly reflecting greater access to 
disposable income to purchase sub tances, compared with unemployed individuals. However, 
substance users did not differ significantly from non-substance users with respect to income, thus 
suggesting that factors other than economic resources and linked to employment status, such as access 
to particular social networks, may also be operative.   
Blacks were the least likely of the RCSGs to smoke cigarettes suggesting that maybe there was a 
protective factor(s) against cigarette smoking among the Blacks in this sample, or a potentially 
increased rate of cigarette smoking in the non-Black population, or a link between being Black and 
being unemployed.  Similarly, individuals of Indian or Asian origin were the least likely to use 
alcohol, cannabis or any substances other than cigarettes. These findings concur with that of studies 
reported by Rodriguez et al. (1999) that, for example, found associations between unemployment and 
substance abuse, but also demonstrated differences between population groups in terms of the impact 
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that factors such as gender, marital status, employment status, job satisfaction and educational level 
had on health and wellbeing. Other reports from the SASH study showed that there were marked 
racial differences on all indicators of economic status including education, income, employment, and 
ownership of material resources (Jackson et al., 2010). The latter authors suggested that it might be 
important to distinguish between minority status and racial-ethnic groups when assessing  the impact 
of sociodemographic factors on the mental health of individuals in South Africa. 
Substance users in the SASH sample were more likely than non-substance users to have had 
lifetime or 12-month anxiety disorders or major depression, irrespective of the choice of substance use 
(Table 2). In addition, the results in the current study indicated some statistically significant 
associations between psychopathology and substance use, irrespective of the substances of use (Table 
4). These findings echo those of several earlier studies reviewed by Saban and Flisher (2010) that 
have indicated increased risk of psychiatric disorder with substance use (Saban & Flisher, 2010).  The 
trends in this younger adult sample are also similar to those in the National Comorbidity Survey- 
Replication (NCS-R), with the prevalence of the anxiety disorders exceeding that of the mood 
disorders (Kessler et al., 2005). Further, the results similarly concur with the findings of the National 
Epidemiologic Survey on Alcohol and Related Conditions (NESARC) (Grant et al., 2004) with the 
odds ratios of associated specific lifetime and 12-month psychiatric diagnoses and substance use 
largely exceeding 1.0.  
More specifically, the results indicated that illicit substances such as cannabis had a manifold 
increased risk of psychopathology with adjustment for age and gender.  The Australian National 
Survey of Mental Health and Well-being (NSMHWB) reported similar findings in relation to adult 
anxiety disorders (OR=1.2, 2.8 and 2.6 for cannabis use, abuse and dependence respectively) 
(Degenhardt et al., 2001).  It is thus important that the risks of psychopathology with cannabis use be 
emphasised, particularly in communities where exposure to cannabis use is high. It is also important 
that the factors that place individuals at risk of cannabis use are identified and addressed, both to 
protect against cannabis use, and to decrease the risk of associated psychopathology.  
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  The results indicated relatively high increased odds of lifetime and 12-month PTSD, particularly 
when PTSD was comorbid with alcohol or cannabis. Earlier studies with substance-using inpatients 
and war veterans also provided evidence for a strong association between  PTSD and substance use 
and related disorders (Triffleman et al., 1995; McFall et al., 1991). However, these studies have 
cautioned that the associations be considered with particular reference to the role of trauma in more 
general family or social dysfunction.  Thus, it might be necessary to identify the factors that 
predispose individuals with PTSD diagnoses to substance use,  and particularly alcohol and cannabis 
use, and to identify the factors that increase the risk of PTSD in substance users (Cacciola et al., 
2009).  
The limitations of the SASH study should, however, be recognised when interpreting these 
results.  For example, firstly, the SASH sample excluded individuals who were in prison, hospital or 
mental institutions, or who lived  on military bases. Thus psychiatric disorders or substance use 
pertinent to these categories of individuals, would have been underestimated or excluded from the 
sample. These include, for example, antisocial personality disorders and available substances of use in 
the prison population, psychiatric or substance use diagnoses that might have precipitated admission 
in hospital or mental institution patients, and PTSD that might have been more prevalent in soldiers 
than in the non-military community.  Secondly, the SASH survey assumed equal chance of 
representation of mentally ill and healthy subjects in the sample, even though individuals with 
psychopathology are  known to be less likely than those without psychopathology to be willing 
participants in surveys, particularly when those surveys relate to mental illness (Tomlinson et al., 
2009, citing Kessler, Wittchen and Abelson, 1998).  These are factors that might have skewed the 
prevalence of psychopathology in favour of mentally-healthy individuals, and provided an under-
estimate of substance use. Thirdly, the SASH data excluded certain psychiatric diagnoses such as 
bipolar disorder, oppositional defiant disorder, conduct disorder, attention deficit hyperactivity 
disorder, obsessive compulsive disorder, specific phobia and separation anxiety disorder, thus limiting 
the associations between psychopathology and substance use that could be examined. Fourthly, the 
cross-sectional nature of the sample did not permit identification of causative factors in the 
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associations, or the temporal order of co-occurring psychopathology and substance use. Fifthly, the 
SASH data relied on self-reports. The reliability of the information obtained might thus have been 
compromised if, for example, use of substances was under- or over-reported, particularly since this 
information was not verified with biomarkers. Lastly, the statistical analyses for this study involved 
multiple comparisons between variables, suggesting that the statistically significant results might have 
been chance findings and, thus, subject to error. This error could have benefitted from adjustment 
using a method such as the Dunn-Bonferroni correction. However, the Dunn-Bonferroni correction 
was not applied in the study since an inherent limitation of the method is to increase the probability of 
false negative results, thus reducing statistical power in the study. 
In conclusion, the results obtained have highlighted the prevalence of substance use in young 
adults, with particular reference to sociodemographic factors and the most commonly-occurring 
psychiatric diagnoses, and have provided compelling evidence for an association between 
psychopathology and substance use.  
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Table 1 
 Prevalence of substance use by demographics [%, (95% CI), chi-squared p-value]. 
   Tobacco  Alcohol  Cannabis Other substancesa Extra-medical substancesb 
   100+ cigarettes (%) p-value Ever (%) p-value Ever (%) p-value Ever (%) p-value Ever (%) p-value 
Total sample   27.4 (24.9-30.1)  38.7 (35.5-41.9)  10.7 (9.0-12.8)  2.7 (1.8-4.0)  20.6 (17.5-24.1)  
Age Mean (95% CI) 23.6 (23.4-23.8)         20.6 (17.5-24.1)  
Gender Males  44.9 (40.2-49.8) <0.001 54.0 (49.8-58.1) <0.001 17.7 (14.5-21.6) <0.001 4.2 (2.5-7.0) 0.001 21.4 (17.2-26.4) 0.497 
 Females  9.8 (7.5-12.6)  22.7 (19.4-26.4)  3.6 (2.5-5.2)  1.1 (0.6-1.9)  19.8 (16.7-23.4)  
RCSG Black  23.7 (21.2-26.3) <0.001 34.0 (30.5-37.7) <0.001 9.3 (7.5-11.4) <0.001 2.1 (1.3-3.4) 0.004 21.2 (18.2-14.5) 0.416 
 White  47.7 (39.4-56.2)  67.4 (57.2-76.2)  25.4 (19.7-32.0)  6.7 (3.3-13.4)  13.8 (6.8-26.2)  
 Coloured  44.0 (30.1-58.9)  59.3 (46.9-70.6)  11.2 (4.4-25.8)  5.1 (2.6-9.5)  25.6 (11.4-48.0)  
 Indian/Asian  32.0 (21.9-44.2)  26.1 (19.1-34.6)  6.5 (3.9-10.6)  0  13.4 (5.6-28.7)  
Education None  40.8 (21.9-62.8) 0.152 55.9 (34.5-75.3) 0.574 21.6 (5.6-56.4) 0.020 0 0.094 11.6 (4.0-29.4) 0.482 
 Grade 1-7  35.8 (28.3-44.2)  37.7 (29.7-46.5)  11.9 (7.0-19.4)  2.0 (0.6-6.8)  19.7 (12.3-29.9)  
 Grade 8-11  26.9 (23.2-31.0)  38.2 (33.8-42.8)  10.4 (7.9-13.6)  3.5 (1.9-6.5)  18.8 (14.7-23.6)  
 Matric  25.1 (20.7-30.0)  37.9 (33.3-41.8)  7.6 (5.3-10.7)  1.1 (0.5-2.7)  21.3 (16.5-27.1)  
 Matric +  29.5 (23.0-37.1)  40.3 (33.1-48.1)  16.8 (12.4-22.5)  4.3 (2.4-7.8)  24.3 (18.2-31.6)  
Marital status Not married  25.9 (23.0-29.1) 0.073 38.8 (34.5-42.8) 0.684 10.0 (8.0-12.5) 0.289 2.7 (1.7-4.2) 0.978 19.8 (16.6-23.4) 0.241 
 Married  31.9 (26.6-37.7)  37.3 (31.4-43.5)  12.8 (8.8-18.2)  2.6 (1.3-5.4)  23.1 (17.7-29.6)  
Employment Employed  40.9 (33.8-48.4) <0.001 56.1 (49.6-62.4) <0.001 16.9 (12.5-22.4) 0.003 4.1 (2.4-7.1) 0.120 25.9 (19.3-33.9) 0.061 
 Unemployed  23.9 (21.2-26.8)  33.8 (30.3-37.5)  9.1 (7.1-11.5)  2.3 (1.4-3.8)  19.2 (16.1-22.8)  
Income c Zero  23.2 (19.3-32.1) 0.912 39.9 (31.9-48.5) 0.715 12.3 (7.7-19.2) 0.167 3.7 (1.2-11.2) 0.401 19.4 (13.5-27.2) 0.404 
 Low  26.6 (31.7-32.1)  36.1 (31.7-40.6)  8.4 (6.0-11.7)  3.3 (1.7-6.6)  21.6 (17.6-26.3)  
 Low-average  28.5 (23.2-34.6)  42.5 (35.6-49.6)  7.3 (4.5-11.7)  0.6 (0.1-4.4)  15.8 (11.1-22.1)  
 High-average  28.7 (23.2-34.9)  37.6 (31.1-44.6)  12.4 (8.7-17.4)  3.5 (1.6-7.8)  20.5 (15.4-26.8)  
 High  28.2 (22.4-34.8)  38.3 (31.4-45.8)  13.0 (9.3-17.9)  1.8 (0.7-4.4)  23.1 (17.7-29.6)  
Urbanicity Rural  22.3 (17.9-27.4) 0.006 31.8 (26.5-37.7) 0.003 13.6 (11.0-16.8) <0.001 1.7 (0.8-3.6) 0.133 15.8 (12.3-20.1) 0.010 
 Urban  30.8 (27.9-33.8)  42.7 (38.9-46.6)  6.2 (4.7-8.2)  3.3 (2.2-5.2)  23.8 (19.5-28.7)  
 
a  
cocaine, heroin, opium, glue, LSD, peyote 
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b 
 non-medical use of sedatives, tranquilisers, stimulants, analgesics 
c 
 personal earnings from employment in the past 12 months, before taxes, excluding pensions and investments 
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Table 2  
Prevalence of anxiety and mood disorders by substance use [%, (95% CI), chi-squared p-value]. 
  TOTAL Tobacco Use Alcohol Use Cannabis Other substancesa Extra-medical substancesb 
  Prevalence (95% CI) 
p- 
100+ cigarettes % (CI) p-value Ever % (CI) p-value Ever % (CI) p-value Ever % (CI) p-value Ever % (CI) p-value 
Lifetime DSM-IV Disorders            
Anxiety Disorders Panic Disorder 0.7 (0.3-1.3) 1.1 (0.4-2.8) 0.211 1.0 (0.4-2.3) 0.287 0.8 (0.1-5.8) 0.815 1.8 (0.2-12.1) 0.321 2.2 (1.0-5.1) <0.001 
GAD with hierarchy 1.1 (0.7-1.7) 1.7 (0.9-3.5) 0.102 1.3 (0.6-2.5) 0.485 2.4 (0.9-6.4) 0.080 1.9 (0.3-13.3) 0.536 1.7 (0.7-4.0) 0.189 
Social Phobia 2.8 (2.0-4.1) 5.1 (2.7-9.6) 0.011 4.4 (2.4-8.1) 0.044 5.9 (2.7-12.5) 0.021 5.8 (0.8-33.4) 0.438 4.1 (2.0-8.3) 0.120 
Agoraphobia 11.1 (9.2-13.4) 10.0 (6.8-14.5) 0.498 12.2 (9.1-16.1) 0.387 8.8 (5.5-13.7) 0.276 4.0 (0.9-16.5) 0.142 10.8 (8.1-14.3) 0.816 
PTSD 4.5 (1.0-2.2) 2.1 (1.0-4.4) 0.230 2.6 (1.5-4.5) 0.004 5.1 (2.0-12.2) 0.003 10.6 (3.9-26.1) <0.001 1.3 (0.4-3.6) 0.758 
Any anxiety disorder 14.7 (12.5-17.2) 16.4 (11.8-22.2) 0.388 17.7 (13.5-22.9) 0.063 17.7 (10.9-27.4) 0.405 24.1 (9.9-48.1) 0.219 16.4 (12.7-20.9) 0.312 
Mood Disorders Major Depression 8.6 (7.1-10.3) 12.1 (8.4-17.1) 0.027 11.8 (9.0-15.5) 0.001 15.4 (10.1-22.7) 0.003 27.2 (10.8-53.6) 0.009 12.8 (9.1-17.7) 0.010 
Any anxiety or mood disorder 19.7 (17.3-22.3) 23.3 (18.0-29.8) 0.092 24.1 (19.7-19.1) 0.007 26.8 (19.4-35.8) 0.054 42.5 (21.0-67.3) 0.021 24.4 (19.8-19.6) 0.027 
12-month DSM-IV Disorders             
Anxiety Disorders Panic Disorder 0.5 (0.2-1.1) 1.1 (0.4-2.8) 0.068 0.7 (0.3-1.9) 0.415 0.8 (0.1-5.8) 0.594 1.8 (0.2-12.1) 0.199 2.2 (1.0-5.1) <0.001 
GAD with hierarchy 0.7 (0.4-1.3) 1.6 (0.8-3.4) 0.005 1.2 (0.6-2.5) 0.062 2.4 (0.9-6.4) 0.007 1.9 (0.3-13.3) 0.295 0.9 (0.3-2.8) 0.691 
Social Phobia 1.9 (1.3-2.8) 2.9 (1.2-6.5) 0.192 2.7 (1.3-5.3) 0.189 4.3 (1.6-10.5) 0.042 4.8 (0.5-35.8) 0.361 3.3 (1.5-7.1) 0.067 
Agoraphobia 5.1 (3.9-6.6) 4.9 (2.9-8.2) 0.872 4.9 (3.1-7.9) 0.898 5.0 (2.5-9.8) 0.958 0 - 4.1 (2.8-6.0) 0.259 
PTSD 0.3 (0.2-0.7) 5.4 (0.2-1.9) 0.296 0.6 (0.2-1.6) 0.030 1.4 (0.4-4.9) 0.006 1.9 (0.3-12.8) 0.055 0 - 
 Any anxiety disorder 7.1 (5.5-9.0) 8.8 (5.8-13.2) 0.102 8.1 (5.3-12.3) 0.340 10.1 (5.5-17.9) 0.181 10.4 (2.5-34.3) 0.532 8.1 (5.3-12.1) 0.384 
Mood Disorders Major Depression 4.3 (3.3-5.6) 7.0 (4.4-10.9) 0.037 6.1 (4.3-8.7) 0.012 11.0 (6.9-17.2) <0.001 21.0 (7.2-47.5) 0.002 6.7 (4.2-40.7) 0.059 
Any anxiety or mood disorder 10.3 (8.5-12.5) 14.7 (10.7-19.8) 0.004 12.9 (9.9-16.8) 0.019 19.6 (13.3-27.7) 0.001 26.6 (10.5-52.6) 0.025 12.9 (9.6-17.2) 0.086 
 
a  
cocaine, heroin, opium, glue, LSD, peyote 
b 
 non-medical use of sedatives, tranquilisers, stimulants, analgesics 
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Table 3  
Crude associations between anxiety and mood disorders, and substance use, using regression analyses [OR, (95% CI), p-value]. 
  Tobacco Use Alcohol Use Cannabis Other substances
a Extra-medical substancesb 
  OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Lifetime DSM-IV Disorders           
Anxiety Disorders Panic Disorder 2.5 (0.6-8.4) 0.223 2.1 (0.5-8.3) 0.298 1.3 (0.2-11.0) 0.815 2.8 (0.3-25.1) 0.342 9.3 (2.4-35.5) 0.001 
GAD with hierarchy 2.2 (0.8-5.8) 0.110 1.4 (0.6-3.4) 0.487 2.7 (0.8-8.9) 0.093 1.9 (0.2-15.6) 0.543 1.9 (0.7-5.2) 0.196 
Social Phobia 2.7 (1.2-5.8) 0.014 2.5 (1.0-6.0) 0.050 2.5 (1.1-5.4) 0.025 2.2 (0.3-16.5) 0.449 1.7 (0.9-3.2) 0.124 
Agoraphobia 0.9 (0.5-1.4) 0.499 1.2 (0.8-1.8) 0.388 0.7 (0.4-1.3) 0.278 0.3 (0.1-1.6) 0.162 1.0 (0.7-1.4) 0.816 
PTSD 1.8 (0.7-4.6) 0.236 3.8 (1.5-9.7) 0.007 5.2 (1.6-16.8) 0.006 9.8 (2.9-32.5) <0.001 0.8 (0.2-2.8) 0.758 
Any anxiety disorder 1.2 (0.8-1.8) 0.388 1.5 (1.0-2.2) 0.064 1.3 (0.7-2.3) 0.406 1.9 (0.7-5.3) 0.226 1.2 (0.9-1.6) 0.312 
Mood Disorders Major Depression 1.8 (1.1-2.9) 0.029 1.9 (1.3-2.8) 0.001 2.2 (1.3-3.6) 0.003 4.3 (1.3-13.7) 0.016 1.8 (1.2-2.9) 0.011 
Any anxiety or mood disorder 1.4 (0.9-1.9) 0.092 1.6 (1.1-2.1) 0.008 1.6 (1.0-2.5) 0.056 3.2 (1.1-8.7) 0.028 1.4 (1.0-1.9) 0.027 
12-month DSM-IV Disorders           
Anxiety Disorders Panic Disorder 4.1 (0.8-20.8) 0.091 1.9 (0.4-9.2) 0.423 1.8 (0.2-16.1) 0.599 3.8 (0.4-35.7) 0.232 49.5 (9.4-259.4) <0.001 
GAD with hierarchy 4.5 (1.4-13.8) 0.010 2.9 (0.9-9.0) 0.074 4.9 (1.4-17.3) 0.015 2.9 (0.3-24.8) 0.318 1.3 (0.3-5.2) 0.691 
Social Phobia 1.9 (0.7-5.0) 0.199 1.9 (0.7-5.0) 0.196 2.7 (1.0-7.4) 0.050 2.7 (0.3-26.6) 0.381 2.2 (0.9-5.0) 0.073 
Agoraphobia 1.0 (0.6-1.6) 0.872 1.0 (0.5-1.8) 0.898 1.0 (0.6-2.1) 0.958 - - 0.8 (0.5-1.2) 0.260 
PTSD 2.3 (0.5-11.3) 0.309 4.6 (1.0-20.7) 0.047 7.2 (1.4-36.3) 0.017 6.8 (0.7-64.5) 0.096 - - 
Any anxiety disorder 1.4 (0.9-2.2) 0.104 1.3 (0.7-2.3) 0.341 1.6 (0.8-3.1) 0.184 1.6 (0.4-6.4) 0.535 1.2 (0.8-1.9) 0.385 
Mood Disorders Major Depression 2.2 (1.1-4.6) 0.034 2.0 (1.2-3.5) 0.013 3.4 (1.9-6.4) <0.001 6.7 (1.7-25.6) 0.007 1.9 (1.0-3.8) 0.063 
Any anxiety or mood disorder 1.8 (1.2-2.7) 0.004 1.6 (1.1-2.3) 0.019 2.4 (1.4-4.0) 0.001 3.3 (1.1-9.8) 0.033 1.9 (1.0-2.0) 0.087 
 
a  
cocaine, heroin, opium, glue, LSD, peyote 
b 
 non-medical use of sedatives, tranquilisers, stimulants, analgesics 
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Table 4  
Adjusted associations between anxiety and mood disorders, and substance use using regression analyses. 
†
 [OR, (95% CI), p-value] 
  Tobacco Use Alcohol Use Cannabis Other substances
a Extra-medical substancesb 
  OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Lifetime DSM-IV Disorders           
Anxiety Disorders Panic Disorder 3.1 (0.7-13.7) 0.129 2.5 (0.8-7.8) 0.0124 1.4 (0.2-11.3) 0.731 3.1 (0.3-33.5) 0.349 9.5 (2.5-36.5) 0.001 
GAD with hierarchy 3.0 (1.0-9.4) 0.061 1.5 (0.6-3.8) 0.373 3.2 (0.9-12.2) 0.082 2.0 (0.2-17.6) 0.516 1.87 (0.7-5.1) 0.214 
Social Phobia 3.9 (1.5-10.1) 0.006 3.0 (1.1-7.9) 0.030 2.9 (1.1-7.5) 0.025 2.3 (0.3-21.6) 0.460 1.7 (0.9-3.4) 0.113 
Agoraphobia 1.2 (0.8-2.1) 0.390 1.6 (1.0-2.5) 0.044 1.0 (0.6-1.8) 0.997 0.4 (0.1-2.0) 0.266 1.0 (0.7-1.4) 0.966 
PTSD 2.7 (0.8-9.1) 0.119 5.2 (2.0-13.4) 0.001 8.1 (2.3-29.2) 0.002 12.5 (3.9-40.6) <0.001 0.8 (0.2-2.8) 0.712 
Any anxiety disorder 1.8 (1.1-2.9) 0.011 2.0 (1.3-3.2) 0.004 1.7 (0.9-3.3) 0.087 2.4 (0.8-6.8) 0.108 1.2 (0.9-1.7) 0.247 
Mood Disorders Major Depression 3.0 (1.7-5.4) <0.001 2.7 (1.8-3.9) <0.001 3.1 (1.8-5.5) <0.001 5.6 (17-18.1) 0.005 1.8 (1.2-2.0) 0.011 
Any anxiety or mood disorder 2.2 (1.4-3.2) <0.001 2.1 (1.5-3.1) <0.001 2.2 (1.3-3.6) 0.003 4.0 (1.5-11.1) 0.008 1.5 (1.1-2.0) 0.020 
12-month DSM-IV Disorders           
Anxiety Disorders Panic Disorder 6.9 (1.5-31.7) 0.014 2.3 (0.6-8.5) 0.215 2.1 (0.3-16.3) 0.471 4.3 (0.4-52.8) 0.247 50.5 (9.5-268.4) <0.001 
GAD with hierarchy 6.2 (1.5-25.7) 0.012 3.1 (0.9-10.3) 0.065 5.5 (1.2-25.4) 0.028 2.9 (0.3-27.6) 0.356 1.3 (0.3-5.1) 0.723 
Social Phobia 3.5 (1.0-12.9) 0.059 2.7 (0.9-8.0) 0.066 4.4 (1.5-13.0) 0.009 3.7 (0.3-42.6) 0.296 2.2 (1.0-5.1) 0.063 
Agoraphobia 1.9 (1.1-3.1) 0.016 1.5 (0.7-3.0) 0.289 1.7 (0.7-3.8) 0.216 - - 0.8 (0.5-1.3) 0.356 
PTSD 3.1 (0.4-24.2) 0.276 5.9 (1.3-27.6) 0.025 10.4 (1.5-70.1) 0.017 7.5 (0.7-75.2) 0.086 - - 
Any anxiety disorder 2.9 (1.8-4.6) <0.001 2.0 (1.0-3.8) 0.043 2.6 (1.2-5.6) 0.012 2.2 (0.5-9.9) 0.284 1.3 (0.8-2.0) 0.302 
Mood Disorders Major Depression 4.7 (2.2-10.0) <0.001 3.0 (1.7-5.4) <0.001 6.3 (3.0-13.2) <0.001 10.2 (2.8-37.0) 0.001 1.9 (1.0-3.8) 0.060 
Any anxiety or mood disorder 3.8 (2.5-5.8) <0.001 2.4 (1.5-3.7) <0.001 4.1 (2.3-7.4) <0.001 4.7 (1.6-14.4) 0.006 1.4 (1.0-2.1) 0.058 
†
 Adjusted for age and gender 
a  
cocaine, heroin, opium, glue, LSD, peyote 
b 
 non-medical use of sedatives, tranquilisers, stimulants, analgesics 
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CHAPTER 7 
Discussion 
Introduction 
The aims of this thesis were i) to examine the association between psychopathology and 
substance use in adolescents and young adults, ii) to identify the role of demographic and 
social factors in comorbidity, and iii) to examine the role of sociodemographic factors and 
comorbid psychopathology in outcomes from substance use inpatient treatment. The 
objectives were i) to quantify the occurrence of psychopathology, substance use and 
comorbidity in adolescents and young adults, ii) to identify associations, and measure the 
strengths of association, between specific forms of psychopathology and the use of specific 
substances of use,  and iii) to identify sociodemographic factors and/or psychopathology that 
influence substance use inpatient treatment outcomes. The thesis has produced five 
manuscripts, two of which have been published, and three that are currently in journal 
review.  
This chapter will provide a synopsis of the thesis, highlighting the salient features of 
comorbidity research and the principal findings of the conducted studies. Specific reference 
will be made to the aims and objectives of the thesis, and to how the conducted studies 
addressed knowledge gaps. To avoid repeating contents from the manuscripts in earlier 
chapters, in its discussion of strengths and limitations, this chapter will concentrate on 
discussing the strengths and limitations of the thesis as a whole, with reference to the relevant 
thesis studies when deemed necessary or appropriate. The chapter will conclude with 
suggestions for continued and future research into comorbid psychopathology and substance 
use. 
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Critical issues in comorbid psychopathology and substance use and related research 
This thesis has confirmed the burden of mental illness and substance use and the contribution 
of these to the global burden of diseases (Hoelzer, 2009), highlighting this among adolescents 
and young adults in Cape Town (in the high schools study), and in South Africa (in the SASH 
survey). In this respect, mental illness and substance use have been identified as accounting 
for significant loss of quality life (Desjarlais, 1995), due to their disabling effects on the 
individuals involved. Mental illness and problematic substance use have been associated with 
suffering, economic loss, victimisation and discrimination associated ith access to housing, 
employment, treatment and familial support (Kakuma et al., 2010). Problematic use of 
substances has been associated with sexually risky behaviour (Pahl et al., 2010), sexually 
transmitted infections such as HIV (Myer et al., 2009b), and scholastic under-achievement 
and school dropout (Myer et al., 2009a). 
The thesis has confirmed the view that comorbid mental illness and substance use is a 
common co-occurrence (Volkow, 2001), with significant associated social and cost burden 
(Clark et al., 2009),   and has highlighted the increased recent (1986 onwards) interest in 
epidemiological comorbidity research, particularly with respect to children and adolescents or 
young adults (Angold, Costello and Erkanli, 1999). In the introductory and literature review 
chapters, various patterns of associated psychopathology and substance use were identified, 
together with biological, social, psychological and environmental factors (Weinberg and 
Glantz, 1999) that appear to play a role in these associations. In addition, pathways that have 
been suggested to explain the development of associated mental illness and substance use 
(Chapter 1) were outlined (Degenhardt et al., 2001). 
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Further issues, pertinent to co-occurring psychopathology and substance use, with 
implications for comorbidity treatment and research, were highlighted. These have served to 
provide a comprehensive overview and understanding of comorbid psychopathology and 
substance use, as well as to identify areas of knowledge where additional information and 
research are needed. The following points provide a summary of these issues as outlined in 
the thesis: 
i) Problems associated with the definition and diagnosis of “comorbidity” were 
discussed. This discussion underscored the differences between dealing with well-
established disease entities in other areas of medicine, compared with the less well 
established, and more diffuse disorders (“behavi ural and psychological 
syndromes that are deviant from some standard normality”) in psychiatry (Angold 
et al., 1999: 58).   Reasons provided for examining comorbidity included an 
attempt to understand the development of neuropsychiatric problems and 
substance use (Volkow, 2001), and the implications that comorbidity have for 
treatment, management and the provision of related services (Degenhardt et al., 
2001). 
ii) Research problems were discussed regarding reference to the term “comorbidity” 
and the use of  differing timeframes, suggesting more specific use of terms to 
distinguish between concurrent, sequential (or successive), or lifetime comorbidity 
(Degenhardt et al., 2001). 
iii) The distinction was made between comorbidity where mental illness is a risk 
factor for the development of substance use and related disorders, and the 
potential for substance use to induce mental illness (Schuckit, 2006), highlighting 
the issue of temporality and causality in comorbidity. 
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iv) The limited understanding about the nature of, and pathways to, comorbidity, 
despite its being considered a common occurrence (Volkow, 2001), was 
emphasised. 
v) Mention was made of the sparse reporting of information regarding research on 
the treatment of comorbidity (Kaminer et al., 2007), and possible reasons for this 
were suggested.  
vi) The need for more studies on the outcomes of treatment for comorbidity were 
discussed (Landheim et al., 2006), with particular mention of the need for 
information on the role of comorbid psychopathology and sociodemographics in 
outcome following substance use treatment (Compton et al., 2003). 
vii) The low research output from developing countries compared with that of 
developed countries was emphasised (de Graft Aikens et al., 2010). Reference was 
made to the need to increase available data on neuropsychiatric disorders that will 
facilitate cross-national comparisons of prevalence rates to guide the allocation of 
resources and the development of interventions. Particular mention was made of 
the need for increased rigorous research into chronic diseases in African countries, 
and the WMH SASH initiative.  
viii) The importance of examining comorbid psychopathology and substance use in 
adolescents and young adults was discussed, with reasons including the evidence 
for increased prevalence of comorbidity in this developmental stage (Deas, 2010), 
the need for more information on comorbidity amongst community youth 
(Langenbach et al., 2010), the potential for longer-term follow-up, and the 
possibility of improved recall compared with older individuals. 
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Principal study findings and their contribution to comorbidity knowledge gaps 
Overall, all the empirical studies in the thesis have contributed to knowledge of comorbid 
psychopathology and substance use in the following ways: 
i) They have highlighted the notion of comorbidity and its relevance in 
understanding the development of psychopathology and substance use. 
ii) They have contributed to the research output and available data on mental illness 
and substance use from the African continent, from a sub-Saharan African 
country, and from a developing country. 
iii) They have addressed the issue of limited information available on comorbidity in 
adolescents and young adults by specifically examining associations between 
psychopathology and substance use in adolescents and adults aged 30 years and 
younger. 
iv) They have provided data regarding the prevalence of psychopathology, substance 
use, and comorbidity, they have identified associations between psychopathology 
and substance use, and they have identified the influence of demographic and/or 
social factors in these associations and in treatment outcomes (the latter in the 
follow-up study).  
More specifically, the principal findings of the individual studies have contributed the 
following information (Table 1): 
i) With regards to high school students in Cape Town, South Africa, 
o Cannabis was significantly associated with all three psychopathologies, 
namely, PTSD, anxiety and depression. Since this was a cross-sectional 
study, the causal or temporal roles of either the cannabis use or the 
psychopathology in the comorbidity are unknown. However, this finding 
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suggests the need to examine the role of cannabis specifically, and mood 
and anxiety disorders in particular, as risk factors for comorbidity in 
school-going adolescents in Cape Town. 
o Alcohol use was significantly associated with PTSD and depression, once 
again suggesting that the specific substance use and specific 
psychopathology be further examined as risk factors for comorbidity. 
o Evidence for the association between grade and specific forms of 
comorbidity (namely PTSD/alcohol/depression; 
depression/alcohol/cannabis; anxiety/cannabis; depression/inhalants), 
suggest that there might be factors related to educational level, or possibly 
age or developmental stage, that influence the association between specific 
forms of psychopathology and specific substances of use. 
o The role of gender in associations between psychopathology and substance 
use in school-going adolescents was highlighted by evidence for stronger 
associations between psychopathology and substance use in females than 
in males. 
Furthermore, though not directly linked to the main study objectives, there were other 
findings that were consistent with the literature and which locate the problem of comorbidity 
in a local context: 
o On average, female students scored higher than male students on 
depression, anxiety and PTSD scales. This finding seems to suggest that 
gender might be associated more with the severity of psychopathology 
rather than having gender as a risk for specific psychopathology. In 
general, females have been found to be more likely to have anxiety and 
mood disorders compared with men (Fernander et al., 2006; Seedat et al., 
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2009). As such, the gender differences in the scale scores might reflect the 
increased risk of young female students for depression, anxiety and PTSD 
compared with males. The severity of psychopathology was not explored 
specifically, limiting further comment on the association between 
psychopathology severity and gender. 
o Black students had higher mean psychopathology scores than Coloured or 
White students, suggesting more severe psychopathology in Black students 
compared with students of other RCSGs, and a possible link between 
RCSG and severity of psychopathology. However, this finding is probably 
best viewed with caution. RCSGs are not biological constructs and might 
thus have no role in the genetic or physiological predisposition of 
members from a particular RCSG for psychopathology. In addition, RCSG 
might have no inherent value as a social construct either in relation to the 
prevalence of psychopathology in these students (Rockett et al., 2009). 
Within the South African context, however, use of RCSG might still 
reflect socioeconomic circumstances, historical injustices and human 
rights violations as a result of earlier Apartheid policies (Stein et al., 
2009). Aspects of these policies might have influenced RCSG differences 
in psychopathology severity, particularly in the Black community who 
represent the largest proportion of the South African community, and had 
the largest proportion of individuals disadvantaged by these policies. The 
SASH survey of adults found lower risks for mental illness in Whites 
compared with all other RCSGs (Seedat et al., 2009), further suggesting 
the possibility of RCSG differences in psychopathology prevalence or 
severity.  However, within the context of the high school student study, 
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reasons for an association between RCSG and mental illness severity 
remain speculative as this association was not explored specifically. 
o As previously mentioned, associations between psychopathology and 
substance use appeared to be moderated by grade, and weakly influenced 
by age and gender. These findings suggest differential associations 
between psychopathology and substance use, possibly moderated by 
developmental stage. It is also possible that the so-called gender paradox 
could be operating in these associations (Monshouwer et al., 2006). Thus, 
if there was an unequal gender distribution for psychopathology [for 
example, more internalising disorders in females, more externalising 
disorders in males (Reinherz et al., 2000; de Graaf et al., 2004)] the group 
with the lower prevalence rate might have an increased severity of 
disorder. 
ii) With regards to the cross-sectional study of inpatient substance users in treatment 
for their substance use, 
o Inpatient substance users in the Cape Town sample were most likely to be 
male, Coloured, Muslim, with some high school education, never married, 
living with immediate family members, and unemployed. These factors 
reflect the demographic profile of the geographical area of the study sites, 
and the profile of substance users who seek treatment in the study region 
(SACENDU, 2009). Non--South African studies have similarly reported 
inpatient substance users being largely male (Marsden et al. 2000; 
Langenbach et al., 2010). However, these demographic profiles might also 
reflect patient preferences for varying treatment modalities offered at the 
different treatment centres. 
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o Substance use onset occurred on average by age 14.7 years (SD=2.4). This 
mean age of onset is consistent with that reported in the SASH community 
survey (van Heerden et al., 2009) that found substance use had usually 
been commenced by age 17 years. However, age of substance use onset 
information is subject to patients’ ability to recall this information 
accurately. Furthermore, first substance use has been reported as 
associated with availability, social circumstances and environmental 
influences (Degenhardt, 2010; Mayet et al., 2010), and these factors might 
have played a role in the age of substance use onset. However, this study 
did not investigate factors that influence initiation of substance use, so the 
role of substance use availability, social and environmental circumstances 
in substance use initiation is unknown for this study sample. 
o First substances of use were most likely to be cannabis or crystal 
methamphetamine.  As mentioned earlier, this finding might reflect the 
social and environmental circumstances of the patients involved (Mayet et 
al., 2010) and  substance use availability (Degenhardt, 2010)  since both 
have been shown to be common substances of use in South Africa 
(Pluddemann et al., 2010; Peltzer et al., 2010). The significance of first 
substances of use and their role in subsequent substance use might thus 
need further exploration. 
o Most patients were in treatment for heroin or crystal methamphetamine 
use. Heroin (Marsden et al., 2000) and crystal methamphetamine 
(Langenbach et al., 2010) have been reported as common primary 
substances of use in non-South African studies of substance users in 
substance use treatment. Primary substance use in substance use inpatients 
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might reflect the predominant substance use trends at a particular time. 
However, primary substances of use seem to differ according to the 
treatment facilities and their locations (Langenbach et al., 2010). Primary 
substance of use might also reflect the ages of inpatients, with relatively 
older inpatients generally accounting for a larger proportion of patients 
with primary use of alcohol (SACENDU, 2009).  
o Most patients smoked cigarettes every day. This finding reflects a common 
trend amongst substance users in treatment for substance use other than 
nicotine (Langenbach et al., 2010).  
o Comorbid current (12-month) non-substance related psychopathology was 
very common (96.8%) and almost entirely previously undiagnosed 
(95.8%). The most common comorbid psychopathology diagnoses were 
anti-social personality disorder, conduct disorder, oppositional defiant 
disorder and depression. Comparable findings were reported in a similar 
study conducted in Germany (Langenbach et al., 2010), with a 
predominance of the conduct, anxiety and mood disorders amongst 
substance users.  
iii) With regards to the follow-up of inpatient substance users, 
o Males were more likely than females to complete their inpatient substance 
use treatment. The findings of Grella (2003) and Knight et al. (2001) seem 
to suggest that females require more support to engage in, and be retained 
in substance use treatment. In particular, females seem to require 
assistance in dealing with family needs, events associated with traumatic 
experiences (Grella, 2003), incarceration and social relationships (Knight 
et al., 2001). 
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o Females were more likely than males to have relapsed by 6 months post-
treatment. This result is possibly a consequence of incomplete treatment 
for substance use, a lack of compliance with substance use treatment, or an 
indication of the need for continuation of care subsequent to completion of 
inpatient substance use treatment. However, few gender differences have 
been found with respect to relapse associated with problematic use of 
alcohol (Walitzer and Dearing, 2006), although female users of substances 
other than alcohol seem less likely than males to relapse (Walitzer and 
Dearing, 2006). These authors found that females were more likely to 
relapse subsequent to negative life experiences while males were more 
likely to relapse following positive life experiences, suggesting that the 
females in the inpatient substance users study for this thesis might have 
had negative affective experiences that could have influenced their relapse, 
while the negative experiences of the male inpatients at the time were 
relatively less likely to encourage their relapse. 
o Primary users of crystal methamphetamine were more likely than other 
substance users to drop out of substance use treatment. The significance of 
this finding has important implications for service provision particularly 
since use of crystal methamphetamine amongst substance use treatment 
seekers has surpassed use of other substances in the Western Cape region 
of South Africa (SACENDU, 2006).  
o The lack of significant associations between psychopathology and 
treatment outcome in this study was surprising in view of the literature (for 
example, Compton et al., 2003). This finding might be a result of nearly all 
study participants (96.8%) having at least one comorbid psychiatric 
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disorder. In addition, the proportion of substance use patients who had at 
least one psychiatric disorder in this study far exceeded the proportion that 
has been found in the South African community (namely 21.3% 
comorbidity for lifetime disorders and 11.5% comorbidity for 12-months 
disorders in the SASH survey) as well as exceeding the generally accepted 
proportion of 70% to 80% comorbidity of substance users in treatment 
(Kaminer et al., 2007). The high proportion of previously undiagnosed 
comorbid psychiatric disorder in the inpatient substance users might be a 
reflection of several factors, for example, a) the severity of their substance 
use, with increased severity being more likely to be associated with 
psychiatric problems, and the majority of these patients having been 
diagnosed with a substance dependent disorder, b) the type of substance 
use being largely illicit and so-called harder drugs (namely heroin and 
crystal methamphetamine), c) the possibility that the symptoms of the 
substance use disorder might have masked the symptoms of psychiatric 
disorder, leading to treatment being sought for substance use rather than 
psychiatric disorder, and d) possible ignorance on the part of the patients 
and their families of the role that psychiatric disorder might play in their 
problematic substance use, particularly when the substance use is viewed 
by them as the primary problem or disorder. 
iv) With regards to the SASH survey, 
o There were significant associations between all the mood disorders and 
substance use. 
o Use of substances was associated with an increased likelihood of anxiety 
or mood disorders. 
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These findings have identified associations, and the strengths of these 
associations, between specific forms of psychopathology (anxiety and 
mood disorders) and using specific substances of use (namely, tobacco, 
alcohol, cannabis), in the South African community. For example, 
significant associations between lifetime PTSD and substance use had 
odds ratios from 5.2 (with respect to alcohol use) to 8.1 (for cannabis use). 
Comparative odds ratios for 12-month PTSD were 5.9 and 10.4 for alcohol 
and cannabis use respectively.  Similarly, significant associations between 
lifetime major depression and substance use had odds ratios that ranged 
from 1.8 for extra-medical substance use to 3.0 for tobacco use, and 5.6 
(for use of opiates), while associations between 12-month major 
depression and substance use ranged from 1.4 for extra-medical substance 
use to 3.8 for tobacco use and 10.2 for use of opiates and other substances. 
These findings demonstrate the potential risk of comorbidity in the 
presence of substance use or psychopathology. Moreover, these findings 
identify both associations between specific substances and specific forms 
of psychopathology, as well as illustrating the strengths of these 
associations. As such, they can inform the development of treatment 
interventions, and they can guide targeted provision of services to address 
the phenomenon of comorbidity. 
 
Thesis strengths and limitations 
This thesis has made some significant contributions to the understanding of associated 
psychopathology and substance use  within the South African context.  
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Firstly, in electing to examine associations between psychopathology and substance use, the 
research for this thesis has addressed a phenomenon which, though regarded as common, is 
poorly understood, has many questions that remain unanswered, and where research 
outcomes have often been unclear or inconclusive. In addition, the introductory and literature 
review chapters of this thesis have highlighted the issues pertinent to the debates regarding 
the significance of comorbidity (for example, its role in treatment seeking, substance use 
treatment outcomes), its challenges (for example, how to define comorbidity, diagnosing 
comorbidity, treatment of comorbid disorders simultaneously rather than in parallel), and 
areas where important gaps in knowledge occur (for example, which psychiatric disorders are 
most commonly associated with which substances of use, what are the risk factors associated 
with comorbidity, what are the temporal associations between comorbid disorders). The 
thesis has also foregrounded mental illness and substance use, both of which contribute 
significantly to South Africa’s, Africa’s, and the global, burden of chronic disease. Moreover, 
the empirical studies for the thesis (Chapter 3 to 6) investigated adolescents and young adults, 
thus addressing groups in which information regarding comorbidity has been lacking. In 
particular, the thesis has provided information about psychopathology in substance users 
receiving inpatient substance use treatment in Cape Town, thus examining a group that had 
previously not been investigated for comorbidity in South Africa. 
Secondly, the thesis has made both theoretical and practical contributions to available 
knowledge about associations between psychopathology and substance use. Theoretically the 
thesis has contributed to the understanding of comorbidity by highlighting the potential role 
of factors such as school grade in the association between psychopathology and substance 
use. The thesis has also contributed information regarding factors (such as gender and 
specific substances of use) that might play a role in outcomes from treatment for inpatient 
substance use. Further information has been provided by identifying specific 
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psychopathology in relation to specific substances of use. For example, the high schools 
study found significant associations between PTSD and tobacco, alcohol, cannabis and 
inhalant use, between depression and alcohol or cannabis use, and between anxiety and 
cannabis use.  Some findings in this thesis have corroborated the findings in studies 
completed in other countries [for example, associations between anxiety or depression and 
alcohol use (Merikangas et al., 1994; Schmidt, 1995)], highlighting the possibility that 
comorbid psychopathology and substance use might transcend geographic location. On a 
practical level, this thesis has contributed to the international database of studies on 
associated psychopathology and substance use, and, in particular, has increased research 
output from South Africa with respect to such comorbidity. 
Thirdly, a major strength of this thesis lies in its providing information about comorbidity 
from differing perspectives. The thesis includes two representative studies of community 
members, namely high school students in Cape Town, and the South African national 
community, and two studies of inpatient substance users. The thesis thus investigates 
comorbid psychopathology and substance use in both community and treatment samples.  
The approach of using different studies to investigate comorbidity provides an opportunity 
for different aspects of comorbidity to be addressed and compared. In this thesis these aspects 
of comorbidity have included identifying factors pertinent to school-going adolescents in the 
high schools study (for example, school grade) and, in the baseline treatment centres study, 
factors pertinent to being in treatment (for example, gender, specific comorbid 
psychopathology). Aspects of comorbidity that can be compared across studies include the 
occurrence and nature of comorbidity (for example, higher rates of comorbidity in substance 
users in treatment for substance use than in the high schools and SASH community samples; 
consistent associations between anxiety/depression and substance use, or treatment outcome 
across the studies), most common types of substances of use, and the strengths of association 
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between substances of use and comorbid psychopathology. The different samples could also 
allow one to generalise to other similar samples, bearing in mind the limitations of sampling 
in each particular study sample. 
By examining both treatment and community samples, the research has simultaneously 
highlighted areas of both community and clinical research that require further investigation or 
attention. For example, it would be useful to track the patterns of substance use and 
psychopathology over time in the high school students and general population (SASH) 
sample. The data from such research could be used to identify factors that influence 
comorbidity as well as to inform the development of interventions to decrease the risk of 
either psychopathology or substance use or comorbidity. Further research could also examine 
factors that influence treatment initiation and retention in prospective substance use 
inpatients, and identify factors that influence relapse or re-entry into substance use treatment.  
Moreover, secondary analyses of datasets for the high schools study and the SASH study 
provided the researcher access to datasets that were of a magnitude that exceeded the 
collection abilities of a single researcher constrained by the cost and time limits of a doctoral 
thesis. 
It is important, however, that the results obtained in the thesis be interpreted with 
consideration of potential limitations of the thesis as a whole, and the studies completed in 
particular. The thesis had four major sources of limitation: 
Firstly, the literature review, completed in 2008, and subsequent literature searches for 
references in the articles, were limited to English articles related to empirical, quantitative 
studies published from 1990 onwards, and these articles were obtained using specific 
keywords. Thus relevant articles written in other languages, or that used largely qualitative 
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analyses, were not accessed by the selected keywords, and were published prior to 1990, 
were excluded.  
Secondly, the articles selected for review concentrated on comorbid psychopathology in 
individuals with substance use and related problems. As such, articles in which individuals 
with mental illness were examined for comorbid substance use, were regarded as peripheral 
to the thesis, although recognition of this form of comorbidity was not overlooked. The 
inpatient studies, by extension, also focussed on individuals who had been identified with 
substance use problems, and examined these individuals for comorbid psychopathology. 
Thirdly, the different studies had some differing demographic variables, substances of use, 
and psychopathology of interest. This strengthened the overall information obtained from the 
studies by examining a variety of factors that might be pertinent to comorbidity, as mentioned 
earlier, but limited potential comparisons between studies. In addition, psychopathology 
comparisons between the studies could not be done because different assessment instruments 
were used in the studies. For example, the CIDI and C-DIS IV are diagnostic instruments 
and, as such, provide diagnoses of psychiatric disorders. In comparison, the high school 
students used epidemiological scales to identify psychopathology. The scaled scores reflect 
symptoms and relative severity of psychopathology, but do not provide diagnoses that are 
comparable to those of the CIDI or DIS. Furthermore, the CIDI and DIS both provide 
diagnoses based on DSM IV criteria. However, the CIDI has been validated for use cross-
culturally (Wittchen et al., 1991), including in South Africa, but has been reported to be time-
consuming to administer (Williams et al., 2004). In comparison, validation of the DIS has 
proven to be more difficult although the instrument has been found to be reliable (mean 
k=0.69), sensitive (mean sensitivity=75%) and of high specificity (mean specificity=94%) 
(Robins et al., 1981), and has greater flexibility with respect to the duration of the interview 
than does the CIDI.   
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Fourthly, the data for the studies were collected at different times. Thus factors pertinent to 
the period in time when the data were collected, and which influenced the factors examined 
in the studies, might have had different effects at these different times, with implications for 
comparisons across the studies. For example, crystal methamphetamine use increased during 
the period in which the studies for this thesis were completed (van Heerden et al., 2009). The 
prevalence of methamphetamine use in the earlier studies [high schools (1997) and SASH 
(2002-2004)] is likely to under-estimate the prevalence of methamphetamine use in the same 
communities at the time that the inpatient substance user studies were conducted (namely, 
2008 to 2009). 
Lastly, the use of self-reports to elicit information about substance use and psychiatric 
disorder could be a source of limitation in the study. The data obtained relied on the honesty 
of study participants to provide information truthfully, and accurately, and relied on 
participants’ ability to recall events accurately. However, the information obtained was not 
verified from sources other than the study participants and the studies did not control for 
factors such as social desirability bias.  
 
Conclusion and suggestions for further research 
This thesis has examined an area of research, namely comorbidity of psychopathology and 
substance use, an area that has not been subjected to rigorous research attention within the 
South African context. The findings of this thesis have highlighted the common occurrence of 
co-occurring psychopathology and substance use, particularly in adolescents and young 
adults in Cape Town and in South Africa. Such co-occurrence has been associated with 
increased service utilisation for mental illness, substance use and physical illness (Clark et al., 
2009), with cost, intervention, treatment and continued management implications for the 
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State and for the families of the individuals involved. In addition, knowledge about the nature 
of associations between psychopathology and substance use and related disorders, remains 
lacking. For example, the pathways to the development of either the psychopathology and/or 
the substance use remain unclear and in need of further investigation (Weinberg and Glantz, 
1999; Volkow, 2001), particularly relating to possible causal associations between 
psychopathology and substance use.  
More specifically, the empirical studies conducted for this thesis can be used to guide further 
research, partly by generating new questions based on the research completed, and partly by 
suggesting ways in which the completed research can be improved upon. 
For example, a replication of the high schools survey could examine comorbid 
psychopathology and substance use in relation to severity of the psychopathology, severity of 
the substance use, and the role of multiple substances of use in comorbidity. These students 
could be assessed to examine details regarding the age of onset of disorders relating to 
psychopathology and substance use. A replication of this study could also (as mentioned 
previously) provide details about the substances used by current students, compared with the 
substances used in the original study (1997), thus allowing for the tracking of substance use 
and associated psychopathology over time. Attempts could be made to verify the sensitive 
information required, for example, relating to substance use or the occurrence of traumatic 
events as this might have been subject to a social desirability bias.  Furthermore, it would be 
useful for the high school students to be followed up in a cohort design as this would provide 
information regarding the antecedents, pre-cursors and possible risk or protective factors of 
subsequent substance use or psychopathology, and identify mediators of associations, or 
potential consequences for baseline characteristics (Kleschinsky et al., 2009). To overcome 
some of the problems encountered with previous attempts at this, the follow up studies will 
need to minimise attrition. The latter authors (Kleschinsky et al., 2009) have cited monetary 
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incentives, comprehensive future contact information, frequent field tracking, and searching 
private and public databases as means of ensuring follow up contact. These techniques might 
be subject to limitations, including funds, ethical and confidentiality considerations, and the 
availability of alternative sources of contact, particularly in developing countries where 
infrastructure might be less-sophisticated than in developed countries. It would thus be 
important that the follow-up be planned, and be built into the methodology of the studies. 
Further research with substance users in inpatient treatment is also needed. A larger and more 
representative sample of inpatient substance users would have enabled the results to be more 
generalisable to other inpatient substance users, as well as enabling greater reliable 
comparisons with representative community studies. As previously mentioned, substance use 
treatment centres vary in their treatment and/or admission modalities. Further investigations 
with more representative samples of inpatients might thus better reflect the characteristics of 
the substance users at these treatment facilities. Studies of comorbid psychopathology and 
substance use in substance using inpatients could record details regarding the onset of 
psychopathology, and possibly examine the role of lifetime psychopathology in substance use 
and its development. The prevalence of tobacco use in this population could be further 
investigated to examine the role of cigarette use in the development of other substance use, to 
identify temporal associations between psychopathology and substances of use, and to 
determine the effects of physical illness associated with tobacco use on psychopathology, 
other substance use and treatment outcomes. Furthermore, studies of comorbidity in clinical 
samples could include investigating samples of psychiatric inpatients who use substances, as 
these could potentially provide comparative information regarding the role of the so-called 
primary disorder in the development of the so-called secondary disorder . 
Similarly, the follow-up study of inpatients would have benefitted from a larger baseline 
sample size as this would potentially have increased the size of the follow-up sample with 
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advantages for study power particularly related to sub-group analysis. The value of studies 
that follow up inpatient substance users, lies in the potential to provide information regarding 
the efficacy of treatment, and to identify the roles of patient and other factors in treatment 
outcomes. It would thus be of benefit to pursue further investigations of substance users 
discharged from inpatient substance use treatment to gauge their progress and identify risks 
for poor outcomes. Such information could inform treatment policies and interventions to 
ensure improved outcomes. In a similar vein, follow up of a general population sample, such 
as the SASH sample, could provide information on the role of comorbidity in mortality, or on 
the development of either the psychopathology or the substance use in the community over 
time.  
Globally, many studies have engaged, and are currently engaged, in identifying the 
prevalence of psychopathology, substance use and associations between these. This thesis has 
contributed to the available data by providing information relating specifically to South 
Africa and the city of Cape Town. However, more research is required to provide information 
on the treatment of comorbid psychopathology and substance use (McHugo et al., 2006; 
Kaminer et al., 2007).  Thus, in conclusion, it is sincerely hoped that this thesis will 
encourage further research into comorbid psychopathology and substance use, with particular 
emphasis on the ways in which the research findings can be used to develop effective 
treatment for the individuals affected by such comorbidity.  
 
,  
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Table 1: Summary of thesis studies 
 
  
STUDY 
 
Study characteristics 
 
 High school students 
 
Inpatient substance 
users (baseline) 
 
Inpatient substance 
users (follow-up) 
 
SASH 
 
Chapter in thesis 
 
3 
 
4 
 
5 
 
6 
 
Design 
 
Cross-sectional, random, 
representative, community  
sample of high school 
students 
 
Cross-sectional, 
consecutive, not 
representative, treatment 
sample of inpatient 
substance users 
 
Cross-sectional follow-
up sample of inpatient 
substance users after 
discharge from inpatient 
treatment 
 
Cross-sectional, 
random, representative, 
community sample 
 
Sample size 
 
939 
 
95 
 
86 
 
1766 
 
Age 
 
14-24 years 
 
17-30 years (Mean 23.0 
years; SD 2.9) 
 
17 to 30 years (Mean 
23.0 years; SD 3.0) 
 
18-30 years (Mean 
23.6 years; CI 23.4-
23.8) 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
270 
 
 
 
Gender 
 
Male (42.5%) and female 
 
Male (89.5%) and female 
 
Male (88.4%) and 
female 
 
Male (46.3%) and 
female 
 
Psychopathology diagnoses 
 
Depression 
Anxiety 
Post-traumatic stress disorder 
 
Any current 
 
Any current 
 
 
Current or lifetime 
mood and anxiety 
disorders 
 
Psychopathology instrument(s) 
 
Beck Depression Inventory 
Zung Self-rating Anxiety 
Questionnaire 
Harvard Trauma 
Questionnaire 
 
Diagnostic Interview 
Schedule for DSM IV 
 
Diagnostic Interview 
Schedule for DSM IV 
 
CIDI 3.0 
 
 
Substance use variables 
 
Ever smoked a whole 
cigarette 
Ever had more than a few sips 
of alcohol 
Ever smoked cannabis 
 
Any, excluding cigarettes 
First substance(s) of use 
Most frequently used 
substance(s) 
 
 
First substance(s) of use, 
excluding cigarettes 
Most frequently used 
substance(s), excluding 
 
Ever smoked >100 
cigarettes 
Ever drank alcohol 
Ever smoked cannabis 
Ever used medication 
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Ever used inhalants cigarettes for extra-medical use 
Ever used hard drugs 
 
Follow up variables 
 
Not applicable 
 
Not applicable 
 
Completed inpatient 
treatment 
Relapsed 
Still/Back in substance 
use treatment 
 
Not applicable 
 
Substance use instrument 
 
Questionnaire 
 
Diagnostic Interview 
Schedule for DSM IV 
Interview Schedule 
 
Interview Schedule 
 
CIDI 3.0 
 
Statistical analyses 
 
Logistic regression using 
survey design analyses 
 
Logistic regression 
 
Logistic regression 
 
Logistic regression 
 
Evidence found for significant 
associations between 
psychopathology and substance use  
or treatment outcomes for 
substance use 
 
Yes 
 
Yes 
 
Not applicable 
 
Yes (marginal) 
 
Yes 
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Specific statistically significant 
associations 
 
PTSD and all substances 
Depression, alcohol and 
cannabis 
Anxiety and cannabis 
 
Specific phobia and 
cannabis as the first 
substance of use 
 
Primary crystal meth 
use, and inpatient 
treatment completion 
(marginal) 
Crystal meth as first 
substance, and relapse 
(marginal) 
Current Major 
Depression and 
resumption of substance 
use treatment (marginal) 
 
 
Increased risk of any 
mood disorder with 
substance use 
 
